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PARTI 
GENERAL INTRODUCTION AND OUTLINE OF THE STUDY 

CHAPTER 1.1 
SPARSOMYCIN ANALOGUES: 
FROM BACTERIAL METABOLITE TO ANTITUMOUR AGENT 

INTRODUCTION 
Sparsomycin, a sulphur-containing antibiotic, is a potent inhibitor of the growth of 
many organisms, including bacteria, mammalian cells, yeast's [243], as well as virus 
growth [310]. Sparsomycin (NCS-059729) was subsequently found to be active against 
tumour cells in tissue culture and to inhibit tumour growth in vivo significantly [243]. 
Two years after its discovery a phase I clinical study in cancer patients on 
sparsomycin, given as continuous treatment, was initiated. This study was 
discontinued, because of a putative sparsomycin-related retinopathy [66,213]. 
Additional and recent studies, however, have shown that sparsomycin is not able to 
pass the blood-retina barrier [229,367] and at the cellular level sparsomycin does not 
penetrate reticulocytes at concentrations which are cytotoxic to tumour cells [68]. 
Furthermore, retinopathy is only found in very sick animals [367]. On the basis of 
these studies, the retinopathy seen in clinical studies is probably caused by the poor 
general condition of the patients and possibly by the inappropriate drug schedule. This 
reassuring explanation together with the usefulness of sparsomycin as a very potent 
protein synthesis inhibitor and as a potential anticancer drug has stimulated the 
synthesis of sparsomycin analogues. 
This chapter presents and discusses the characteristics of sparsomycin and its 
analogues of which some might possess greater opportunities for cancer chemotherapy 
than the parent compound. 
DISCOVERY, ISOLATION AND ANTITUMOUR ACTIVITY 
Sparsomycin has been isolated from the culture filtrate of Streptomyces sparsogenus. 
The genus Streptomyces is the major source of antibiotics [135] such as streptomycin, 
nystatin, amphotericin B, chloramphenicol and aureomycin (Chlortetracycline), as well 
as antitumour antibiotics such as daunorubicin, doxorubicin, bleomycin, mitomycin-C 
and sparsomycin (Table 1). 
Streptomyces sparsogenus belongs to the order Actinomycetales [280], which 
include a number of bacteria with hyphae similar to those of some fungi. The narrow 
(1.5 μπι diameter) hyphae can be short, infrequently branched units that fragments into 
rods, or extensive, non-fragmenting units that produce a fungus-like mycelium. 
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TABLE 1: Streptomyces species as source of antibiotics and antitumour agents 
ANTIBIOTIC (NSC No a) 
aureomycin (Chlortetracycline) 
bleomycin (125066) 
chloramphenicol 
cycloheximide (185) 
dactinomycin (actinomycin D - 3053) 
daunorubicin (daunomycin - 82151) 
doxorubicin (adnamycin - 123127) 
kanamycin 
mitomycin-C (26980) 
neomycin 
novobiocin 
phcamycin (mithramycin 24559) 
puromycin (3055) 
sparsomycin (59729) 
streptomycin 
Streptomyces 
SPECIES 
S aureofaciens 
S vertictllus 
S venezuelae 
S gnseus 
S parvulus 
S peucetius 
S peucetius 
var caesius 
5 kanamycetius 
S caespitosus 
S fradiae 
S niveus 
S tanashiensis 
S albomger 
S sparsogenus 
S gnseus 
REFERENCE 
Duggan, 1948 [85] 
Umezawa, 1966 [319] 
Bartz, 1948 [22] 
Ford, 1948 [104] 
Waksman, 1940 [323] 
Di Marco, 1963 [79] 
Arcamone, 1969 [15] 
Umezawa, 1957 [320] 
Hata, 1956 [135] 
Waksman, 1949 [324] 
Hoeksema, 1956 [144] 
Rao, 1962 [267] 
Porter, 1952 [257] 
Owen, 1962 [243] 
Schatz, 1944 [286] 
"NSC no ¡s the number for new screened compounds by the National Cancer Institute of the USA 
Classification within the order is based on wall chemistry, mycelium development, 
and reproductive features All members are gram-positive and abundant in soil, fresh 
water, sea water, decaying material and dung The characteristic odour of freshly 
ploughed soil and the foul taste of some drinking water can be attributed to substances 
produced by actinomycetes Streptomyces produces extensive, non-fragmenting hyphae 
that are fungus-like as shown in Figure 1 Special aerial branches produce chains of 
unicellular reproductive units, conidia The branches can be straight or coiled, and the 
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conidia of most species are smooth. 
The isolation and characterisation of sparsomycin has been described by Argoudelis 
in 1962 [17]. The antibiotic was initially detected in beers by means of antibacterial 
bioautographic techniques and was subsequently found to be active against KB human 
epidermoid carcinoma cells in tissue culture. In vivo, sparsomycin significantly inhibits 
the growth of 11 of 20 rumours tested [243]. 
FIGURE 1: Streptomvces. Typical filamentous growth, χ 5000 [280]. 
SYNTHESIS OF SPARSOMYCIN 
The structure of sparsomycin (Sm) was elucidated in 1970 by Wiley and MacKellar 
[342,343], and the absolute configuration was determined by Ottenheijm and co­
workers in 1981 f240] and is shown in Figure 2. Since then three total syntheses of 
Sm have been reported in the literature [137,158,239], and recently (1992), Parry et 
al. [247] unravelled the biosynthesis of Sm by administration of isotopically labelled 
precursors to Streptomytes sparsogenus. 
These results showed that the dithioacetal moiety of Sm is derived from L-cysteine via 
the intermediacy of S-methylcysteine and S-(methylthiomethyl)cysteine, with reduction 
of the carboxyl group of S-(methylthiomethyl)cysteine preceding attachment of the 
uracil moiety (Fig. 3). Investigations of the origin of the uracil moiety of Sm revealed 
that it is derived from L-tryptophan by a process that involves loss of the side chain 
and oxidative ring opening of both rings of the amino acid. 
ОНО.. 
C r ^ N ^ O 
6-methyluracil 
FIGURE 2: Retrosynthetic analysis of sparsomycin as presented by Ottenheijm [238] 
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SYNTHESIS OF ANALOGUES 
All reported syntheses followed the retrosynthetic scheme as shown in Figure 2 Thus 
the target compound was synthesised by coupling an amino cysteinyl derivative with 
an acid, thereby establishing the amide linkage present m Sm Initial attempts often 
started with either L-cysteine or a racemic mixture of cysteine, due to the high cost of 
D-cysteine The synthesis of analogues had two objectives The first one was to create 
Sm analogues to study the mechanism of action The second point of view was to 
synthesise molecules with improved protein synthesis inhibitory and antitumour 
activity 
STUDIES ON THE MECHANISM OF ACTION 
The broad spectrum of biological activities exhibited by Sm prompted additional 
studies to elucidate its mode of action The different metabolic parameters altered by 
Sm were studied in E coli by Slechta et al [293] In E coli the protein synthesis was 
affected at lower concentrations than needed to block RNA and DNA synthesis, 
causing inhibition of cell growth and accumulation of tRNA Thus, inhibition of 
protein synthesis seemed to be the primary mechanism of action, causing secondary 
effects such as blocking the DNA and RNA synthesis Unlike chloramphenicol, Sm is 
also a potent inhibitor of mammalian cell-free polypeptide synthesis [119] This means 
that Sm is one of the few agents which specifically inhibits protein synthesis in both 
70S and 80S nbosomal systems Sm is used in biochemical studies to investigate the 
protein synthesis machinery by accumulation of 80 S initiation complexes [142] The 
inhibitory effect of Sm on protein synthesis in intact chicken embryo fibroblast control 
cells as well as virus transformed cells was tested by Contreras and Carrasco [69] 
They found that after 30 min exposure to Sm (4 μΜ) protein synthesis was decreased 
Sm inhibits protein synthesis in a cell-free system prepared from reticulocytes, giving 
50% inhibition at 0 1 /xg/ml (= 0 29 μΜ), but not in intact reticulocytes at 
concentrations as high as 0 25 M for a period of 10 min This indicates that the 
plasma membrane of reticulocytes is impermeable for Sm The same reticulocytes 
were permeable for other antibiotics like cycloheximide, and streptovitacin A [68] In 
a cell-free system prepared from these reticulocytes the presence of Sm prevented the 
degradation of polysomes, although this effect was measurable not before 10 minutes 
from the beginning of the incubation [68] Later on this preincubation effect was 
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explained by invoking a chemical reaction (Pummerer rearrangement) between Sm and 
the P-site bound donor (peptidyl-tRNA) as proposed by Ash [19] and Flynn [99] The 
sulfoxide group appeared to be necessary for exhibiting this "preincubation effect" 
since sulphide- and sulfone-containing analogues failed to yield increased inhibition of 
peptidyl-puromycin formation after preincubation with polysomes [98] This oxidation 
state of the sulphur atom is also important for entry of Sm into bacteria with normal 
permeability barriers [135] Sm blocks the puromycin-induced release of 
polyphenylalanine from prelabelled nbosomes [120,160] Kinetic analysis revealed that 
Sm is a competitive inhibitor of puromycin and Golgberg et al [119] suggested that 
Sm interferes with the peptide bondforming step, either directly or by an allostenc 
mechanism Monro et al reported that this interference by Sm exists by formation of 
an inert complex between the peptidyl donor substrate and the 50S nbosomal subunit 
[222] Sm stabilises the initiation complex Stabilisation of binding by Sm requires the 
addition of the 50S nbosomal subunit to the 30S subunit and is associated with the 
formation of 70S nbosomes [139] Tada and Trakatellis proposed in 1970 that the 
peptidyl transferase has at least two sites, one for the peptidyl-tRNA (or initiator 
tRNA) and one for the tRNA-amino acid In E coli chloramphenicol binds in the 
latter site and thus inhibits protein synthesis by preventing the CCA-amino acid 
terminus of tRNA from binding to the peptidyl transferase Sm binds only when 
peptidyl-RNA (or initiator RNA) is already bound to the peptidyl transferase, and the 
site of Sm binding overlaps with that of chloramphenicol [303] Furthermore, Busiello 
et al [43] pointed out that Sm, in order to inhibit the peptide-bond formation, 
necessarily requires that the tRNA in the donor nbosomal site does not carry an 
aminoacyl with a free amino group Goldberg [121] suggested that Sm acts at or close 
to the actual site where peptide-bond formation takes place, the peptidyl transferase, 
and that Sm interferes with the acceptor recognition area in the peptidyl transferase 
(on the larger nbosomal unit), thereby blocking interaction with the aminoacyl end of 
an incoming aminoacyl tRNA and fixing the peptidyl-tRNA in the donor site The 
pseudoundine-hke moiety of Sm, which is attached to a peptide-like grouping, may 
play a role in its biological activity Complete removal of the sulphur-containing side 
chain of Sm eliminated its nbosomal binding affinity Moreover, for nbosomal 
binding the stereogenic carbon atom must possess the chirality of D cysteinol [194] 
By comparing the inhibitory effects on the hepatic protein synthesis in vivo at 1 h and 
24 h after intraperitoneal Sm treatment the microsomal protein synthesis is inhibited 
by 95 98% and 50-58%, respectively, indicating that the short-term effects on protein 
synthesis in vivo are the more pronounced [166] Intraperitoneal administration of Sm 
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to mice induced marked disaggregation of hepatic membrane-bound polyribosomes, 
possibly by interfering with the initiation complex, but did not cause detachment of 
nbosomes from the membranes [278] Sidransky et al [292] suggested that hepatic 
nbosomes on membranes after Sm treatment in vivo are attached via peptides as well 
as by ionic bridging influenced by potassium cations Normally, membrane-bound 
polyribosomes disaggregate into monomers that do not contain peptides (run-off 
nbosomes) Sm treatment leads to disaggregation of polyribosomes into monomers that 
still contain peptides (fall-off nbosomes) [136] Furthermore they found that after 24 h 
the cytoplasmatic changes caused by Sm reversed almost completely in many liver 
cells Recently, Theochans and Coutsogeorgopoulos characterised more precisely the 
nature of the "stabilisation of the donor substrate" by Sm and investigated whether a 
covalent intermediate involving the donor exists or not [309] They suggested that Sm 
is a slowly-equilibrating nbosomal inhibitor The nbosome that has accepted Sm 
readjusts its binding site and binds Sm more efficiently The dual effect might concern 
two complex forms The first form is involved in competitive kinetics, whereas the 
second form is involved in mixed non-competitive kinetics The stabilising effect on 
the de novo binding of substrates at the peptidyl-site appears to be an indirect effect of 
Sm, due to a slow equilibration reaction They found no support for a chemical 
reaction of Sm with the P-site bound donor catalysed by the putative nbosomal 
peptidyltransferase Lázaro et al also concluded that there is no covalent association 
between Sm and the nbosome [192,193] The preincubation effect is probably caused 
by conformational changes involving macromolecules such as the nbosomal RNA(s), 
t-RNA, nbosomal proteins, etc [293] 
ANALOGUES WITH IMPROVED BIOLOGICAL ACTIVITY 
After the elucidation of Sm structure in 1970 the synthesis of analogues has been 
approached in different ways [203] and the first structure-activity relationship studies 
of Sm appeared in 1975 [84] These studies can be categorised into two classes. The 
first involves modifications of the amino alcohol part related to the stereogenity of 
both carbon [321]) and sulfoxide sulphur atoms [86] The other class of studies deals 
with modification of the uracil acrylic acid part, with attention focused on replacement 
of the uracil ring by another ring such as benzene or furan [100,201], or direct 
modification of the uracil ring [37,174] The results of all structure-activity 
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relationship studies are pictured in Figure 3. 
Kanatomo et al. reported the synthesis of 52 derivatives [172,173], of which only two 
compounds were biologically active. They concluded that the ethylene moiety of the 
acryloyl portion and the side chain of the amino alcohol portion of Sm is essential for 
biological activity. The sulfoxide function and its (R) configuration as well as the (S) 
configuration of the chiral carbon of Sm analogues are essential for biological activity 
[192,203]. 
The first Sm derivative of interest was octylsparsomycin reported by Liskamp et. 
al. in 1984 [204], who found that the protein synthesis inhibition and, moreover, the 
cytostatic activity of Sm was related to its lipophilicity. Octylsparsomycin was shown 
to be three times as effective as Sm [204]. Another modification of Sm at the hydroxyl 
group gives discrepancy in the inhibition of protein synthesis in L1210 cells and the 
yeast polymerisation inhibition assay; this discrepancy might be due to differences in 
permeation into cells or a mode of action different from protein synthesis [191]. The 
chemical and biological aspects of 90 Sm analogues synthesised until 1986 are 
summarised by Ottenheijm et al. [241]. Since then various pyrimidine ring-modified 
analogues have been synthesised by Kanatomo et al. [173]. Until now none of these 
promising derivatives has been studied in animal tumour models. 
++ 
important for activity 
unimportant for activity 
++ ++ 
FIGURE 3: Conclusions from structure-activity relationship studies Assays used inhibition of 
protein biosynthesis in cell-free systems and in vitro L1210 clonogenic assay [37] ++ = 
essential, + = important, - = unimportant for biological activity. 
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Van den Broek et al , on the other hand, demonstrated that replacement of the 
uracil C(6)-CH3 group by a Η reduces the activity of the molecule [37] In addition, it 
appeared that the configuration of the sulfoxide atom is important for the expression of 
antitumour activity of Sm analogues The (R) configuration is more active than the (S) 
configuration [175] They also showed that Sm analogues having the SCRS chirality, 
are the most potent of the four possible stereoisomers and that the presence ot an 
oxygen atom on the S(a) is essential The same SCRS stereochemical requirement was 
shown by Kanatomo [176] for octylsparsomycin Van den Broek et al also reported 
that isomenzation of the trans double bond into the cis double (cis-Sm)inactivates this 
molecule [37] 
From the analogues studied only the lipophilic analogues octylsparsomycin, 
benzylsparsomycin and S-oxo-S-decylsparsomycin (Fig 4 and Table 3) are stronger 
growth inhibitors than Sm against L1210 cells [37] Van den Broek et al synthesised 
another 14 Sm derivatives, which are more lipophilic than Sm [38] The water 
solubility and drug toxicity in mice were found to be linearly correlated with drug 
lipophilicity The deshydroxy-sparsomycin analogues showed that an increase in 
hydrophobicity, by replacing the S-methyl group with larger alkylthio groups, 
enhanced the water solubility and improved the biological activity of the drug (Fig 4, 
Table 2 and 3) 
FIGURE 4: Lipophilic derivatives of sparsomyan [242] 
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ANTITUMOUR ACTIVITY OF SPARSOMYCIN AND ANALOGUES 
In vitro 
The in vitro activity of several Sm analogues against leukaemia L1210 cells [37,204] 
or against Ehrlich ascites carcinoma cells [172,173] has been reported. These assays 
were used to select compounds having a higher antitumour activity than the 
unmodified drug itself. For the L1210 system, good correlation was found between the 
in vitro and the in vivo antitumour activity of the tested drug [204]. Thus, the in vitro 
system is of predictive value for the L1210 in vivo system in the mouse (Table 2). 
TABLE 2: Cytostatic activity in vitro (IC50) and antitumour activity (%T/C) in mice of 
sparsomycin and selected analogues against L12I0 leukaemia [37,242,364] 
Name 
Sparsomycin (Sm) 
n-butyl-Sm 
n-pentyl-Sm 
n-octyl-Sm 
benzyl-Sm 
deshydroxy-Sm 
ethyldeshydroxy-Sm 
n-butyldeshydroxy-Sm 
Rl 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH2OH 
CH3 
CH3 
CH3 
R2 
CH, 
(CH2)3CH3 
(CH2)4CH3 
(CH2)7CH3 
CH2C6H5 
CH3 
CH2CH3 
(CH2)3CH3 
ICV (μΜ) 
0 48 
0 10 
0 06 
0 10 
0 60 
0 07 
0 15 
0 05 
LD50
b
 (mg/kg) 
0 26 
2 33 
4 7 
29.5 
5 0 
2 33 
8 7 
16 5 
%T, 
117 
156 
386 
151 
141 
216 
184 
164 
" ICS0 is the drug concentration to give 50% inhibition of tumour cell growth. 
b
 LD„ ¡s the lethal drug dose to kill 50% of experimental mice 
c
 %T/C is the effect of treatment divided by that of the control χ 100%. 
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In vivo 
Sparsomycin was adequately tested in vivo against four tumour types Cure of tumour-
bearing animals was not observed In general, multiple dose schedules were more 
effective than single ones [228,364] Sm was active, 166% Treatment/Control 
(%T/C), against lymphocytic leukaemia (P388), but showed borderline activity (131% 
T/C) against lymphoid leukaemia (L1210) It was active against Walker 
carcinosarcoma (219% T/C), but inactive (112% T/C) against B16 melanoma 
The antitumour activity of only a limited number of earlier synthesised analogues 
of Sm was evaluated in vivo [84,86] Although some of these derivatives exhibited 
antitumour activity, superiority to the parent compound was not found The first 
analogue reported to be more active against L1210 cells than Sm was 
octylsparsomycin [204] Subsequently, more active analogues were synthesised [37], 
and presented in Table 2 The increased antitumour activity [37,364] of these 
derivatives as compared with Sm correlates well with their high activity in cell-free 
protein synthesising systems and in the L1210 clonogenic assay as shown in Table 2 
Thus, again the in vitro L1210 assay is of predictive value for the in vivo L1210 
model in the mouse The analogues that were most active in vitro showed also the 
highest activity in vivo (Table 3) The most sensitive tumours were the 
intraperitoneally inoculated RC, L1210 and P388, but minimal activity was found 
against B16 No activity was found against subcutaneously implanted C22LR, M5076, 
C38 and LL The most active compounds are deshydroxy-Sm, ethyldeshydroxy-Sm 
and n-pentyl-Sm There was a considerable loss of activity when L1210 leukaemia was 
implanted subcutaneously while the drugs were administered intravenously Only one 
drug, ethyldeshydroxy-Sm appeared to be active in this assay [364] 
In conclusion, although several Sm analogues show improved antitumour activity 
in comparison with Sm, the overall antitumour activity as single drug, however, is still 
disappointing 
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MODULATION OF ANTITUMOUR ACTIVITY 
Inhibitors of protein biosynthesis can positively modulate the responsiveness of 
malignant cells to classical anticancer drugs [89,153,333] Also for Sm a potentiating 
effect has been observed In vitro, the response of Sm in combination with cisplatin 
was dependent of the treatment schedule, resulting in protection to cisplatin when Sm 
was given before cisplatin, and in potentiation when Sm was given after cisplatin 
[363] 
Sm was found to modulate the cytostatic activity of seven other conventional 
anticancer agents when tested on Chinese hamster ovary (CHO) cells in vitro [366] 
Pre-incubation with Sm antagonised the activity of the following S-phase specific 
agents methotrexate, 5-fluorouracil, cytosine arabinoside and vincristine, whereas 
post-incubation potentiated the activity of these agents Contrariwise, pre-incubation 
with Sm enhanced the activity of non-S-phase specific compounds like cisplatin and 
bleomycin, but not melphalan, while post-incubation was less effective The overall 
effects with doxorubicin were less clear 
Sm showed also interesting synergy with cisplatin in vivo Treatment of 
intraperitoneal inoculated L1210 leukaemia bearing mice with Sm in combination with 
cisplatin cured 66% of the animals while each drug alone showed only minor 
antitumour activity [362] The antitumour activity of cisplatin was also studied when 
the L1210 leukaemia rumour was inoculated subcutaneously, not only in combination 
with Sm, but also with three analogues n-pentyl-sparsomycin, deshydroxy-
sparsomycin and ethyldeshydroxy-sparsomycin Ethyldeshydroxy-sparsomycin (EdSm) 
was clearly superior to the other drugs in potentiating the cisplatin antitumour activity 
[365] Therefore this last combination was studied intensively in the L1210 leukaemia 
tumour model [146] The following treatment conditions were examined drug doses, 
number of tumour cells implanted intraperitoneal^ (I Ρ ), the interval between and 
order ot administration of the two drugs, and the route of drug administration It was 
shown that EdSm significantly enhanced the cisplatin antitumour activity No 
differences were observed when EdSm was given before, together or after cisplatin 
administration However, when the L1210 tumour was more advanced at the start of 
drug treatment the antitumour effect of both EdSm and cisplatin was lost, but the 
effect of this drug combination was less influenced In addition, when one or both 
drugs were given intravenously the synergy of the combination disappeared 
completely Moreover, the degree of synergy in vivo between EdSm and cisplatin 
correlates nicely with the in Miro sensitivity of the tumour cells for EdSm and 
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cisplatin [147,149] These results indicate that this synergy is a function of the cellular 
properties of the target rumour cell population and is less dependent of host factors 
CONCLUSIONS 
Sm analogues seem to be promising agents for combining with other cytostatic drugs 
From the available sparsomycin analogues ethyldeshydroxy-sparsomycin is the drug of 
choice for further preclinical and possible clinical studies 
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CHAPTER 1.2 
OUTLINE OF THE STUDY 
Up to now, the development of active agents against human cancers has relied 
essentially upon the following strategies: (1) random screening of natural and synthetic 
products in experimental tumours; (2) rational development of new compounds based 
on of observed biochemical properties of tumour vs. normal cells; (3) synthesis of 
analogues of known agents, usually in seeking to eliminate an undesirable feature such 
as an unwanted side-effect or to incorporate an advantageous property such as a 
broader spectrum of action or maintenance of activity in resistant tumours; and (4) 
serendipitous observation. In practice, a combination of these approaches is often the 
case. 
Selected chemotherapeutic agents are very often used in combination with other 
drugs for the treatment of cancer. The purpose of using these drugs in combination is 
to achieve therapeutic effects that are more favourable than using a single drug alone. 
The benefits may include increased therapeutic efficacy, decreased toxicity toward the 
host or nontarget tissues, increased selectivity of effect or therapeutic index, and 
minimisation of, or delay in, the development of drug resistance. By virtue of drug 
combination, the multiple-target approach is an effective way to achieve a therapeutic 
end-point in heterogeneous cell populations. 
An understanding of the mechanisms of interaction between agents and an ability 
to measure and quantify such interactions is important because of the influence such 
interactions can have on the success of chemotherapy. A better understanding of the 
mechanisms of drug action and drug resistance can be useful in the design of novel 
individual agents as well as of novel combinations of drugs with potential clinical 
utility. 
The usefulness of Sm as a very potent inhibitor of protein synthesis and as a 
potential anticancer drug has stimulated the synthesis of Sm analogues, some of which 
possess greater opportunities for cancer chemotherapy than the parent compound. Of 
all analogues ethyldeshydroxy-sparsomycin (EdSm) appeared to be clearly superior in 
potentiating the cisplatin antitumour activity. 
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The aim of this study is to determine and to evaluate the potential use of EdSm 
in cancer chemotherapy For this purpose the following questions are studied 
(1) Wfiat is the antitumour activity of EdSm in animal tumour models and human 
tumour xenografts as a single agent? 
(2) What are the effects of EdSm at the cellular level9 
(3) What are the optimum conditions for synergistic antitumour effects for the 
combinations of EdSm with cisplatin and other classic antitumour agents? 
(4) Can we define and quantitatively measure the effect of drug interactions in terms 
of synergism, antagonism, addition, or potentiation7 
In this thesis these questions will be answered as follows 
In chapter 2 the results of the studies concerning the antitumour activity of EdSm in 
different tumour models is summarised With regard to the effects of EdSm at the 
cellular level we measured the intracellular drug concentration and biochemical 
changes Chapter 3 presents and discusses the accumulation dynamics in a parent and 
an EdSm-resistant leukaemia cell line In chapter 4, the effects of EdSm with respect 
to the intracellular detoxification systems of glutathione and glutathione-S transferase 
are described The answer to the third question is discussed in the chapters 5 to 9 
First of all, the results of the use of the combination of EdSm with cisplatin are 
reported in chapter 5, 6 and 7, and subsequently the results with other cytostatic 
agents in chapter 8 and 9 - in chapter 8 for the in vitro situation and in chapter 9 for 
the m vivo situation The answer to the fourth question, concerning quantitative 
measures of drug interaction is formulated in chapter 7 and 8 Finally, the preclinical 
data and clinical results of other inhibitors of the protein synthesis are reviewed in 
chapter 10 
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PART II 
ETHYLDESHYDROXY-SPARSOMYCIN 
Chemical structure of ethyldeshydroxy-sparsomycin (SCRJ 

CHAPTER 2 
ANTITUMOUR ACTIVITY AND RETINOTOXICITY OF 
ETHYLDESHYDROXY-SPARSOMYCIN IN MICE 
HOFS HP, DJTh WAGENER, D DE VOS, HCJ OTTENHEIJM, 
HJ WINKENS, PHM BOVEE, WJ DE GRIP 
The European Journal of Cancer 1995 (in press) 
Conclusion: 
EdSm is active against the L1210 and P388 leukaemia, the B16 melanoma, and 
the renal cell carcinoma RC, but in general this antitumour activity is only 
modest. 

SUMMARY 
The colony formation in agar of human tumour xenografts was used as a test system 
to study the cytostatic activity of ethyldeshydroxy-sparsomycin (EdSm) at the cellular 
level EdSm was additionally studied in vivo in human tumour xenografts and murine 
tumour models The comparison of in vitrolin vivo activity allows an assessment of the 
relevant in vitro dose based on in vivo pharmacological behaviour of the drug EdSm 
showed a clear dose/response effect in vitro At continuous exposure with 0 01 μg/ml 
2 out of 11 of the tumours responded (colony number of the test < 30% of the 
control group) a gastric and a small cell lung carcinoma At 0 1 μg/ml EdSm the 
tumour response was 5/11 tumours and 1 ^g/ml was active in all tumours The 
maximal tolerable doses of EdSm in vivo has been determined in non-tumour bearing 
CDF, mice In the intraperitoneal^ ( I P ) given multiple dose schedules the respective 
LD10 doses indicated that the tolerable cumulative dose increases when lower doses 
are given more frequently This also enhances the antitumour activity in L1210 
leukaemia to 172% T/C On the other hand, continuous infusion diminished the 
tolerable dose as well as the antitumour activity strongly EdSm was also active 
against Ι Ρ inoculated P388 leukaemia (150% T/C), B16 melanoma (156% T/C), and 
RC carcinoma (197% T/C), and the subcutaneously (S С ) inoculated L1210 (139% 
T/C) and RC (138% T/C) Absence of tumour responses was found in the S С 
implanted murine tumours M5076 sarcoma, osteosarcomas C22LR and CP369, and 
the LL carcinoma, as well as in the human tumour xenografts LXFG 529, a non-
small cell lung carcinoma, GXF 251, a gastric carcinoma and FMa, an ovary 
carcinoma Possible long-range retinotoxic effects of EdSm were investigated in 
tumour-bearing mice, cured after surviving treatment with LD50 doses of EdSm by 
assaying the protein biosynthetic capacity of the retina by assaying the ocular 
rhodopsin and opsin levels as parameters In none of these cases a significant 
reduction in either opsin or rhodopsin level could be measured and no changes were 
seen histologically 
INTRODUCTION 
The natural product sparsomycin (NSC-59729) is an antibiotic produced by 
Stieptomvces sparsogenes and Streptomyces cuspidosporus It was discovered in 1962 
by Owen et al [243] and characterised by Argoudehs et al in 1962 [17] Antitumour 
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activity was observed towards P388 leukaemia only [230]. A clinical phase I study 
with sparsomycin was initiated in 1964 by Close et al., using a daily schedule for 10-
14 days [66]. This study was discontinued because two out of five patients reported 
blurred vision, probably caused by degeneration of the retinal pigment epithelium 
[66,213]. 
Despite these disappointing phase I results sparsomycin (Sm) and its derivatives 
have attracted attention for the following reasons. Nowadays the use of high daily 
doses of cytotoxic drugs in phase I studies has been abandoned because of the high 
risk of accumulation and toxicity. Furthermore, intensive histopathological and 
biochemical analysis of animal models failed to show retina toxicity of sparsomycin 
and one analogue, even at repeated toxic doses [229,367]. Moreover, the synthesis of 
suitable analogues might overcome the putative ocular toxicity. Finally, an important 
aspect is that their mode of action differs from classical antitumour agents. These 
sparsomycin compounds are potent inhibitors of protein synthesis by blocking the 
ribosomal peptidyl transferase centre [69,118-120,303,309]. Because of this different 
mode of action Sm and several derivatives were used in combination chemotherapy 
studies and were shown to enhance the antitumour activity of cisplatin [146,362,365]. 
The structure-activity relationship of sparsomycin derivatives has been explored and 
several of them were found to have a therapeutic index broader than that of 
sparsomycin itself. Overall, ethyldeshydroxy-sparsomycin (EdSm) showed the best 
biological activities [38,364,365]. 
Therefore, the antitumour activity and retinotoxicity of EdSm have been studied 
extensively. In this chapter the results are summarised and discussed. 
MATERIAL AND METHODS 
Drugs 
EdSm was synthesised at the department of Organic Chemistry of the University of 
Nijmegen, the Netherlands [38], and was acquired in a lyophilised form. The drug 
was dissolved in phosphate buffered saline (pH 7.4) and stored at 4°C in dark flasks. 
Solutions with the required drug concentration were prepared just before 
administration by dilution with isotonic NaCl 
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Tolerable dose 
The acute toxicity of EdSm has been determined in normal CD2F1 mice The 50% 
and 10% lethal doses (LD50 and LD10, respectively) were determined after 
administration on various routes and schedules There were 5 dose levels and 6 mice 
for each dose For continuous administration of EdSm to normal and tumour-bearing 
mice, we used Alzet osmotic minipumps 1003 D and 1007 D (Alza, Palo Alto, CA, 
USA) The 1003 D minipump has a volume of 100 μΐ and a flow capacity of 1 06 + 
0 05 μΐ/h continuously over 3 days The 1007 D minipump also has a volume of 100 
μΐ, but a flow capacity of 0 5 μΐ/h continuously over 7 days These minipumps were 
filled with an EdSm solution in isotonic NaCl Pumps were implanted intraperitoneally 
or subcutaneously under ether anaesthesia We used 3 mice per dose level 
In vitro xenografts 
Experiments with human tumours xenografts were performed by Dr H H Fiebig, 
Department of Internal Medicine, Division of Haematology-Oncology, University of 
Freiburg, D-7800 Freiburg, Germany Human tumours, established in serial passage 
in nude mice, as described by Fiebig [95], were used A single-cell suspension of the 
solid human tumours was obtained by mechanical disaggregation with scissors and 
subsequent incubation with enzymes, as described by Fiebig [96] The two-layer soft-
agar culture system introduced by Hamburger and Salmon [132] was modified as 
described by Fiebig [95] In the colony assay EdSm was applied by continuous 
exposure until the end of the experiment Three dose levels were studied in triplicate 
and in each experiment six untreated cultures were used as controls 5-Fluorouracil 
(100 μg/ml, continuous exposure) was added as a positive reference drug A 
compound was considered active if it reduced colony formation to 30% or less of the 
control value 
Antitumour activity 
Three human tumours were used to study the antitumour activity of EdSm in vivo a 
non-small cell lung carcinoma (LXFG 529), a gastric carcinoma (GXF 251), both 
tested by Dr H H Fiebig, and an ovary carcinoma (FMa), tested by Dr E Boven 
(Free University Hospital Amsterdam, The Netherlands) The murine leukaemia 
tumours P388 and L1210 and the solid tumours B16 melanoma and RC renal cell 
carcinoma were obtained from G Atassi, Brussels They were passaged and 
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maintained in animals as recommended by the NCI The experiments with the 
osteosarcomas C22LR and LL, the Lewis Lung carcinoma and M5076 sarcoma were 
performed at the Radiobiological Institute TNO in Rijswijk as reported by Zylicz 
[364] The osteosarcoma CP368 was tested at CIVO-TNO, Zeist, The Netherlands, by 
Dr Ρ Lelieveld In the treatment of subcutaneously growing human and murine 
tumours EdSm was administered to tumour bearing animals, with tumour sizes 
between 25 and 50 mm1, at dose levels of 5 and 10 mg/kg on days 1, 5 and 9 
Animals were randomised before treatment 
Studies on retinotoxic effects 
CD2F1 mice were obtained from Charles River Breeding Laboratories, Ine Male 
mice weighing between 18 and 22 g were inoculated intraperitoneally with IO1 L1210 
cells Acceptable median control survival times range from 8-11 days for the L1210 
I Ρ tumour EdSm and cisplatin were administered at various doses I Ρ on days 1, 5 
and 9 after tumour implantation Eye toxicity was investigated in tumour-bearing 
animals which were recorded as cures after drug treatment [147] 
Rhodopsin assay. Animals were dark-adapted for 24 hours to ensure maximal 
regeneration of rod visual pigment (opsin to rhodopsin) All procedures were carried 
out in dim red light ( > 610 nm) After pentobarbital anaesthesia the eyes were 
extirpated, placed in light-tight containers and directly frozen at -80°C The animals 
were sacrificed afterwards Extraction and assay of rhodopsin have been described 
before [125] Rhodopsin was measured by difference spectroscopy and the rhodopsin 
concentration was calculated from the difference in absorbance at 500 nm before and 
aller illumination, using a molar absorbance coefficient of 403000 
Opsin assay. For quantitative determination of opsin the earlier described enzyme-
linked immunosorbent assay (ELISA) was used [284,285] 
Histopathology. Eyes were fixed in Bouin solution and embedded in paraffin 
according to standard procedures [356] Sections of 5 μιτι were stained with 
haematoxylin and eosin, and subsequently analyzed microscopically 
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TABLE 1: In vitro effect of Ed Sm on 11 human tumour cells derived from xenografts in nude 
mice expressed as the number of responses/the number tested Tumours are considered to be 
responsne if the colony count is <30% of the control at continuous exposure 
TUMOUR* 
DRUG CONCENTRATION ^g/ml) 
PASSAGE no 0 01 0 1 1 
CXF 609 
GXF251 
GXF97 
LXFA 526 
LXFG 529 
LXFK 605 
LXFK 650 
LXFL 1029 
MAXF 401 
TXF 423 
XF299 
8 
15 
23 
15 
6 
10 
12 
4 
12 
11 
15 
+ + 
+ + 
-
+ + + 
+ 
+ + 
+ + 
-
+ + + 
-
+ + 
-
+ 
+ + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
+ + + 
sensitive** 2/11 6/11 11/11 
* CXF, Colon Cancer Xenograft, GXF, Gastric, LXF, Lung A adeno, G large cell, К small cell, 
MAXF, Mammary, TXF, Testicular, XF miscellaneous Cancer Xenograft 
** sensitive = + + and + + + TIC > 50% = , 30% < TIC < 50% = +, 10% < TIC < 
30% = + + , TIC < 10% = + + + 
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RESULTS 
Cytostatic activity of EdSm was studied in 11 human tumour xenografts in vitro in 
dosages ranging from 0.01 ^g/ml to 1.0 μg/ml (0.0278 to 2.78 μΜ) given by 
continuous exposure (Table 1). A clear dose/response relationship was found. At the 
dose of 0.01 /¿g/ml 2 out of 11 human tumours (18%) were sensitive, at 0.1 μg/ml 
this was 45% and at 1.0 μg/ml all tumours responded, suggesting that if an EdSm 
concentration of about 2.8 μΜ can be maintained at the cellular rumour level over a 
longer period in vivo, this rumour should respond positively to EdSm treatment. 
TABLE 2: Tolerable doses of EdSm m mice after administration on various schedules 
Schedule3 
S D 
Dl,5,9 
Dl-9f 
C.I 
S D 
Dl-7f 
Route 
I P . 
I P . 
I P . 
I.P. 
I.V. 
I.V. 
LD10b 
24.9 
37.2 
54.0 
2.96 
48.8 
48.3 
LD50C 
30.0 
44.1 
72 0 
4.48 
57.7 
m
d 
11.8 
13 0 
5 3 
13.1 
Re 
0.959 
0.993 
0.998 
0.995 
"SD, single dose, Dl,5,9, treatment on day 1, 5 and 9, Dl-7 and Dl-9, daily treatment for 7 or 
9 days, respectively, С i , continuous infusion during 3 days, using osmotic minipumps (1003D), 
I Ρ , intraperitoneal, I V., intravenous 
"LD10, cumulative doses in mg/kg that results in ¡0% lethality 
'LD50, cumulative doses in mg/kg that results in 50% lethality 
d
 m, the coefficient signifying the shape of the dose-effect curve for the agent used. 
' R, the linear correlation coefficient of the dose-effect curves 
'Results presented by Zylicz et al., 1988 [364] 
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Before delermining the antitumour activity of EdSm in different animal tumour 
models, the acute toxicity in normal CD2F1 mice was investigated. The 50% and 10% 
lethal doses (LD50 and LD10, respectively) were determined after I.P. EdSm 
administration on various schedules and is summarised in Table 2. For single dose 
treatment the I.V. route was more tolerable than the LP. route (LD10 of 48.8 and 
24.9 mg/kg, respectively). This preference disappeared upon daily administration. 
Additionally, these data indicate that EdSm is better tolerated when it is given more 
frequently at lower doses. Daily I.P. administration for 9 days results in a LD10 of 54 
mg/kg, although the opposite effect is obtained when EdSm is given at continuous 
infusion, resulting in a LD10 dose of 2.96 mg/kg over three days. 
Based on these LD10 values the antitumour activity of EdSm was determined in 
animal tumour models. As presented in Table 3, all LP. inoculated murine tumours 
(L1210, P388, B16 and RC) responded positively to daily LP. EdSm administration 
(%T/C > 135%). The L1210 model was used to investigate the effect of different 
treatment schedules. When EdSm was given in three doses (Dl,5,9), the anti-L1210 
tumour activity was still comparable with that observed upon daily administration 
(158% and 172%, respectively). However, continuous infusion LP. during 3 or 7 days 
lowered the activity to 130 and 120%, respectively. Moreover, when these minipumps 
were placed S.C. no effect was seen at all, even when the EdSm dose was increased 
from 1 to 2 mg/kg. From the S.C. implanted tumours acceptable results (T/C > 
135%) were only obtained with L1210 and RC. No significant antitumour response 
was measured in the M5076, C22LR, CP369 and LL tumour models. The two, for 
EdSm in vitro most sensitive human tumour xenografts in vitro, the large cell lung 
cancer LXFG 529 and the gastric carcinoma GXF 251, as well as the ovary carcinoma 
FMa were tested in vivo. EdSm at a dose of 5 or 10 mg/kg, given LP. on days 1,5 
(LXFG 529) or 1,5,9 (GXF 251 and FMa), did not exert any antineoplastic effect in 
any of these tumours. 
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TABLE 3: Summary of the апшитоиг actnity of EdSm m eight murine tumours and three 
human tumour xenografts in vivo 
TUMOUR 
L1210 
L1210 
L1210 
L1210 
L1210 
L1210 
L1210 
P388 
B16 
RC 
RC 
M5076 
C22LR 
CP369 
LL 
LXFK 529 
GXF 251 
FMa 
SITE3 
Ι Ρ 
Ι Ρ 
Ι Ρ 
Ι Ρ 
I P 
Ι Ρ 
s с 
Ι Ρ 
Ι Ρ 
Ι Ρ 
s с 
s с 
s с 
s с 
s с 
sc 
s с 
sc 
SCHEDULE 
Dl-9 
Dl,5,9 
CI Dl-3 
CI Dl-3 
CI Dl-7 
CI Dl-7 
Dl-7 
Dl-9 
Dl-7 
Dl-9 
Dl-7 
Dl-9 
D2-10 
Dl,5,9 
Dl,5,9 
Dl,5 
Dl,5,9 
Dl,5,9 
ROUTE 
Ι Ρ 
Ι Ρ 
Ι Ρ 
S C 
Ι Ρ 
sc 
I ν 
Ι Ρ 
Ι Ρ 
Ι Ρ 
I ν 
Ι Ρ 
Ι Ρ 
Ι Ρ 
Ι Ρ 
Ι Ρ 
Ι Ρ 
Ι Ρ 
DOSE" 
55 
15 
1 
2 
2 
2 
48 
55 
35 
37 
42 
55 
55 
15 
22 5 
20 
30 
30 
RESPONSE' 
172 
158 
130 
100 
120 
100 
139 
150 
156 
197 
138 
100 
100 
100 
100 
100 
100 
100 
REF 
[364] 
[146] 
[364] 
[364] 
[29] 
[364] 
[364] 
[364] 
[364] 
[364] 
For explanations see also Table 2 "SC subcutaneously ь Cumularne dose in mg/kg ' Median 
sur\i\al tune in % of treated over control (%T/C) 
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TABLE 4: Rhodopsin and opsin concentrations in eyes of CD2F1 mice, 6-8 months of age, 
which were alive and tumour free 100 days after combined treatment with asplatin and EdSm in 
the L1210 tumour model 
TREATMENT 
GROUP I 
GROUP II 
GROUP III 
GROUP IV 
GROUP V 
CONTROL 
% SURVIVORS 
33 
67 
60 
67 
67 
*RHODOPSIN/EYE 
0.64 ± 0.05 
0 66 + 0.03 
0 67 + 0.04 
0 66 + 0.02 
0 63 ± 0.05 
0 71 ± 0.07 
**OPSIN/EYE 
0.65 ± 0.06 
0.65 ± 0.03 
0.68 + 0 02 
0 68 ± 0 06 
0 61 ± 0.07 
* Spectroscopy, η = 4 ± SD 
** ELISA, η = 4 ± SD 
Group I = asplatin 4 mg/kg, II = asplatin 4 mg/kg and EdSm 10 mg/kg, III = cisplatin 3 mg/kg 
and EdSm 5 mg/kg, TV = asplatin 3 mg/kg and EdSm 10 mg/kg, V = asplatin 3 mg/kg and Sm 
1 5 mg/kg [147,362] 
@ Mice from all these groups were histologically checked for degeneration of the neural retina 
and retina pigment epithelium 
Retinopathy 
Toxic effects of EdSm on the protein biosynthetic capacity of the retina were assessed 
by assaying the rhodopsin and opsin levels in tumour-bearing mice, cured after 
treatment with doses of EdSm, which were toxic for normal animals (LD50). The 
photoreceptor cell-RPE (retinal pigment epithelium) complex accomplish as a high 
turnover rate of visual pigment (ca 10% per day) and in order to maintain a constant 
level the photoreceptor cell has a high biosynthetic capacity for the protein opsin (5-10 
pmol/106 cells per day) [341]. Perturbations like inhibition of this process will 
therefore rapidly lead to a reduction in ocular opsin content, and may eventually 
effectuate a nearly complete loss in visual pigment protein. For conversion of the 
apoprotein opsin into the photoactive pigment rhodopsin, the photoreceptor cell relies 
on the production of the required chromophore, 11-eis retinal, by the enzymatic 
machinery of the retinal pigment epithelium [311]. Selective inhibition of this process 
could result in impaired ocular opsin levels and reduced rhodopsin levels. In order to 
incorporate possible additive effects due to tumour- and other disease-related 
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pathogenicity, the toxicity of EdSm was investigated in tumour-bearing mice which 
survived on relative high doses of EdSm or Sm, in combination with cisplatin, which 
at high doses also can cause retinotoxicity [348]. In none of these cases a significant 
reduction in either opsin or rhodopsin level could be measured (Table 4). None of the 
eyes of mice treated with cisplatin and EdSm showed histological changes (Fig. 1). 
FIGURE 1: An example of the retinal pigment epithelium of mice of group II from Table 4, Eyes 
were fixed in Bouin solution and embedded in paraffin according to standard procedures. Sections 
of 5 μm were stained with haematoxylin and eosin, and subsequently analyzed microscopically. 
Sclera, SC; choroid, CH; retinal pigment epithelium, RPE; rod outer and inner segment layers, 
ROS and RIS; outer nuclear layer, ONL; outer plexiform layer, OPL; Inner nuclear layer, IPL; 
inner plexiform layer, IPL; ganglion cell layer, GC. 
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DISCUSSION 
The toxicity of sparsomycin analogues in mice is related to their lipophilicity and 
decreases with increasing lipophilic character [38] Therefore EdSm could be 
administered at much higher doses than Sm, e g 8 mg/kg I Ρ for EdSm compared to 
0 26 mg/kg I Ρ for Sm for the schedule Dl-9 
Osmotic minipumps have been very useful to study the effects of continuous drug 
treatment [30,138,229,277,302] Chronic administration of EdSm using 100 μΐ 
osmotic minipumps over 3 days turned out to be less tolerable (LD10 = 2 96 mg/kg) 
and less therapeutic than repeated bolus injections Thus, the therapeutic window of 
chronic EdSm treatment seems to be low 
Previous studies have demonstrated that exposure of Chinese hamster fibroblast 
cells to sparsomycin for 1 h inhibits over 99% of their protein synthetic capacity, but 
is lethal for only 25% of these cells This appeared to be due to the fact that after 
removal of the drug the cells recovered their protein synthesising ability This 
reversibility disappeared after longer periods of incubation [68] Similarly, chronic 
EdSm treatment might cause an irreversible protein unbalance due to permanent 
inhibition of protein synthesis, which would enhance its toxicity to normal tissues 
When lower doses are given at frequent intervals the cumulative tolerable dose for 
EdSm increases and the antitumour response is improved Under those conditions, 
acceptable antitumour activity for EdSm (%T/C > 135%) is obtained when the tumour 
site as well as the drug treatment is I P , as well as in two models which S С 
implanted rumours (L1210 and RC) when EdSm was given I V (139 and 138% T/C 
respectively) In those models where the tumour was implanted S С and drug 
treatment was I Ρ no antitumour activity of EdSm was noticed It is not clear yet 
whether this is due to the treatment schedule (Dl,5,9 instead of Dl-9) or mainly to 
1 Ρ instead of I V administration The strongest antitumour responses were obtained 
upon daily EdSm administration, I Ρ when the tumour was implanted I Ρ and I V 
when the tumour was implanted S С Thus, we conclude that future studies on EdSm 
in animal tumour models should implement I Ρ administration for I Ρ tumours and 
I V administrations for S С tumours 
Under the auspices of the National Cancer Institute (Bethesda, MD) additional 
toxicological studies in rats and monkeys have been performed [149] Retinotoxicity 
was assessed by electroretinography (ERG) and eye histology Abnormal 
electroretinograms were only observed in moribund rats, probably due to their poor 
general condition No ERG changes were seen in monkeys Histopathological changes 
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were not detected in any animal If sparsomycin should penetrate the retina, its toxic 
effect should be seen as inhibition of proteins which are vital for the visual function 
Sparsomycin inhibits protein synthesis in a cell free system prepared from 
reticulocytes, giving 50% inhibition at 0 1 μg/ml (= 0 29 μΜ), but not in intact 
reticulocytes at concentrations as high as 0 25 M for a period of 10 mm This 
indicates that the plasma membrane of reticulocytes is rather impermeable for 
sparsomycin The same reticulocytes were permeable for structurally related 
antibiotics like cycloheximide, and streptovitacin A Furthermore, treatment or healthy 
albino rats and Royal College of Surgeon (RCS) rats with subtoxic doses of 
sparsomycin was unable to produce ocular toxic effects [367] Disruption of the blood-
retina barrier with sodium iodate allowed Sm to reduce the opsin content only 
moderately, suggesting that sparsomycin might become retinotoxic solely upon 
extreme conditions such as permeabilisation of the blood-retina barrier On the basis 
of these studies, the sparsomycin-related retinopathy is suggestive of a poor general 
condition and possibly of inappropriate drug schedules Earlier we reported that 
administration of maximally tolerable doses of Sm to rats did neither lead to short-
term effects on opsin biosynthesis and rhodopsin regeneration, nor on retinal 
morphology [367] Since the ancient reports on retinal toxicity of Sm preparations 
concern late-stage patients, to a large degree in cachectic condition [66,213], these 
analyses were extended to tumour-bearing mice and included the more lipophilic Sm 
derivative EdSm, which will more easily cross the blood-retina barrier These novel 
observations are fully in line with our previous results No shred of evidence was 
found for any retinotoxic action of Sm or EdSm, neither on a supracellular level 
(retinal morphology) nor on a subcellular level (protein biosynthesis, intracellular and 
intercellular transport) These results suggest that enantio-pure sparsomycin derivatives 
are not retinotoxic and that these earlier reports may be attributed to the use of impure 
samples 
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CHAPTER 3 
CELLULAR PHARMACOKINETICS OF ETHYLDESHYDROXY-
SPARSOMYCIN IN SENSITIVE AND RESISTANT TUMOUR 
CELLS 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, D TELTING, H 
VAN RENNES, HCJ OTTENHEIJM, WJ DE GRIP 
Submitted for publication in Cancer Chemotherapy and Pharmacology 
Conclusions: 
The uptake of EdSm by LI 210 cells is a dose, time and temperature dependent 
process. 
EdSm enters LI 210 tumour cells at a very poor rate. Resistance to EdSm can be 
partly explained by a decreased drug influx. 

SUMMARY 
Ethyldeshydroxy-sparsomycin (EdSm) is a strong inhibitor of nbosomal protein 
synthesis, which has interesting modulating capabilities in preclinical combination 
chemotherapy of cancer In order to measure the intracellular EdSm concentration we 
developed an extraction method in combination with a sensitive high-performance 
liquid chromatographic (HPLC) technique EdSm uptake was studied in an EdSm 
resistant and in the parent non-resistant L1210 leukaemia cell line The results show a 
dose, time and temperature dependent EdSm uptake, which is a linear process during 
the first 15 minutes, resulting in a maximum rate (Vmai) of 0 156 and 0 100 
pmol/min/106 in sensitive and in resistant cells, respectively Thereafter, drug 
accumulation continues very slowly, but does not reach an equilibrium in either cell 
type The decreased EdSm accumulation in resistant cells appears not to be caused by 
an increased efflux, the efflux rates of both cell lines are comparable The difference 
in cytotoxicity of EdSm in both cell lines cannot completely be explained by cellular 
pharmacokinetics Therefore, our results suggest that, although resistant cells show a 
decreased EdSm uptake, other mechanisms are involved in resistance to EdSm as well 
INTRODUCTION 
Sparsomycin (Sm) is a sulphur-containing antibiotic which has been isolated from the 
culture filtrate of Streptomyces sparsogenus [17] Sm (NCS-59729) is a potent 
inhibitor of the growth of many organisms and was subsequently found to be active 
against tumour cells in culture as well as in animal tumour models [243,310] Sm 
treatment leads to the disaggregation of polyribosomes into monomers that still contain 
peptides (fall off nbosomes) [136] Recently, Theochans and Coutsogeorgopoulos 
[309] have described the kinetics of Sm interaction at the level of the ribosome A 
nbosome that has accepted an Sm molecule readjusts its binding site and binds Sm 
more efficiently The stabilising effect on the de novo binding of substrates at the 
peptidyl site appears to be an indirect effect of Sm, due to a slow equilibration 
reaction In addition, it was shown that Sm does not covalently bind to the nbosomes, 
which has also been described by Lázaro et al [193] 
Ever since it has become possible to synthesise Sm in the laboratory 
[137,158,239], many Sm derivatives have been synthesised, of which only a few have 
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shown enhanced antitumour activity [241-242] Replacing the S-methyl group by 
larger alkylthio groups increased their hydrophobicity as well as their antitumour 
activity [38,191,204,309,364] These results correlated well with their high activity in 
inhibiting cell-free protein synthesis and in the cellular toxicity in the L1210 
donogenic assay Thus, the in vitro L1210 assay is of predictive value for the in vivo 
L1210 model in the mouse for sparsomycin compounds Of all the derivatives tested 
ethyldeshydroxy-sparsomycin (EdSm) was superior in potentiating cisplatin antitumour 
activity [365] The degree of synergy in vivo between EdSm and cisplatin correlates 
nicely with the in vitro sensitivity of the tumour cells for EdSm and cisplatin 
[146,147,149] These results indicate that this synergy is a function of the cellular 
properties of the target tumour cell population and is less dependent on host factors 
EdSm must traverse the plasma membrane of a cell to explore its cytotoxicity 
Resistance to EdSm might therefore be caused by a reduced cellular accumulation 
Indeed, it has been shown that a decrease in uptake of sparsomycin analogues in E 
coli and HeLa cells caused a loss of activity [19] Also, reticulocytes were shown to 
be resistant to Sm because of their impermeability, although these same reticulocytes 
were permeable for structurally related antibiotics like cycloheximide and 
streptovitacin A [68] In this context, insight in the accumulation dynamics and the 
plasma membrane transport mechanism of EdSm will be of help to understand the 
ditlerence between tumour cells in sensitivity for sparsomycin compounds This could 
provide important directions for chemical modifications of these drugs in the future 
As a first contribution in this direction, the uptake and efflux kinetics of EdSm are 
reported for a control and an EdSm resistant cell line 
MATERIALS AND METHODS 
Tumour cells 
The murine L1210 leukaemia tumour (L1210-WT) was kindly supplied by Dr G 
Atassi (Inst Jules Bordet, Lab for Experimental Chemotherapy, Brussels, Belgium) 
From this tumour we developed a sparsomycin resistant subclone by repeated in vivo 
treatment with increasing doses of deshydroxy-sparsomycin (L1210 Sm) This 
subclone is stably resistant for up to 6 months in a drug-free medium Culture 
methods for murine L1210 leukaemia cells have been described earlier [146] 
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FIGURE 1: Cytotoxicity of EdSm in a sensitive (LÌ210-WT 9) and an EdSrn resistant (L1210-
Sm O) cell ¡me after 1 hour exposure Cytotoxicity was measured using a sofl-agar clonogemc 
assay 
Cytotoxicity 
Exponentially growing L1210 leukaemia cells were treated for one hour at 37°C with 
concentrations of EdSm ranging between 0.01 and 100 μΜ After drug treatment, the 
leukaemia cells were washed with PBS and counted (Coulter counter). The clonogenic 
ability was evaluated by a soft-agar colony assay. Leukaemia colonies were grown by 
plating the cells in 0.3% agar in 6-wells plates (Costar) in a drug-free medium. After 
8 days of incubation, the colonies (>50 cells) were scored using an inverted 
microscope. The surviving fraction was calculated by dividing the absolute survival of 
the treated sample by the absolute survival of the control sample at the same time. 
Each experimental point was determined in duplicate and all experiments were 
repeated twice. 
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Drugs 
EdSm was synthesised at the department of Organic Chemistry of the University of 
Nijmegen, the Netherlands [38], and was acquired in a lyophilised form. Solutions 
with the required EdSm concentration for cell treatment were prepared by diluting 
them with phosphate buffered saline (PBS, pH 7.4) just before administration. 
Drug treatment 
Exponentially growing rumour cells were treated at a cell density of lxlO6 cells/ml. In 
uptake studies, EdSm was added in concentrations of 1, 10, 30, 100 or 300 μΜ for 
time periods from 1 min. to four hours at 37°C. After drug treatment, the tumour 
cells were washed with ice-cold PBS and centrifuged at 4°C for ten minutes at 150xg. 
This step was repeated three times. Thereafter, the cell numbers of the samples were 
determined using a haemocytometer in combination with the trypan blue exclusion 
assay to check for cell viability. All experiments were performed in triplicate. Drug 
efflux was measured after incubating cells with 100 μΜ EdSm for 60 min at 37°C. 
The cells were then washed, as described above, and reincubated at 37°C. Thereafter, 
the cells were harvested at designated times and frozen immediately at -70°C. Samples 
from several experiments were collected (after each experiment) and stored for a long 
period of time so that as many samples as possible could be analyzed at the same 
time. In order to use these samples we had to be certain that EdSm was stable during 
that period and in that temperature. Standard solutions of EdSm of different concentra­
tions were therefore stored at -70°, -20°, 4° and 20°C. Stability and recovery were 
analyzed for a storage period from 1 to 26 weeks, with concentrations ranging from 
25 ng/ml to 5000 ng/ml. EdSm remained stable in cellular extracts for storage periods 
of up to 26 months (97.4% ± 1.2, η = 15), as long as these samples were kept in the 
dark at or below 4°C. 
Extraction method 
EdSm is inactivated by light; all samples were therefore protected from light during 
extraction and analysis. Because analysis of cellular extracts requires wash steps to 
remove extracellular material, the loss of EdSm was examined after each wash step. 
All wash steps were performed at 0°C in order to decrease cellular efflux by 
inhibition of cellular metabolism [77]. Two wash steps were sufficient to remove 
extracellular EdSm Non-specific surface adsorption of EdSm was estimated by 
measuring binding at 0°C following exposure of cells to 100 μΜ for time periods of 
up to four hours In this report the amount of drug accumulation is defined as the total 
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cellular content of EdSm extracted after three washes at the end of the exposure 
period. Before further analysis, the tumour cells were sonified and deproteinized with 
8 M perchloride acid. For an optimal recovery of EdSm from cellular material an 
extraction of 30 minutes was required. This extract was centrifuged at 3000 rpm for 
two minutes (lOOOxg) after which the supernatant was ready for EdSm assay. 
High-performance liquid chromatography 
To quantify the EdSm in extracted cell samples, a semi-automatic high-performance 
liquid chromatography (HPLC) system (Kratos Analytical, Ramsey, N.J., USA) was 
utilised. EdSm concentrations were determined by a two-column HPLC backflush 
method, as described before [345]. By using a concentration column, the samples 
could be concentrated and cleaned from interfering peaks. The chromatographic 
equipment consisted of a double head solvent pump (Orlita, DHP 1515, Bakker & 
Co., Zwijndrecht, The Netherlands) for solvent A and solvent B. The concentration 
column (5 cm χ 3.0 mm I.D.) was filled with LiChrosorb RP-8, 10 μιτι; the analytical 
column (15 χ 4.6 mm I.D.) was packed with reversed-phase material Cp'm Spher C8, 
spherical particle size 8 μιτι. A spectrophotometric detector was used at a wavelength 
of 302 nm (Spectroflow monitor SF 770 + UV monochromator GM 770, Schoeffel, 
The Netherlands). Solvent A, demineralised water, was flushed via the injection loop 
through the concentration column with a flow-rate of 2 ml/minute. After 4.5 minutes, 
the concentration column was flushed back with solvent B, methanol-demineralised 
water (40:60), onto the analytical column with a flow-rate of 1.3-1.5 ml/minute. 
Calibration with standard EdSm concentrations was performed before every HPLC 
analysis. Data points in uptake and efflux figures represent mean values for 2-4 
experiments, measured in duplicate, using 20 χ IO6 cells. 
RESULTS 
Cytotoxicity 
Figure 1 shows the effect of EdSm exposure in both tumour cell lines. Obviously, 
there is a large contrast between the cell lines: an one hour drug treatment causes 80% 
cytotoxicity in the L1210 sensitive line. The cytotoxic effect of EdSm in the resistant 
clone is minimal (10%) and is not enlarged with higher drug concentrations. 
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FIGURE 2: Influence of absolute cell number on the recovery of the sparsomycm extraction 
Recovery 
Although the recovery of EdSm from cellular material was validated with respect to 
the removal of extracellular drug molecules and the duration of acid extraction, the 
recovery may still have been influenced by the number of tumour cells in each 
sample. Therefore, an experiment was performed to extract EdSm from the same 
experimental sample, but starting with a different number of cells. L1210-WT cells 
were incubated for 120 minutes at 37°C with 100 μΜ EdSm. After centnfugation, 
washing and resuspension of the pellet to a cell concentration of 30x106 per ml, 
duplicate samples were taken containing 5-30 χ IO6 cells per ml. The outcome of this 
recovery experiment is illustrated in Figure 2 and shows that the recovery of EdSm 
does not depend on the amount of tumour cells (R = 0.9977). 
Cellular dynamics 
Figure 3 represents the accumulation of EdSm in L1210-WT cells. These experiments 
show that the uptake of EdSm is dose- and time-dependent. A rapid influx is observed. 
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At an extracellular concentration of 100 μΜ, the drug uptake is linear during the first 
15 minutes, resulting in an uptake of 6 pmol/106 cells. 
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FIGURE 3: Uptake of EdSm by L1210-WT leukaemia cells in time at 37°C, using different drug 
doses Possible "background" due to surface binding was determined from the cell-associated drug 
levels after exposure to 100 μΜ EdSm at 0°C, and appears to be negligible 
Thereafter drug accumulation continues, but at a very slow rate resulting in a maximal 
level of 8.1 pmol/106 cells after four hours. The initial uptake rate in the resistant cell 
line is quite similar (Fig. 4), but the late rate of EdSm uptake is even slower, resulting 
in a maximum drug uptake of less than 75% of the parental cell line (Fig 4). Non­
specific surface adsorption of EdSm is estimated by measuring binding at 0°C 
following exposure of cells to 100 μΜ. Because this adsorbed drug (< 0.25 pmol/lO6 
cells) is negligible with respect to the amount of transported drug, no correction is 
applied. 
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FIGURE 4: Uptake of EdSm by LI210 leukaemia cells resistant to EdSm (L12]0-Sm) 
With the use of a Lineweaver-Burk plot of our data, a V
mix and K^ , could be calculated 
for the one hour drug exposure period (Table 1). The parent and resistant cell lines 
show a difference in the V
max
· 0 156 and 0 100, respectively, but not in the K
m
 25 0 
and 24 4, respectively The measuring of drug accumulation, using variable drug 
doses at specific time points, can give an impression of the type of membrane 
transport mechanism which that specific drug has EdSm uptake is a concentration 
dependent mechanism with a saturation behaviour 
46 
TABLE 1: On basis of a Lineweaver-Burk plot a V^ and Km could be calculated for the uptake 
ofEdSm in LÌ210-WT and L1210-Sm. The following result is based on the amount of intracellular 
EdSm molecules after a 60 minutes exposure period 
L1210-WT L1210-Sm 
Vm„ 0.156 0.100 pmol/106/min 
Kra 25 0 24.4 μΜ 
R .9989 9858 
Drug efflux 
The kinetics of drug efflux from the cell, i.e. so-called washout kinetics, are shown in 
Fig. 5 and reveal that the EdSm efflux has a fast initial phase (50% within the first hour) 
and then slows down. The washout kinetics of both cell lines were identical. 
DISCUSSION 
This chapter describes the cellular pharmacokinetics of EdSm in murine leukaemia 
cells in culture. The aspect of membrane transport plays a central role in studies on 
the biological effects of antitumour agents. Membrane transport determines the rate of 
drug entry and exit from cells and the drug concentration at the intracellular target. 
The most common form of multidrug-resistance (MDR) involves hyperexpression of 
the ATP-driven P-glycoprotein efflux pump leading to reduced cellular drug 
accumulation. Because the sensitive and resistant leukaemia cells used in this study are 
comparable with regard to their population doubling time, cell size, amount of protein 
and glutathione level, and because no P-glycoprotein expression was found [150], it is 
possible that resistance to EdSm is caused by differences in the plasma membrane 
transport facilities. Resistance, caused by decreased accumulation which is not related 
to P-glycoprotein expression, has been shown for other antitumour drugs such as 
cisplatin [13] and methotrexate [113]. In a number of tumour cell lines a combination 
of reduced uptake and increased efflux has been shown to be the limiting factor for 
cytotoxicity. In general, resistance to cisplatin is caused by a decrease in cellular 
membrane permeability and drug accumulation [152,186]. 
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FIGURE 5: Efflux of EdSm from L1210 leukaemia cells LJ2J0 WT, R = 0 9637 (squares). 
L1210 Sm, R = 0 9860 (circles) Cells were premcubated with 100 μΜ EdSm for I h at 37°C, 
washed with ice-cold PBS and resuspended ¡n drug free medium of 37°C for selected times 
Points are means of two experiments 
The results show that the accumulation of EdSm over a four hours period in the 
resistant line is only 50-75% of that in the sensitive line, for all drug doses tested On 
the other hand, the efflux is fast but does not vary between the two cell lines Despite 
these differences in drug accumulation the EdSm resistance cannot be explained solely 
on the basis of drug accumulation Considering the drug accumulation in both tumours 
after 10 μΜ exposure, it is obvious that there is only a small difference in uptake, but 
a large difference in cytotoxic effect Hence, resistance to EdSm can only be partly 
due to a decrease in cellular drug accumulation An additional mechanism might 
function at the molecular level of nbosomal binding In conclusion, EdSm enters 
tumour cells at a very poor rate, which is even poorer in resistant cells, while the 
efflux is similar in both cell types Furthermore, our data suggest that other 
mechanisms may be operative as well 
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Because the plasma membrane is the first barrier in cultured tumour cells, this 
should be the crucial criterion for selecting active cytostatic agents Only agents which 
can penetrate rumour cells in sufficient amounts during short exposure times, e g one 
hour or less, will be able to create an effective antitumour response in man In the 
design of chemotherapeutic agents and other drugs, consideration must be given to the 
rale and the mode of permeation of these agents across the plasma membranes of 
various cells Secondly, if the intracellular target is known, additional measurements at 
the target level will provide valuable information about the efficacy of the drug after 
cellular penetration [37] This information will be of potential use as a basis for 
changing the molecular structure of the agent to promote a more rapid entry and 
higher steady-state concentrations in target cells in preference over non-target cells 
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Conclusion 
The synergistic combination of EdSm and cisplatin might be explained b\ switching 
off the cellular detoxification mechanism for cisplatin by EdSm, ι e by inhibition 
of de novo synthesis and subsequently depletion of GSH and GST 

SUMMARY 
Ethyldeshydroxy-sparsomycin (EdSm) is a nbosomal protein synthesis inhibitor which 
synergistically enhances the antitumour activity of cisplatin against L1210 leukaemia in 
vivo Because cellular glutathione (GSH) and glutathione S-transferases (GST) are 
reported to interfere with the antitumour activity of cisplatin, we analyzed the effect of 
EdSm and cisplatin on GSH and GST activity in selected tumour cells For this 
purpose three murine leukaemia tumours were used with different sensitivities towards 
EdSm and cisplatin L1210-WT, sensitive to both drugs, L1210-Sm, resistant to 
EdSm, and L1210-CDDP, resistant to cisplatin No significant differences were 
detectable between these three cell lines regarding the population doubling time, the 
cell size, and the cellular level of protein and glutathione Neither of the resistant 
L1210-subclones showed P-gp expression Drug exposure, however, changed the 
intracellular dynamics Exposure to EdSm strongly decreased the amount of cellular 
protein, decreased the overall GST activity, and led to GSH depletion, whereas 
exposure to cisplatin induced a rise in the amount of protein, in GSH, and in the total 
GST activity These effects are dose-dependent and correlate well with the sensitivity 
of the rumour cells for EdSm or cisplatin In addition, exposure to EdSm lowered the 
V
m
„ of GST in L1210-WT and L1210-Sm, however, in L1210-CDDP both the V
m
„ 
and the K
m
 were increased That this was not a direct effect of EdSm on GST was 
shown in a cell-free system, where EdSm did not influence the GST activity nor could 
it act as a substrate for GST Our results suggest that the synergistic combination of 
EdSm and cisplatin might be explained by EdSm switching oft the cellular 
detoxification mechanism for cisplatin, ι e by inhibition of de novo synthesis and 
subsequent depletion of GSH and GST 
INTRODUCTION 
Ethyldeshydroxy-sparsomycin (EdSm) is a potent inhibitor of nbosomal protein 
synthesis [38] and is one of the sparsomycin analogues which show enhanced 
antitumour activity in comparison to sparsomycin [364] In addition, EdSm 
synergistically enhances the antitumour activity of cisplatin in vivo in mice bearing 
L1210 leukaemia tumour cells sensitive to both drugs [146] but is unable to do so 
when these tumour cells are resistant to one of these drugs [147] The in vitro 
sensitivity of L1210 leukaemia cells correlates well with the antitumour activity ot 
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EdSm and cisplatin in vivo. The cellular factors of these leukaemia tumours, which 
are responsible for the enhanced chemosensitivity to combined drug treatment, are 
unknown. Likewise, it is not known for these leukaemia cell lines which mechanism is 
involved in cisplatin resistance or EdSm resistance. 
Glutathione, a tripeptide containing a sulfhydryl group, protects cells from 
oxidative damage, participates in the transport of amino acids, and is a cofactor for 
ribonucleotide reductase, which is required for deoxynbonucleotide synthesis. 
Glutathione conjugation, established by a family of glutathione-S-transferases, provides 
a defence mechanism because it removes potentially toxic low-soluble and/or 
electrophilic compounds by converting them into better water-soluble and non-
electrophilic conjugates. A logical but undesirable effect of glutathione therefore is its 
potential involvement in cellular resistance after long or repeated exposure to 
anticancer agents Tumour cells may adapt to chemical or nutritional depletion of GSH 
by producing a rebound elevation of GSH levels and the induction of elevated levels of 
specific glutathione S-transferase iso-forms. Cellular concentrations are maintained by 
de novo synthesis of GSH from the constituent amino acids, using the enzymes r-
glutamyl cysteine synthetase and glutathione synthetases. A number of reports describe 
an elevated level of glutathione in tumour cells, which are resistant to cisplatin 
[155,215,245,274J, but a decreased cisplatin uptake [186,269] and increased DNA 
repair have been reported as well, resulting in less DNA înterstrand cross-links 
[106,151,290]. Moreover, the activity of glutathione S-transferase (GST) in cisplatin-
resistant tumour cells is often increased compared to cisplatin-sensitive tumour cells 
[263,275]. Glutathione depletion can increase the chemosensitivity to cisplatin 
[10,12,31,153,214], or partially reverse cisplatin resistance [13]. On the other hand, 
conflicting results were obtained upon in vivo glutathione depletion using DL-
buthionine sulfoximine (BSO). One report failed to observe an increase of the 
antitumour activity of cisplatin [195], yet another report shed an increase in sensitivity 
to cisplatin [31]. 
EdSm, being a potent inhibitor of ribosomal protein synthesis, might inhibit de 
novo synthesis of enzymes like glutathione S-transferase and of enzymes needed for 
glutathione synthesis, thereby potentiating the antitumour activity of cisplatin. 
In this study we addressed these questions using three murine leukaemia tumours 
which show significant differences in cytotoxic IC,0 levels for EdSm or cisplatin, and 
gieat differences in antitumour responses [147]. The mechanism responsible for these 
sensitivity differences is unknown. Therefore, information about cellular changes in 
tumour cells after EdSm exposure could be very valuable in order to predict the 
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chemomodulatonal antitumour activity of EdSm in drug combinations and possibly for 
other protein synthesis inhibitors as well In an attempt to explain the patterns of 
synergistic drug interactions in these leukaemia murine tumours we investigated the 
dynamics of a panel of cellular parameters protein content, GSH and GSSG content, 
and GST activity 
MATERIALS AND METHODS 
Cell culture 
The culture conditions for murine L1210 leukaemia cells have been described earlier 
[147] The murine L1210 leukaemia wild type (L1210 WT) and the cisplatin-resistant 
subclone (L1210-CDDP) were kindly supplied by Dr G Atassi (Inst Jules Bordet, 
Lab for Experimental Chemotherapy, Brussels, Belgium) We have established 
another subclone of the mouse rumour cell line L1210 with acquired resistance to 
sparsomycin by repeated in vivo treatment with increasing doses of deshydroxy-
sparsomycin (L1210-Sm) In vitro these subclones are stably resistant in drug-free 
media for up to 6 months 
Drugs 
EdSm was synthesised at the department of Organic Chemistry of the University of 
Nijmegen, the Netherlands [38], and was acquired in a lyophihsed form The drug 
was dissolved in phosphate buffered saline (PBS, pH 7 4) and kept in dark flasks at 
4°C Cisplatin was kindly provided by Pharmachemie В V , Haarlem, The 
Netherlands Solutions with the required drug concentration were prepared just before 
administration by dilution with isotonic NaCl 
Drug treatment 
The L1210 leukaemia cells were seeded and allowed to grow in a fresh, drug-free 
medium for 24 h Thereafter, EdSm or cisplatin were applied in increasing 
concentrations from 0 01 μΜ to 30 μΜ for a period of 20 hours To investigate the 
effect of drug exposure on enzyme kinetics of GST the tumour cells were exposed to 
30 μΜ EdSm during 4 hours After drug exposure, the tumour cells were washed 
55 
twice with PBS and used for different assays. The cell viability was checked by dye 
exclusion using trypan blue and the cell numbers were determined using a 
haemocytometer. All experiments were performed in triplicate 
Cytotoxicity assays 
The clonogenic ability of drug-treated cells was evaluated by a soft-agar colony assay 
Leukaemia colonies were grown by plating the cells in 0.3% agar in 6-wells plates 
(Costar) in a drug-free medium. After 8 days of incubation, colonies (>50 cells) were 
scored using an inverted microscope. The surviving fraction was calculated by 
dividing the absolute survival (# colonies) of the treated sample by the absolute 
survival of a parallel control sample. Each experimental point was determined in 
duplicate and all experiments were repeated twice. 
Flow cytometry 
Cell cycle distributions. Single-cell preparations were obtained from control cultures 
and fixed in 70% ethanol. The cells were removed from the fixative by centnfugation 
and washed with phosphate-buffered saline (PBS). The cells were stained in 400 μΐ 
PBS containing 20 ^g/ml propidium iodide and were measured with a flow cytometer 
50H (Ortho Instruments, Weatwood, CA). Red fluorescence, for DNA-content 
measurements, was detected through a 630 nm long pass filter, and photomultiplier 
pulses were amplified linearly 
P-glycoprotein. For flow-cytometnc analysis of P-glycoprotein expression, tumour 
cells were labelled with the P-glycoprotein specific monoclonal antibody MRK16 (a 
gilt from Prof. Τ Tsuruo) according to the method of Hamada [131]. Thereafter, cells 
were stained with fluoresceinated rabbit anti-mouse IgG (Dakopatts, Glostrup, 
Denmark), FITC-RAM-F9(ab')2 fragments 1:50 diluted in PBS. Cells stained with 
FITC were analyzed by flow cytometry using a 515/530 bandpass filter. The area of 
the green fluorescence signal and both area and peak value of the red fluorescence 
signal were recorded in list mode and analyzed with a PDP11/34 computer (Digital 
Equipment, Galway, Ireland) 
Cell size. Flow cytometry of the samples was done with a cytofluorograph equipped 
with on-line computer analysis The exact relationship between scattered light and cell 
size is difficult to quantify It depends on the light collection, angle, aperture, and 
index of refraction of the suspending fluid Usually, however, the scattered light 
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increases monotonically with the cell volume In this study, latex microspheres of 10 
and 20 μιτι were used to calibrate any differences in cell size between these three cell 
lines All samples were light-microscopically checked for differences in size. 
Protein 
For an estimation of the amount of protein we used the fluorometnc assay of 
Udenfnend [318], as modified by Lai [189] Bovine serum albumin was used for 
calibration 
Glutathione 
Glutathione consists of two forms, reduced (GSH) and oxidised (GSSG), and can be 
determined by established enzymatic techniques [312] Cellular glutathione content 
was determined from the deproteinated cell homogenates with the fluorometnc method 
of Hissin and Hilt using 
o-phthalaldehyde [143] 
Glutathione S-transferase 
Glutathione S-transferase (GST) catalyses the transfer of the -SH group of glutathione 
to specific substrates The activities of GSH transferases were measured at 25°С 
spectrophotometncally with l-chloro-2,4-dinitrobenzene (CDNB) as a substrate 
according to the procedure of Habig [130] The conjugate, CDNB-glutathione, has an 
absorbance band at 340 nm, and the activity of the enzyme can therefore be estimated 
by measuring the kinetics of the change in optical density at this wavelength Assays 
were performed in 100 mM potassium phosphate, pH 7 4, ImM EDTA, 5 mM GSH, 
1 mM CDNB and 0 1 mg/ml cytosohc protein Michaehs-Menten kinetics of cytosohc 
GSH transferases of sonicated cells were measured using CDNB as a substrate GSH 
concentrations in the assay system were fixed at 1 mM The K
m
 and V
mdX were 
calculated using the Lineweaver-Burk plot 
Statistics 
A comparison of the different sample distribution is usually performed on the log-scale 
in order to reduce skewness, be more robust against outliers or make the SD's more 
comparable Even if this transformation to the log-scale seems unnecessary - as in this 
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study - there is hardly any harm in doing so. Differences between the means of 
different groups were compared using the analysis of variance (ANOVA) in 
combination with the Ryan multiple F-test. All computations were done by SAS, proc. 
ANOVA. The results have been expressed as the mean ± standard error (SE), and P-
values less than 0.05 were considered to be significant. 
RESULTS 
Biological characteristics of the L1210 leukaemia cell lines 
IC,0 levels of the various cell lines for EdSm and cisplatin are compiled in Table 1. 
The cisplatin-resistant L1210 line (L1210-CDDP) acquired some resistance to EdSm 
as well, resulting in a resistance factor of 4 compared to 18 in L1210-Sm. Yet, the 
L1210-Sm has normal sensitivity for cisplatin. No detectable, significant difference 
was found between the three cell lines regarding population doubling times, cell 
diameter and P-glycoprotein expression. Only the cisplatin-resistant cell population 
harbours a few positive cells (2.2%). However, the intensity of their fluorescence was 
low as a consequence of which we ignored this information. Whilst the population 
doubling time is the same for all 3 cell lines, the analysis of the cell phase distribution 
during exponential growth (Table 2) revealed significant differences (p = 0.03) with 
respect to the number of cells in the S-phase. To be more specific, the percentage of 
L1210-CDDP tumour cells in the S-phase cells is significantly higher than that of 
L1210-Sm cells, which are 62.3 and 49.4%, respectively. Moreover, the percentage 
of L1210-CDDP cells (6 8%) in the G2M-phase is low compared to these values of 
L1210-WT (11.6%) and L1210-Sm (12.7%) cells. The percentage of Gl-phase cells is 
not significantly different within the three cell lines. Furthermore, no difference was 
found in the average protein content of these cell lines (Table 3). The average 
glutathione levels in the resistant cell lines also did not change significantly: ρ = 0.35 
for GSH oxidised, ρ = 0.48 for GSSG, and ρ = 0.32 for total glutathione (Table 3). 
Moreover, a 2:1 molar ratio between GSH and GSSG was found in all cell lines. The 
specific GST activities are different (Table 3). In particular if we compare the L1210-
Sm with the L1210-CDDP cell line, we notice an elevated level of 58 versus 38.2 
nmol/mm/mg protein, respectively (p = 0.04), or 2.36 and 1 84 nmol/min/lO6 cells, 
respectively (p = 0.09) 
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TABLE 1: 
Characteristics of three different murine leukaemia cell lines, with regard to population doubling 
times, expression of plasma membrane P-glycoprotem and sensitivity for EdSm and cisplatin 
during exponential cell growth Cell lines are wild type (LI210-WT), cisplatin resistant (L1210-
CDDP) and deshydroxy-sparsomycm resistant (LJ210-Sm) 
PARAMETER 
T-doubling time3 
Relative Cell 
diameter 
P-glycoprotein 
IC„,-EdSmc 
RF-EdSmò 
ICS0-CDDP 
RF-CDDP 
L1210-WT 
13.6 ± 1.2" 
1.0 ± 0.17 
<1 
0.22 ± 0.08 
1 
2.0 ± 1.25 
1 
L1210-CDDP 
13.2 ± 1.4 
1.0 ± 0.17 
<1 
0.88 ± 0 16 
4 
3.8 ± 0.3 
1.9 
L1210-Sm 
13.9 ± 1.2 
1.2 ± 0 17 
2.2 
4.0 ± 1.4 
18 
1.5 ± 0.2 
0.75 
UNIT 
Hours 
% positive cells 
μΜ 
μΜ 
"Based on 40 analysis for each cell line 
b
 Mean ± standard error 
c
 /C
w
 is the drug concentration needed during an exposure time of 20 h to give 50% growth 
inhibition in a colony forming assay 
ä
 RF is the resistance factor, representing the fold increase m 1С
w
 for a specific drug m a resistant 
cell line relative to the wild type 
TABLE 2: Cell Phase distribution of the three L1210 cell lines, during exponential cell growth 
m tissue culture, in the absence of any drug treatment The p-value is calculated by ANOVA m 
combination with the Ryan multiple F-test 
Cell phase 
Gl 
S 
G2M 
L1210-WT (10) 
35.3 ± 6 6 
53.1 ± 2 6 
1 1 6 + 5.3 
L1210-CDDP (4) 
31 0 ± 2 8 
62.3 ± 3.0 
6.8 ± 1.4 
L1210-Sm (12) 
37.9 ± 1.8 
49 4 ± 2.1 
12.7 ± 0 9 
p-value 
0 19 
0.03 
0.07 
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Effects of EdSm and cisplatin on the intracellular protein and glutathione levels and 
on the glutathione S-transferase activity 
The dose-effect curves for cisplatin and EdSm diverge in all three cell lines Inhibition of 
the protein synthesis by EdSm has a strong impact on the cellular protein content (Figure 
1) EdSm causes a dose dependent decrease in protein level, which is most extensive and 
most rapid in L1210-WT, and already starts at submicromolar EdSm concentrations This 
decrease is more gradual in L1210-CDDP L1210-Sm is clearly less sensitive and requires 
at least 10 μΜ to see the same effect Cisplatin causes the opposite effect, ι e a dose 
dependent increase in protein level in the L1210-CDDP and L1210-WT cell lines with 
little etfect on L1210 Sm The curves of drug treatment with cisplatin or EdSm and the 
100% control level were statistically analyzed The curves of L1210-WT and L1210-
CDDP are significantly different, ρ = 0 04 and 0 05, respectively Worth mentioning is 
the situation in L1210 Sm, in which EdSm exposure only caused a moderate effect, while 
Lisplatin had no effect at all (p = 0 45) Comparable effects were observed for GST 
activity Because we are interested in the total effect per rumour cell, we decided to 
express the values for the glutathione level and glutathione S-transferase activity in units 
per 106 cells instead of mg protein The effeU of both drugs on the overall cellular GST 
activity is represented in Figure 2 These results parallel the effects observed for the 
intracellular protein level, but significant differences between EdSm and cisplatin were 
found only in the L1210 WT cell line (p = 0 01), while the effect in the L1210-CDDP 
cell line comes close to significance (p = 0 06) Thus, the decrease in GST activity 
(when treated with EdSm) parallels the decrease in total protein Similarly, the increase in 
GST activity (when treated with cisplatin) follows the increase in protein content This 
implies that if the specific activity of GST was expressed in nmol/min/mg protein, no 
significant differences are found in these cell lines - neither between EdSm- and cisplatin 
treatment, nor between drug treated and control cells 
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Effects of EdSm and cisplatin on the intracellular glutathione dynamics 
Figure 3 shows the results of drug treatment on the intracellular glutathione level in 
these leukaemia tumours. Again, EdSm and cisplatin showed opposite effects in these 
three cell lines, and again these effects are dose- and cell line- dependent. Significant 
differences have only been observed in the L1210-WT cell line (p = 0.05). Only 
about 3 μΜ was required to induce strong GSH depletion in L1210-WT. In the 
sparsomycin-resistant tumour 3 μΜ EdSm evoked a 50% increase in GSH level, and a 
significant decrease was only observed at 30 μΜ. In the cisplatin-resistant tumour the 
GSH depletion dropped with EdSm > 3μΜ, albeit slowly compared to the wild type. 
The effect of cisplatin treatment on the GSH levels followed the same pattern as seen 
with GST and protein. 
Enzyme kinetics 
First we investigated whether EdSm and cisplatin could directly affect the activity of 
GST or the assay. The results in a cell-free system (Table 4) indicate that only a very 
high dose of cisplatin provides a lower value, but we do not know whether this is due 
to inhibition of the enzyme, a low substrate-potential, or interference with the assay 
(e.g. reaction with GSH, CDNB or the product). We did not pursue this any further 
since, under our standard conditions ( < 30 μΜ), no effect was observed and the 
intracellular-free concentrations of CDNB will certainly not reach the 10 mM level. 
The next question we addressed was whether EdSm could interfere with intracellular 
GSH transferases. We therefore used the Michaeles-Menten kinetics to estimate the 
V
nux
 and K
m
 of cellular GST in the presence of 30 μΜ EdSm for a period of 4 hours. 
These results are summarised in Table 5. In the control situation we saw a significant 
difference in
 ІШЛ
 between L1210-CDDP (150 nmol/min/mg Protein) and the other 
cell lines, L1210-WT (107 nmol/min/mg Protein) and L1210-Sm (95 nmol/min/mg 
Protein). This is even more pronounced for the K
m
 values. The K
m
 value for CDNB in 
the L1210-CDDP cell line is almost 3-fold higher than that of L1210-WT and L1210-
Sm. Exposure to EdSm reduced the maximal activity on a protein base in L1210-WT 
and L1210-Sm, although not significantly, and increased the V
ma
, in L1210-CDDP cell 
lines. These EdSm effects, however, were not significant, which is in part due to the 
small sample number. 
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TABLE 4: 
Influence of EdSm and cisplatin on the glutathione S-transferase actiuty m a cell-free system 
relative to untreated control (+CDNB) in the presence (+CDNB) or absence ( CDNB) of substrate 
(I mM CDNB) 
DRUG DOSE 
30 μΜ 
10 mM 
ethyldeshydroxy-
-CDNB 
0 0a 
0 0 
-sparsomycin 
+ CDNB 
99 2% 
97 9% 
Cl 
-CDNB 
0 0 
0 0 
splatin 
+ CDNB 
102% 
69% 
' The enz\me acti\tt\ of GST (nmol/mm/mg protein) is expressed as percentage of the treated 
sample o\er the +CDNB control (%T/C) 
DISCUSSION 
At the onset of our study no information was available about the mechanisms' 
underlying resistance against cisplatin in L1210-CDDP and against EdSm in L1210-
Sm Our results show (Table 1) that these three leukaemia tumour cell lines are 
comparable as to the population doubling time and cell size Also, the protein content 
and total glutathione level are similar in these cell lines (Table 3) The GST activities, 
however, are statistically significantly different The GST in L1210-CDDP also shows 
a relatively high K,„ To explain these results, we should bear in mind that the 
glutathione S-transferases are a multigene family of isoenzymes which catalyses the 
reaction between numerous electrophilic compounds and glutathione [210,211] The 
cytosolic GST is divided into four gene families the alpha-, mu-, pi- and theta-class 
The pi-class is preferentially expressed in tumour cells They function as dimers, with 
heterodimers occurring in the same class [211] The various classes have different 
specific activities and different substrate specificity We have measured the overall 
cellular GST pool, and the differences we observed between the cell lines most likely 
indicate a substantial variation at the isoenzyme level An other difference between 
these cell lines was detected in the cell phase distribution L1210-CDDP cells contain 
more S-phase cells and less G2M cells than L1210-WT and L1210-Sm, which 
indicates a prolonged S-phase, probably due to enhanced DNA-repair Another 
parameter often involved in resistance to chemotherapy is the elevated expression of a 
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P-glycoprotein of 170 Kd, which acts as a broad spectrum membrane pump and 
removes chemotherapeutic drugs as well. Although P-gp expression has never been 
implied in cisplatin resistance, other antitumour agents have been shown to be able to 
induce P-gp expression in murine leukaemia cells [266] Even alkylating agents, like 
mitomycin C, can induce resistance in L1210 leukaemia cells through changes in the 
membrane P-glycoprotein population [83], but these tumour cells remain sensitive to 
cisplatin. A possible P-gp induction by Sm derivatives has not yet been investigated. 
These results show what was expected, i.e. that the cisplatin-resistant L1210 subclone 
shows no P-gp induction. The sparsomycin-resistant L1210 cell line also does not 
show a significant elevation of the P-gp level. Hence, we conclude that resistance 
towards EdSm does not involve P-gp. 
TABLE 5: 
Effect of 4 hour incubation with 30 μΜ EdSm on Michaelis-Menten parameters of glutathione S-
transferase in the various L1210 cell lines (see materials and methods) 
L1210-WT L1210-CDDP L1210-Sm p' 
ш а х
:
ь
 control 107 ± 23 (3) 150 ± 10 (3) 95 ± 25 (2) 0.28 
+ EdSmc 77 + 19 (3) 131 ± 41 (3) 72 + 15 (2) 0.39 
p-valued 0.34 0.63 0.35 
K„,:L control 0.62 ± 0.12 (3) 1.52 ± 0.34 (3) 0.58 ± 0.13 (2) 0.06 
+ EdSnf 0.66 ± 0.08 (3) 2.61 ± 1.05 (3) 0.52 + 0.01 (2) 0.24 
p-valued 0.65 0.78 0.18 
° p-value given for one-way ANOVA between cell lines * nmol/min/mg protein. 
c
 %TIC (treated over control) ''p-value gnen for the contrast between the control group and the 
treated group. ' mM 
As for glutathione, these results show that EdSm is no likely target for GSH 
conjugation, since EdSm did not directly influence the GST activity (Table 4). 
Exposure of intact tumour cells to EdSm yielded a dose- and cell line-dependent 
decline in cellular protein content, glutathione level, as well as in the total GST 
67 
activity This dose-dependency of the decline in protein content in the individual cell 
lines upon EdSm treatment correlates directly with the sensitivity of each cell line for 
EdSm Under normal conditions the cellular level of a protein is determined by the 
balance between the rates of its synthesis and degradation The average turnover times 
for individual proteins range from several minutes to months or even years [140] 
Many intracellular proteins that have half lives of 10 minutes or less are proteins with 
key regulatory roles whose cellular level is rapidly regulated by modulating their rate 
of synthesis [288] Inhibition of protein synthesis by EdSm will directly disturb short­
lived protein balance, which could cause effects such as depletion of GSH and GST 
The cellular glutathione level is maintained by de novo synthesis of GSH from the 
constituent amino acids, using the enzymes τ-glutamyl cysteine synthetase and 
glutathione synthetase Furthermore, glutathione cycles between a reduced thiol form 
(GSH) and an oxidised form (GSSG) in which two GSH-tnpeptides are linked by a 
disulfide bond, and GSSG can be reduced to GSH by glutathione reductase [216] 
Because GSH is non-nbosomally synthesised, depletion of GSH must be caused by 
inhibition of the synthesis of these enzymes Because glutathione depletion parallels 
the declining protein content, EdSm apparently has a strong effect on these enzymes 
which also implicates that these enzymes have relatively short turnover times and 
require a high level of de novo synthesis 
In combined chemotherapy we must be cautious not to interpret many of the effects 
as the result of simple direct interaction between cytostatic agents As this study has 
also shown, administration of cisplatin can cause the induction of endogenous GSH 
synthesis, as well as enhanced levels of enzymes such as glutathione-S-transferase 
which can catalyse the detoxification of agents such as cisplatin [74] GSH depletion 
by DL-buthionme-SR-sulfoximine (BSO) suggests two roles for GSH in cisplatin 
resistance, namely cytosolic elimination, resulting in less DNA platination, and a 
nuclear effect on the formation and repair of DNA platinum adducts [215] Cisplatin 
can also conjugate non-enzymatic with sulfhydnl compounds like glutathione 
[64,74,268] This reaction involves nucleophihc displacement of chloride ligands, 
either directly or subsequent to a reaction with water This type of reaction could 
explain the apparent reduction in GST activity that we observe at very high cisplatin 
concentrations In addition to GSH, other thiols, like the metallothioneins (MT), can 
act as a nucleophile towards electrophilic agents like cisplatin, but the involvement of 
MT in acquired resistance to cisplatin is rather controversial [11,181,186,286] In the 
murine leukaemia cell line L1210, the degree of resistance was reported to be 
associated with the level of MT (186), however, in another study the resistance of 
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L1210-CDDP cell towards cisplatin could neither be based on an increased level of 
MT nor on an enhanced ability to increase the synthesis of MT after cisplatin exposure 
[94]. Thus, MT may be associated with the induction of cisplatin resistance, but its 
causal role remains to be established. It should be noted that resistance to cisplatin is a 
relative term, which is at least partially attributable to its narrow therapeutic index. 
Because of fatal toxicity, it is often not possible to successfully treat tumours, which 
exhibit even a small inherent resistance to cisplatin, by increasing the dose level of 
cisplatin. As a consequence, combination therapy with an agent like EdSm, which 
enhances cisplatin's antitumour effects with little or no enhancement of cisplatin's 
toxicity [146,147], may be of value in the treatment of tumours which resist treatment 
with cisplatin alone. 
To summarise, our results suggest that the synergistic combination of EdSm and 
cisplatin can, at least partly, be explained by the EdSm-induced block of protein 
synthesis, with subsequent depletion of the cellular detoxification mechanism for 
cisplatin, and will very likely involve a reduction in the intracellular level of GSH. 
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PART III 
MODULATION OF THE ANTITUMOUR ACTIVITY OF 
CISPLATIN BY EDSM 

CHAPTER 5 
CORRELATION OF THE IN VITRO CYTOTOXICITY OF 
ETHYLDESHYDROXY-SPARSOMYCIN AND CISPLATIN WITH 
THE IN VIVO ANTITUMOUR ACTIVITY IN MURINE L1210 
LEUKAEMIA AND TWO RESISTANT L1210 SUBCLONES. 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, H VAN RENNES, 
AJ VAN ZEIST, LAGM VAN DEN BROEK, HCJ OTTENHEIJM 
Cancer Chemotherapy and Pharmacology 31 289-294, 1993 
Conclusion 
Synergism of combined treatment with cisplatin and EdSm is largely dependent on 
the cellular properties of the target tumour cell populations 

SUMMARY 
The cultured murine leukaemia L1210 cell populations used in the present study were 
derived from L1210 cells that had been grown in vivo Subclones resistant to 
sparsomycin (L1210-Sm) or cisplatin (L1210-CDDP) were also developed in vivo The 
doubling times of the cultured cell populations were identical Fractions surviving after 
drug treatment in vitro were determined by colony formation in soft agar The results, 
based on the differential sensitivity of the cell populations to Ethyldeshydroxy-
Sparsomycin (EdSm) and cisplatin, indicated that after a short exposure, cultured 
L1210-CDDP cells were cross resistant to EdSm L1210-Sm cells, however, were not 
cross-resistant to cisplatin The results obtained in cultured cell populations were 
confirmed in vivo CD2fl mice bearing intraperitoneal (I Ρ ) implants of 1 χ IO5 
tumour cells were given EdSm or cisplatin and a combination of the two agents 
Drugs were given once daily every 4 days for 3 doses starting 24 h after tumour 
implantation Treatment of mice bearing L1210-WT leukaemia with combined EdSm 
and cisplatin caused strongly synergistic antitumour activity In animals bearing the 
two resistant subclones, however, combined drug treatment did not improve the 
antitumour activity The corresponding median survival of mice receiving combined 
drug treatment was 60 days in each group containing 6 mice bearing L1210-WT, with 
4-6 cures being noted, 19 days in animals harbouring L1210-Sm, with 2 cures being 
recorded among 6 mice, and 11 days in mice bearing L1210-CDDP, with no cure 
being obtained The results of this study indicate that the synergism resulting from 
combined treatment with cisplatin and EdSm is a function of the cellular properties of 
the target tumour-cell populations and is independent of host factors 
INTRODUCTION 
Cisplatin is a metallic antineoplastic agent that is used in the treatment of cancers such 
as testicular, ovarian and head and neck tumours It is thought to act via inter- and 
intrastrand cross-linking of duplex DNA [270] 
Sparsomycin (Sm) is a known inhibitor of nbosomal protein synthesis [118,238) Pre-
treatment of L1210 leukaemia cells in vitro [363J with Sm strongly enhanced the 
cytotoxic effects of cisplatin In vivo, Sm potentiates cisplatin's antitumour activity 
when it is given 3-6 h prior to cisplatin and results in prolongation of the median 
survival time ( > 6 0 days) and in a 66% cure rate [362]) Sm-analogues that are more 
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active in vitro than the parent drug have been tested for their antitumour activity in 
eight in vivo murine tumour models [364]. The most active compounds appeared to be 
deshydroxy-Sm (dSm), ethyldeshydroxy-Sm (EdSm) and n-pentyl-Sm (pSm) 
In vivo potentiation of cisplatin's antitumour activity has been studied for Sm and 
the three above-mentioned active analogues in S.C. implanted LI210 leukaemia [365]. 
In this tumour model, cisplatin treatment (5 mg/kg) resulted in 156% treated/control 
(T/C) value. Treatment with sparsomycin and its analogues alone resulted in an 
increase in survival for EdSm only (139%). Although Sm itself was incapable of 
potentiating the antitumour activity of cisplatin in this model, two analogues, dSm and 
EdSm, were active. At a dose of 10 mg/kg, EdSm potentiated cisplatin's antitumour 
activity by 2.8 times. PSm, the third analogue, showed no potentiation of the 
antitumour activity of cisplatin in this tumour model. 
On the basis of these results, EdSm was chosen for further preclinical studies on 
the synergism between sparsomycins and cisplatin. To investigate the relationship 
between the results of combined drug treatment in vivo and the drug sensitivity of 
tumour cells in vitro, we derived two resistant sublines from L1210 murine leukaemia. 
Our further goal was to examine the correlation between in vitro sensitivity testing and 
in vivo antitumour activity. The outcome of this investigation might facilitate further 
studies on the synergistic antitumour effects of EdSm on other cytostatic agents. 
MATERIAL AND METHODS 
Cell culture 
Murine L1210 leukaemia cells (L1210-WT) were kindly supplied by Dr.G. Atassi 
(Institute Jules Bordet, Laboratory for Experimental Chemotherapy, Brussels). Cells 
were maintained in logarithmic growth as suspension cultures in RPMI 1640 medium 
containing 10% foetal bovine serum and antibiotics. Cells were grown in a humidified 
atmosphere containing 5% CO, at 37°C. 
Drug resistant sublines 
The murine L1210 cisplatin-resistant subclone (L1210-CDDP) was kindly supplied by 
Dr G. Atassi and was developed in vivo . We established another subclone of mouse 
tumour cell line L1210 with acquired resistance to sparsomycins by repeated in vivo 
treatment with increasing doses of deshydroxy-sparsomycin (L1210-Sm). In vitro, 
these subclones are stably resistant for up to 6 months in drug-iree media The 
76 
doubling times of the cultured cell populations (mean ± SD, η = 40) were 13 9 + 
1 2 h for L1210-Sm, 13 2 ± 1 4 h for L1210-CDDP, and 13 6 ± 1 2 h for L1210-
WT Both subclones were evaluated for their response to those drugs using a 
clonogenic assay to measure cell survival 
Clonogenic assay 
L1210 cells were exposed to different drug doses After drug exposure, the drug-
containing medium was removed and the cells were washed with balanced salt solution 
and counted (Coulter counter) The clonogenic ability of treated cells was evaluated by 
a soft agar colony assay Leukaemic colonies were grown by plating the cells in 0 3% 
agar in six well plates (Costar) in drug-free medium After 8 days of incubation, 
colonies (>50 cells) were scored using an inverted microscope The surviving fraction 
was calculated as the absolute survival of the treated sample divided by the absolute 
survival of the control sample at the same time Each experimental point was 
determined in duplicate and all experiments were repeated twice 
TABLE 1. Resistance factors of EdSm and asplatin in the two resistant LI210 subclones in 
vitro 
Subclone exposure time RFa 
EdSm cisplatin 
L1210Sm 1 hour >25 12 
continuous 26 1 4 
L1210CDDP 1 hour >25 >3 
continuous 2 6 10 2 
"Resistance factor calculated as the ICS0 value for the subclone/1С¡0 for the wild type [ICS0 = drug 
concentration (μΜ) that gives 50 % growth inhibition] 
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COLONIES (% o l control) COLONIES (% of control) 
A > hOUr 
10 100 
В 1 hour 
uM EdSm 
1 10 
μΜ COOP 
100 
COLONIES (% ol control) 
100 
100 
COLONIES (% Oí control) 
100 
μΜ EdSm 
1 i o 
μΜ CDDP 
1 0 0 
FIGURE 1 Α-D: In atro chemosensitmty of L1210 leukaemia (o) and two drug-resistant 
subclones, L1210-Sm f) and L1210-CDDP (m), exposed to EdSm and cisplaun А, В Effect of J h 
exposure C, D Effect of continuous exposure А, С Cytotoxicity of EdSm B, D Cytotoxicity of 
asplatin Data represent mean \alues for experiments performed in triplicate 
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Drugs 
Ethyldeshydroxy-sparsomycin was synthesised as previously described [38,238] and 
was acquired in a freeze-dned form. The drug was dissolved in phosphate-buffered 
saline (PBS) and kept in dark flasks at 4° С Cisplatin was kindly provided by 
Pharmachemie В V (Haarlem, The Netherlands) These drugs were prepared just 
before administration and were diluted with isotonic NaCl until the dose per gram of 
mouse body weight was contained in 0 01 ml. 
Animals 
CD2f, mice weighing between 18 and 22 g were used in this study In each 
experiment, PBS-treated tumour-bearing animals served as controls 
Antitumour activity 
Mice were inoculated I Ρ with 10s cells suspended in 0 2 ml PBS (pH 7 4) In each 
experiment tumour-bearing mice were randomised into treatment and control groups, 
each group consisted of six animals Drugs were administered I Ρ into mice using 
0 01 ml/g body weight at various doses Drug treatment was started on day 1 after 
tumour implantation In all experiments, drugs were given I Ρ every 4 days until day 
9 (q4dx3) As previously shown [362], Sm potentiates the activity of cisplatin when 
the former is given 3 to 6 h prior to cisplatin The 3-h pre-treatment schedule was 
used in the present experiments Animal survival was recorded daily and the median 
survival of each group was calculated The final results obtained in these rumours are 
presented as the median survival times (MST) expressed in days after tumour 
implantation The MST value was computed on the basis of the entire population, and 
there was no deletion of early deaths or survivors 
Statistical analysis 
For statistical analysis of the data, we used Wilcoxon's rank-sum test for independent 
samples followed by student's Mest, and Ρ values of < 0 05 were considered to be 
significant 
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RESULTS 
Cytotoxicity 
The in vitro results, based on the sensitivity of the cell populations to EdSm and 
cisplatin, are shown in Fig. 1. The resistance factors (RF) for EdSm and cisplatin in 
two resistant L1210 subclones are summarised in Table 1. Cultured L1210-CDDP 
cells were cross-resistant to EdSm following 1 h exposure (RF, >25) L1210-Sm 
cells, however, were not cross-resistant to cisplatin (RF = 1.2). On continuous drug 
exposure, the magnitude of cross-resistance was decreased from >25 to 2.6. 
Antitumour activity 
The combination of EdSm and cisplatin was studied in L1210 tumour-bearing mice. 
On the basis of the loss of body weight after single cisplatin treatment (data not 
shown), we used 5 mg/kg cisplatin as maximal tolerable dose (MTD) for this 
treatment schedule. The MTD used for EdSm single treatment on this schedule was 10 
mg/kg per injection. For combined drug treatment, the MTDs were 5 mg/kg cisplatin 
and 5 mg/kg EdSm. Increasing the dose of one of the drugs in the combination 
resulted in early deaths as shown in Table 1 for EdSm 10 mg/kg per injection All 
results obtained following single or combined treatment of mice bearing L1210-WT 
with EdSm and cisplatin are presented in Table 2. Death of untreated tumour-bearing 
animals invariably began on day 9, and all mice had died by day 12. The MST values 
determined for untreated mice were 10± 1.1 days for L1210-WT, 10.4 + 0.75 days for 
L1210-Sm and 9.5+0.71 for L1210-CDDP The dose-response effects of cisplatin in 
all three rumour populations are illustrated in Fig. 2. From a comparison of the 
cisplatin data obtained in the L1210 clonogenic assay (Fig 1) with those acquired in 
L1210 cells growing in vivo (Fig. 2), it can be concluded that a direct correlation of 
tumour cell sensitivity exists for cisplatin. 
The combination of EdSm and cisplatin appeared to be highly effective against 
tumour cells sensitive to both drugs, resulting in a strong synergism between EdSm 
and cisplatin in the L1210-WT cell population. Combination treatment of tumour cells 
resistant to EdSm (L1210-Sm) showed no improvement as compared with single-agent 
cisplatin treatment (Fig. 3). Tumour cells resistant to cisplatin (L1210-CDDP) were 
also resistant to combined drug treatment (Fig. 3), moreover, the L1210-CDDP cells 
were cross-resistant to EdSm treatment. Figure 4 shows the duration of host survival 
after treatment ot mice with a combination of EdSm (5 mg/kg) and cisplatin (3 
mg/kg) The corresponding MST values were 60 days in mice bearing L1210-WT, 
80 
with 4-6 cures being noted in each group consisting of 6 mice; 19 days in mice 
harbouring L1210-Sm, with 2 cures being recorded among 6 animals; and 11 days in 
animals bearing L1210-CDDP, with no cure being obtained. These observations 
suggest that synergistic improvement of antitumour activity of cisplatin by combined 
treatment with EdSm is successful only when the tumour cells are sensitive to both of 
the drugs used in combination. 
60 -r— MST (days). 
50 
40 
3 0 -
2 0 -
L1210/wt 
L1210/Sm 
L1210/CDDP 
0 2 4 6 
CISPLATIN (mg/kg) 
FIGURE 2: Dose-response determination for cisplatin in LP inoculated LI210 leukaemia cells 
Beginning at day 1 following the implantation of 10s tumour cells, mice were treated I Ρ once 
dailx every 4 davs for 3 dose1; 
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60-1—MST (days) 
L 1 2 1 0 / w l L 1 2 1 0 / S m L1210 /CDDP 
FIGURE 3: In vivo antitumour activity of EdSm (5 mg/kg) and cisplalm (3 mg/kg) after single-
drug injection and combined drug treatment in L1210 leukaemia and two drug-resistant subclones. 
Beginning at dax 1 following tumour implantation, mice were treated IP once daily every 4 days 
for 3 doses. Results are expressed as median survival tune (in days) as mean values far 2-4 
experiments. Vertical bars represent the SEM. 
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SURVIVORS 
12 η" 
10-
8 -
6 -
4 -
>Li_¿ 
30 
DAYS 
40 50 60 
FIGURE 4: Survnal of mice inoculated LP with IO5 LI210 cells as determined after combined 
drug treatment Groups of 6 mice received LP EdSm (5 mg/kg) and cisplatin (3 mg/kg) 
Beginning at day I following tumour implantation, mice were treated once daily every 4 days for 3 
doses (O) LÌ210-WT, (·) L1210-Sm, im) L1210-CDDP Data represent the combined results of 2 
experiments Arrows indicate the days of treatment Death was due to the toxicity of the tumours. 
83 
TABLE 2: Median survival and number of 60 days survivors for combined drug treatments of 
CD2fl mice inoculated Ι Ρ with l(f L1210 leukaemia cells 
Treatment Median survival3 60 days survivors11 
EdSm (mg/kg) 
0 
5 
10 
0 
0 
0 
0 
0 
5 
5 
5 
5 
10 
10 
10 
cisplatin (mg/kg) 
0 
0 
0 
1 
2 
3 
4 
5 
2 
3 
4 
5 
3 
4 
5 
(days ± SEM) 
10 0 ± 0 34 
15 8 ± 0 84 
15 0 
12 
17 5 
30 5 
39 7 
48 6 
47 
51 
60 
60 
60 
60 
19 
± 1 6 
± 1 5 
± 7 5 
± 1 1 0 
± 7 0 
± 1 0' 
± 6 0* 
± o-
± 0 N S 
η 
0/60 
0/30 
1/12 
0/6 
2/12 
8/24 
6/18 
14/30 
5/12 
18/30 
15/18 
18/24 
4/6 
4/6 
0/6 
% 
0 
0 
8 
0 
17 
33 
33 
47 
42 
60 
83 
75 
67 
67 
toxic 
Treated mice received drugs νια I Ρ administration with EdSm being given 3 h before cisplatin 
Control animals received injections of saline only NS, Not significant as compared with single-
agent cisplatin treatment 
" Average of individual experiments using 6 mice each 
h
 Tumour free at the time of evaluation (number of survivors/total number of mice) 
* Significant (P <0 05) as compared vutli single agent cisplatin treatment 
NSNot significant compared to single cisplatin treatment 
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DISCUSSION 
The combination of EdSm and cisplatin produces potentiation of antitumour activity in 
L1210 leukaemia cells that are sensitive to both drugs but fails to do so in L1210 
leukaemia cells that are resistant to one or both of these drugs Furthermore, the 
present study indicates that the in vitro sensitivity of LI210 leukaemia cells after a 
short drug exposure correlates well with the antitumour activity of EdSm and cisplatin 
obtained in vivo after I Ρ bolus injection, whereas their sensitivity to continuous 
exposure in vitro does not However, the factors that determine on a molecular level 
this observed increase in chemosensmvity are not yet known Similarly, the 
mechanisms that are active in the cisplatin resistance of L1210-CDDP or the EdSm 
resistance in L1210-Sm are unknown Cisplatin interferes at various levels with cell 
physiology, and on each of these levels, different mechanisms of resistance could be 
operative A number of reports have indicated that tumour cells resistant to cisplatin 
can show an elevated level of glutathione [152,215,245,274], a decreased cisplatin 
uptake [186,269,295] or, sometimes, an increased level of DNA repair [290], 
resulting in a decreased amount of DNA înterstrand cross-links [106,152] Moreover, 
the activity of glutathione S-transferase (GST) in cisplatin-resistant tumour cells is 
often increased in comparison with that in cisplatin-sensitive tumour cells [263,275] 
Glutathione depletion can increase chemosensitivity to cisplatin [12,31,154,215] 
or partially reverse cisplatin resistance [13] On the other hand, it has recently been 
shown that in vivo glutathione depletion by D L-buthionme sulfoximine (BSO) does not 
enhance the antitumour activity of cisplatin [195], whereas another study has 
demonstrated increased sensitivity to cisplatin [31] In addition to reduced glutathione 
(GSH), metallothioneins (MT) may act as another nucleophile towards electrophilic 
agents The involvement of MT in acquired resistance to cisplatin is rather controver-
sial MT can be induced by heavy metals such as cadmium and zinc and has led to 
cross-resistance with cisplatin in human ovarian carcinoma cells [11] However, in 
vitro selection with cisplatin does not trigger this mechanism (1) Cells with acquired 
resistance to cisplatin frequently show an increase in MT levels and over-express MT 
mRNA [181,186], but one study has failed to correlate over-expression of MT mRNA 
with cisplatin resistance [287] 
In the murine leukaemia cell line L1210, the degree of resistance has been 
associated with an elevated MT content [181], however, in another study the basis for 
the resistance of L1210-CDDP cells to cisplatin was neither an increased level of MT 
nor an enhanced ability to increase the synthesis of MT after cisplatin exposure [94] 
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Thus, MT may be associated with induction of cisplatin resistance, but its causal role 
remains to be established 
EdSm is a potent inhibitor of nbosomal protein synthesis [38] Due to this 
property, one would expect it to have a strong effect on enzymes such as GST and 
enzymes related to DNA repair Decreased cellular enzyme activities might restore the 
sensitivity of cisplatin-resistant tumour cells L1210-CDDP cells are cross-resistant to 
EdSm after a short period of exposure, but on continuous exposure their sensitivity to 
EdSm is comparable to that of L1210-WT cells These results indicate that changing 
the administration schedule of EdSm in vivo might increase its antitumour activity in 
L1210-CDDP leukaemia cells and might even change the sensitivity of these tumour 
cells to cisplatin, in consequence, cisplatin-resistant tumour cells might become 
sensitive to cisplatin in the presence of EdSm 
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CHAPTER 6 
POTENTIATION OF CISPLATIN ANTITUMOUR ACTIVITY BY 
ETHYLDESHYDROXY-SPARSOMYCIN IN L1210 LEUKAEMIA 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, H VAN RENNES, 
AJ VAN ZEIST, LAGM VAN DEN BROEK, HCJ OTTENHEIJM. 
Anticancer Research 12: 167-170, 1992. 
Conclusion: 
The order of drug administration does not influence the antitumour activity of 
cisplatin. EdSm can be given before, during or after cisplatin. 

SUMMARY 
The combination of ethyldeshydroxy-sparsomycin (EdSm) with cisplatin caused 
significant antitumour activity against murine L1210 leukaemia Although single drug 
treatment by cisplatin did generate some cures, all schedules of combined treatment, 
using nontoxic doses of EdSm (5 mg/kg) and cisplatin (3 mg/kg), resulted in the cure 
of 4 to 6 mice in each group consisting of 6 mice No differences in antitumour 
activity were observed between pre-treatment, simultaneous treatment or post-
treatment of cisplatin with EdSm Increasing the number of tumour cells implanted 
I Ρ diminished the antitumour effect of both EdSm as well as cisplatin, but not for the 
drug combination Changing the route of administration from I P to I V for one of 
the drugs out of the combination resulted in loss of antitumour activity 
INTRODUCTION 
Combination chemotherapy programs have improved significantly the cure rate of 
cancer patients, but in general the success rate is still low Most currently used drugs 
have direct or indirect effects at the DNA level or the microtubules of the mitotic 
spindle figure Sparsomycin (Sm) is a known inhibitor of ribosomal protein synthesis 
and therefore has an attractive anticancer potential Sm has antibiotic activities against 
viruses [69,310], bacteria [36,262], fungi [243], and parasites [32] The antibiotic has 
achieved prominence in the past years as a tool to study the protein biosynthesis 
machinery [119,120,303] Since the isolation of sparsomycin from Streptomyces 
sparsogenes in 1962 [243], much attention was focused on its early observed 
antitumour activity After the development of the total synthesis of sparsomycin in 
1981 [239] more than 60 derivatives have been prepared and their chemical and 
biological activities studied [38,238] 
From the literature is known that protein synthesis inhibitors like L-histidinol 
[333] and anguidine [153] can modify the toxicity of cisplatin These properties offer 
novel possibilities for its use in combination chemotherapy Because the target of 
sparsomycin differs from those of other cytostatics, a potentiating effect can be 
expected by combining it with classical cytotoxic agents In vitro and m vivo studies of 
sparsomycin (Sm) and cisplatin in the L1210 mouse model supported this hypothesis 
[362,363] We have found that Sm derivatives are even more active as antitumour 
agents than Sm itself and that Ethyldeshydroxy-Sparsomycin (EdSm) is the most potent 
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derivative against various experimental tumours including P388 leukaemia, L1210 
leukaemia, renal cell carcinoma and B16 melanoma [364] Moreover, EdSm showed 
antitumour activity on S С implanted tumours [365] 
The purpose of this study was to examine the effect of EdSm on the antitumour 
activity of cisplatin We investigated the optimal treatment conditions with regard to 
doses, number of tumour cells implanted Ι Ρ , interval between and priority of 
administration of the two drugs, and route of drug administration 
MATERIALS AND METHODS 
Cell culture 
Murine L1210 leukaemia cells were kindly supplied by Dr G Atassi (Inst Jules 
Bordet, Lab for Experimental Chemotherapy, Brussels, Belgium) These tumour cells 
are syngeneic in CD2f, mice Cells were maintained in logarithmic growth as 
suspension cultures in RPMI 1640 medium containing 10% foetal bovine serum Cells 
were grown under a humidified 5% C02 atmosphere at 37°C 
Drugs 
EdSm was synthesised as previously described [38] and was acquired in a freeze-dned 
form The drug was dissolved in phosphate buffered saline and kept in dark flasks at 
4° С Cisplatin was kindly provided by Pharmachemie В V , Haarlem, The 
Netherlands The drugs were prepared just before administration and diluted with 
isotonic NaCl solution until the dose per gram of mouse was contained in 0 01 ml 
Animals 
CD2f( mice weighing between 18 and 22 g were used in this study In each 
experiment, phosphate buffered saline treated tumour-bearing animals served as 
controls 
Antitumour activity 
Mice were inoculated intraperitoneal^ with IO4 or 106 cells suspended in 0 2 ml 
phosphate buffered saline, pH 7 4 In each experiment tumour-bearing mice were 
randomised in the treatment and control group Each group consisted of six animals 
Drugs were administered I P or I V into mice using 0 01 ml/g body weight at 
various doses Drug treatment started on day 1 after tumour implantation Drug 
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administration was every 4 days until day 9 (q4dx3). Animal survival was recorded 
daily during 60 days and the median survival time of each group was calculated. Final 
antitumour results were computed as median survival time in days after tumour 
implantation. 
TABLE 1 : Effects of lime and order of administration of EdSm (5 mg/kg) and asplatm (3 
mg/kg) Drug administration was I Ρ every 4 days until day 9 (q4dx3) Combinations. (-) EdSm 
pre-treatment, (+) EdSm post-treatment 
Control 
EdSm 
Cisplatin 
Combinations 
Time interval 
-24 h 
- 6 h 
- 3 h 
0 
+ 3 h 
+ 6 h 
+ 24 h 
MST (in days) 
10 ± 
16 ± 
30 ± 
60 
60 
60 
60 
60 
60 
60 
1.1 (10)* 
1.9(5) 
15 (4) 
60-days survivors 
0/60 
0/30 
8/24 
5/6 
5/6 
4/6 
4/6 
6/6 
5/6 
5/6 
*number of experiments 
RESULTS 
The mean MST in 10 groups of 6 control mice inoculated with IO5 L1210 cells I.P. 
was 10.0 + 1.1 days (Table 1). Death of control mice began almost invariably on day 
9 and all mice were usually dead by day 12. As shown before [362] Sm potentiated 
the activity of cisplatin only when Sm was given 3 to 6 hours before cisplatin. The 3 
hour pre-treatment schedule was used in the starting experiments. 
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However, as shown in Table 1, no differences in antitumour activity were observed 
after pre-treatment (3, 6 or 24 h), simultaneous treatment or post-treatment (3, 6 or 24 
h) of cisplatin with EdSm, using nontoxic doses of EdSm (5 mg/kg) and cisplatin (3 
mg/kg). All schedules of combined drug treatment generated 4 to 6 cured mice in each 
group consisting of six mice. 
60 -ι— MST (days) 
2 3 4 5 
CISPLATIN (mg/kg) 
FIGURE 1: 
Апшшпоиг effects of cisplatin in LI210 leukaemia Drug treatment was I Ρ e\ery 4 days until day 
9 (q4dx3) cisplatin single (fc|) or in combination (m) with EdSm (5 mg/kg) EdSm was given 3 hours 
before cisplatin administration Values are means ± SEM of at least three experiments 
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In single drug treatment with EdSm 5 mg/kg (MST=160%) no cures were noticed. 
Using cisplatin, however, at a dose range of 2 to 5 mg/kg a number of long term 
survivors were obtained. But combined drug treatment always produced a larger 
number of cures. Lifespan data for the optimal effects obtained in L1210 experiments 
are summarised in Fig. 1. Changing the route of drug administration for one of the 
drugs of the combination from LP. to I.V. resulted in loss of antitumour activity (Fig. 
2). Increasing the number of tumour cells implanted LP. diminished the antitumour 
effect of both EdSm as well as cisplatin, but less for the drug combination (Fig. 3). 
TABLE 2: Summary of long term survivors after cisplatin treatment, single or in combination 
with EdSm LI210 leukaemia cells were inoculated I.Ρ on day 0 Drug administration was I P. or 
iv every 4 days until day 9 (q4dx3) 
Drug treatment 
mg/kg per injection 
EdSm 
0 
5 
0 
0 
0 
0 
0 
5 
5 
5 
5 
5 
cisplatin 
0 
0 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
60 days survivors/total 
treatment LP. 
10s cells* 
0/60 
0/30 
0/6 
2/12 
8/24 
6/18 
14/30 
2/6 
5/12 
18/30 
15/18 
18/24 
106 cells 
0/18 
0/18 
--
0/12 
0/12 
0/12 
0/12 
-
4/12 
4/12 
4/12 
4/12 
treatment I.V. 
10' cells 
0/6 
0/6 
--
--
0/6 
0/6 
0/6 
--
--
0/6 
0/6 
0/6 
Number of tumour cells implanted I Ρ 
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60-i-MST (days)-
CDDP-lv 
EdSm-lv/CDDP-lv 
EdSm-lv/CDDP-lp 
EdSm-lp/CDDP-lv 
0 1 2 3 4 5 6 
CISPLATIN (mg/kg) 
F I G U R E 2: 
Tlierapeutic effects dependent ση the route of drug administration EdSm (5 nig/kg) was combined 
nuli cisplatin doses of 3, 4 ad 5 mg/kg Drug administration nas every 4 days until day 9 
(q4dx3) EdSm was given 3 hours before cisplatin administration Drug administration (m) single 
iisplatm I V, (q) EdSm I. V and cisplatin IV, (·) EdSm I. V and cisplatin I Ρ ; (&) EdSm 1 Ρ 
and cisplatin I V 
DISCUSSION 
From these in vivo experiments we concluded that treatment with a subtoxic dose of 
EdSm potentiates cisplatin antitumour activity. In vivo the enhanced sensitivity to 
cisplatin is retained for at least 24 h and independent of the order of drug 
administration. 
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A series of experiments were performed using I.V. treatment of I.P. implanted L1210 
leukaemia in order to establish whether the drug could be delivered at therapeutic 
levels to this sensitive tumour implanted at a distal site. These results show a complete 
lack of antitumour activity after I.V. drug treatment, which suggest insufficient I.P. 
drug delivery. 
I T — M S T (days) 
1 2 3 4 
CISPLATIN (mg/kg) 
FIGURE 3 : 
Therapeutic effects of combined drug treatment dependent on the number of leukaemia L12I0 cells 
inoculated ¡P.. l(f tumour cells were implanted I. P. into CD2f, mice on day 0. Drug 
administration was every 4 days until day 9 (q4dx3). EdSm was given 3 hours before cisplatin 
administration Antitumour activity of single cisplatin treatment fcjl, and m combination with EdSm 
5 mg/kg (V Values are means ± SEM of at least three experiments 
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On the other hand, recent studies indicated that low concentrations of sparsomycin 
afforded significant resistance to cisplatin [271] Consequently, the loss of activity 
after I V administration of EdSm and/or cisplatin might be explained by antagonistic 
effects when the I Ρ EdSm concentration is too low Although the outcome of cancer 
chemotherapy may depend mainly on the sensitivity of the tumour under treatment, 
pharmacokinetic factors such as drug absorption, metabolism and elimination are 
extremely important in determining the dose schedule and route of administration A 
drug enters the circulation by being injected there directly, or by absorption from 
depots where it has been placed The most obvious advantage of the intravenous route 
is that the drug is placed in the circulation with minimal delay The intraperitoneal 
route is commonly used in animal experiments where diffusion into the blood is rapid 
owing to the large surface area of the absorbing surface Careful selection of the route 
of administration may improve the antitumour effect of a given drug by allowing it to 
reach high concentrations in the areas of clinical need 
Recently, it was shown that the platinum concentration in intraperitoneal tumour 
nodules is always higher after I Ρ than after I V treatment [205], suggesting that the 
higher drug concentration measured in peritoneal tumours after I Ρ administration is 
due to direct drug diffusion from the peritoneal cavity into the tumour Combination 
therapy with an agent which enhances cisplatin antitumour effects which no 
enhancement of cisplatin toxicity, may be of value in the treatment of human tumours 
which fail to respond to treatment with cisplatin alone The molecular events 
responsible for the observed increase in chemosensitivity, however, have not yet been 
established 
Pre-treatment with EdSm might inhibit the synthesis of enzymes like glutathione S-
transterase in tumour cells and can also cause glutathione depletion Both effects are 
ot benefit for cisplatin antitumour activity Because less cisplatin is intracellularly 
inactivated by glutathione conjugation, more cisplatin molecules reach the DNA, 
which is the target of cisplatin Post-treatment with EdSm might inhibit the synthesis 
of DNA repair enzymes, causing a persisting DNA damage by cisplatin which 
increases cisplatin cytotoxicity Anyhow, the synergistic effect of EdSm on cisplatin 
antitumour activity is consistent with the assumption of different mechanisms of action 
of these two drugs Studies directed to the elucidation of the mechanism of the 
observed potentiating effect seem to be of great relevance 
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CHAPTER 7 
PRECLINICAL ANTITUMOUR ACTIVITY OF 
ETHYLDESHYDROXY-SPARSOMYCIN IN COMBINATION 
WITH CISPLATIN. 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, H VAN RENNES, 
D DE VOS, WH DOESBURG, HCJ OTTENHEIJM, WJ DE GRIP. 
Investigational New Drugs 1994 (in press). 
Conclusion: 
EdSm can have significant synergistic capabilities in several animal tumour models, 
but strong therapeutic enhancement of cisplatin efficacy is only seen if the tumour 
is sensitive to both cisplatin and EdSm. 

SUMMARY 
The efficacy of cisplatin in combination with the protein synthesis inhibitor 
ethyldeshydroxy-sparsomycin (EdSm) has been tested in two tumour models at various 
schedules. Mice with L1210 leukaemia or B16 melanoma were treated with cisplatin 
alone or in combination with EdSm. Against L1210 leukaemia, which is sensitive to 
cisplatin, combinations elicited increases in life-span for all treatment schedules 
compared to those achieved with the corresponding dose of cisplatin. Moreover, the 
combination of EdSm with this platinum compound yielded a cure rate >80%, 
compared to <35% for single cisplatin treatment. Although the B16 melanoma is 
rather resistant to both cisplatin and EdSm, combinations of these agents against B16 
melanoma showed schedule dependent efficacy and in certain schedules significant 
therapeutic advantage over individual drug treatment, but cures were not observed. 
Our results suggest that EdSm has significant synergistic capabilities in both animal 
tumour models, but strong therapeutic enhancement of cisplatin efficacy is only seen 
when the tumour is sensitive to cisplatin. 
INTRODUCTION 
Cisplatin is one of the most active of currently available cytotoxic agents and has 
efficacy against a wide range of malignancies. It is thought to act via inter- and 
intrastrand crosslinking of duplex DNA [270]. The main clinical toxicities induced by 
cisplatin include nephrotoxicity and ototoxicity. When it was evident that cisplatin 
produced significantly less myelosuppression than other cytotoxic drugs [163], it 
became interesting to look for additive or synergistic combinations with other agents, 
which also might further reduce toxic side effects. 
Synergism with cisplatin was clearly found for various drugs against the L1210 
tumour in BDF1 mice [111,112,349]. The advantages of cisplatin in combination 
chemotherapy were soon verified in other tumour models, like Sarcoma-180 [44], 
P388 leukaemia and human small cell lung carcinoma (SCLC) [296]. Recently, other 
chemical response modifiers have been studied in combination with cisplatin, and it 
was found that inhibitors of adenosine-ribose transferase like 3-aminobenzamide and 
nicotinamide, are able to potentiate the antitumour activity of cisplatin on Ehrlich 
ascites carcinoma in mice [53]. 
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The effect of combined treatment often is schedule dependent For instance, 
administration of N-methylformamide (NMF) to mice bearing MCA-K tumours 
enhanced tumour growth delay induced by cisplatin only when NMF treatment was 
begun after cisplatin administration [159] Schedule dependent synergy of combined 
treatment has also been studied at the cellular and biochemical level in vitro Cisplatin 
showed schedule dependent synergistic activity in \itro in combination with 4-
hydroperoxy-cyclophosphamide [248], ARA-C [28,182], and NMF [314] A special 
group of chemical modifiers used in combination studies with cisplatin are protein 
synthesis inhibitors like cinnamaldehyde, anguidine and L histidinol In combination 
with cinnamaldehyde synergism was found to occur only when cisplatin was given 
simultaneously [82] In contrast, anguidine potentiates cisplatin efficacy only after pre­
treatment of Chinese hamster ovary cells with anguidine [153] in vivo tumour cells 
were efficiently killed by cisplatin in combination with L-histidinol, given in five 
consecutive injections or by continuous infusion [89,333,357] 
Sparsomycin (Sm) and analogues are potent inhibitors of protein synthesis by 
blocking the nbosomal peptidyl transferase centre [69,118-120,303,309] 
Although Sm itself enhanced the cytotoxic effects of cisplatin in vitro [363] as well as 
cisplatin antitumour activity in vivo [362], analogues have now been synthesised [37], 
which have belter antitumour activity [364] and stronger potentiation of cisplatin 
anlitumour activity than Sm itself [365] 
The present study was undertaken to evaluate the effects of different treatment 
schedules of the analogue EdSm on the efficacy of cisplatin in the cisplatin sensitive 
L1210 leukaemia, in comparison with the rather cisplatin resistant B16 melanoma 
MATERIAL AND METHODS 
Tumour cells 
Murine L1210 leukaemia cells and B16 melanoma were kindly supplied by Dr G 
Atassi (Inst Jules Bordet, Lab for Experimental Chemotherapy, Brussels, Belgium) 
Cells were maintained in logarithmic growth as suspension cultures in RPMI 1640 
medium containing 10% foetal bovine serum (Gibco), 2 mM glutamine (Boehrmger-
Mannheim GmbH, Mannheim, FRG), and 50 μg gentamycin/ml (Boehnnger-
Mannheim GmbH) and 60 μΜ mercaptoethanol (Sigma Chemical Co , St Louis, 
MO) Cells were grown under a humidified 5% C02 atmosphere at 37°C B16 
melanoma cells were grown routinely as monolayer culture in closed tissue culture 
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flasks (Costar, Cambridge, MA) at 37°C in a humidified atmosphere (Heraeus 
incubator) of 5% C02 in air. We used Eagle minimum essential medium with Earle's 
salts (Gibco, Grand Island, NY) supplemented with 25 mM HEPES (4-(2-
hydroxyethyl)-l-piperazine ethanesulfonic acid) buffer, 10% heat-inactivated foetal calf 
serum (Gibco), 2 mM glutamine (Boehringer-Mannheim GmbH, Mannheim, FRG), 
and 50 μg gentamycin/ml (Boehringer-Mannheim GmbH). Cells were harvested by 
treatment with 0.025% trypsin (type III; Sigma Chemical Co., St. Louis, MO) and 
0.05% EDTA for 3 minutes at 37°C. 
Cytotoxicity assays 
Clonogenic assay: L1210 cells were exposed to different drug doses. After drug 
exposure, the drug-containing medium was removed, the cells were washed with 
balanced salt solution, and counted (Coulter counter). The clonogenic ability of treated 
cells was evaluated by a soft-agar colony assay. Leukaemic colonies were grown by 
plating the cells in 0.3% agar in 6-wells plates (Costar) in drug free medium. After 8 
days of incubation colonies (>50 cells) were scored using an inverted microscope. 
The surviving fraction was calculated by dividing the absolute survival of the treated 
sample by the absolute survival of the control sample at the same time. Each 
experimental point was determined in duplicate and all experiments were repeated 
twice. 
Microculture Tetrazolium Test (MTT): The MTT assay used was essentially the 
same as previously described by Mosmann [223]. This assay is based on the reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide by mitochondrial 
dehydrogenase in viable cells to a blue formazan product that can be measured 
spectrophotometrically. The basic feature of the test is the dependent conversion of a 
yellow tetrazolium salt into a purple formazan precipitate. This reaction directly 
indicates cell viability [50]. B16 melanoma cells were seeded at 1000 cells/well at 
time 0, allowed to grow for 24 h, and then treated with drugs for 1 or 24 hours as 
indicated. Seven days after cell plating 0.02 mg tetrazolium salt was added to each 
well and incubated at 37 °C for a further 4 h. The formazan was dissolved in DMSO 
and measured spectrophotometrically at 550 nm. 
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TABLE 1: 
Cytotoxicity of Cisplatin and EdSm in B16 melanoma and L1210 leukaemia celli after drug 
exposure times of 1 or 24 hours m vitro 
IC50 (μΜ)* 
L1210 leukaemia B16 melanoma Ratio B16/L1210 
IH 24H IH 24H IH 24H 
EdSm 8 0 0 85 13 3 17 1.7 2.0 
cisplatin 39.3 2 7 47 0 5 0 1.2 18 
Ratio 4.9 3.2 3 5 2 9 
CDDP/EdSm 
^Concentration of drug giving 50% growth inhibition Values are means of at least three 
separated experiments performed m triplicate The standard error of the mean was less than 10% 
Animals 
CD2f, mice weighing between 18 and 22 g were used to study the L1210 leukaemia, 
and C57B1/6 mice were used for В16 melanoma implants. In each experiment, 
phosphate buffered saline treated tumour-bearing animals served as controls. All mice 
were obtained from Charles River Breeding Laboratories, Inc. 
Antitumour activity 
Mice were inoculated intraperitoneally with IO4 L1210 cells or IO6 B16 melanoma 
cells suspended in 0.2 ml phosphate buffered saline, pH 7.4. Acceptable median 
control survival times range from 8-11 days for L1210 LP. tumour and 14-22 days for 
B16 LP. tumour [116]. In each experiment tumour-bearing mice were randomised in 
the treatment and control group. Each group consisted of six animals. Drugs were 
administered at various doses LP. into mice using 0.01 ml/g body weight. Different 
treatment schedules were used, mostly starting on day 1, which was 24 hours after 
tumour implantation. Animal survival was recorded daily during 60 days and the 
median survival time (MST) of each group was calculated. Final antitumour results 
were computed as median survival time in days after tumour implantation. A T/C% of 
>135% is generally taken as a positive indication for antitumour activity according to 
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the NCI criteria [116] T/C is the median survival time of the test group divided by 
that of the control group L1210 and B16 experiments were terminated after day 60 
Mice alive at the end of an experiment were autopsied and judged to be cured if no 
signs of tumour were visible 
Drugs 
EdSm was synthesised by the department of Organic Chemistry of the University of 
Nijmegen, the Netherlands [38], and was acquired in a lyophilised form The drug 
was dissolved in phosphate buffered saline and kept in dark flasks at 4° С Cisplatin 
was kindly provided by Pharmachemie В V , Haarlem, The Netherlands cisplatin was 
provided as a formulated compound Solutions with the required drug concentration 
were prepared just before administration by dilution with isotonic NaCl 
Statistical analysis 
Our experimental data have been analyzed by Cox's proportional hazards regression 
model (PH-model) [171] Each presented data point was calculated on basis of 
repeated experiments As usual, in this PH-model dummy variables were used to 
indicate the given doses of EdSm and of cisplatin Product terms of these dummy 
variables were included in the model to account for interaction effects of both drugs 
on survival A tumour specific hazard has been obtained by censuring death within 6 
days for L1210 and within 14 days for B16 as due to drug toxicity This occurred only 
in some В16 experiments The median survival times, separately for each treatment 
schedule, were calculated within this (complete) PH-model The percentages long term 
survivors (LTS) were also calculated using the PH survival function, and were in very 
good agreement with the observed number of LTS after 60 days The risk-ratios of 
individual as well as of combined drug treatment, compared to the non-treated 
animals, are directly given by PH-analysis All P-values were calculated according to 
Wald's chi-squared test P-values less than 0 05 were considered to be significant We 
call the risk ratio for combined drug treatment given by this PH-analysis the risk-ratio 
observed (RRO) The nsk-ralio expected for combined treatment (RRE) is the product 
ot individual risk-ratios of EdSm and cisplatin The quotient RRO/RRE is called the 
combination ratio (CR) The drug interaction is called synergistic when RRO is lower 
than RRE, or CR < 1, and antagonistic when RRO is higher than RRE, or CR > 1 
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RESULTS 
Studies in vitro 
The murine tumour cell lines L1210 leukaemia and B16 melanoma were used to 
evaluate the activity of EdSm and cisplatin in an in \itro growth delay assay The 
single agent IC50 values of EdSm and cisplatin for each cell line after 1 and 24 hours 
of exposure are reported in Table 1 The cytotoxicity of both EdSm and cisplatin was 
higher in L1210 than in B16 The IC50 doses of EdSm were 1 7 and 2 0 times higher 
in В16 relative to L1210 after 1 and 24 hours of drug exposure respectively For 
cisplatin these figures were 1 2 and 1 8 times respectively Compared with cisplatin, 
EdSm was 3 2 to 4 9 times more potent in L1210 cells, and 2 9 to 3 5 times in B16 
cells 
Combined chemotherapy in L1210 leukaemia 
Treatment schedule was varied in several experiments performed with I Ρ implanted 
L1210 It was previously shown [347] that in the Ι Ρ L1210 leukaemia cisplatin was 
active on all schedules of I Ρ administration with appropriate dosage and, therefore, 
would not be considered to be schedule dependent for activity The combination of 
EdSm and cisplatin was independent of drug sequence as well as of time interval 
between drug administration [146] Thus, for practical reasons we gave EdSm in all 
schedules 3 hours before cisplatin treatment The results of combined drug treatment 
in L1210 are summarised in Fig 1 and 2 Figure 1 shows the results expressed as 
median survival time for cisplatin in Ι Ρ L1210 leukaemia after different treatment 
schedules in combination with EdSm The median survival time of 96 placebo treated 
control animals was 10 days ± 0 35, and the tumour take was 100% The maximum 
tolerated dose of EdSm has been published before by Zylicz et al [364] In summary, 
the LD50 after daily treatment during 9 days I Ρ was 8 mg/kg, and a dosage of 
higher then 5 mg/kg within any schedule caused diarrhoea for several hours The 
maximum antitumour activity of EdSm was 172 %T/C, obtained in the L1210 
leukaemia tumour modal after daily I Ρ treatment with 6 2 mg/kg for 9 days 
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FIGURE 1: 
Schedule dependent antuumour activity of EdSm (5 mg/kg) and cisplatin (3, 4 or 5 mg/kg), given 
as single agents or in combination against L1210 Leukaemia implanted I Ρ Treatment schedules 
1 Ρ treatment only on day I or day 5 (A), I Ρ treatment on day 1 and 5 (B), I Ρ treatment on 
day 1, 5 and 9 (C), I Ρ treatment on day 1, 8 and 15 (D) A censored MST of larger than 60 
days is plotted at 60 days 
The effect of EdSm on cisplatin antitumour activity was studied at a fixed dose of 5 
mg EdSm/kg in combination with cisplatin of 3, 4 or 5 mg/kg. Figure 2 shows the 
percentage survivors after 60 days EdSm itself showed a largest MST of 12 days, 
using the Dl,5,9 treatment schedule, and long term survivors were not seen in any 
treatment schedule at any dose 
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FIGURE 2: 
Percentages long term survivors (>60 days) of mice with IP implanted L121Ü leukaemia after 
single cisplatin treatment or m combination with EdSm (5 mg/kg/mjection) using different 
treatment schedules 
The optimal antitumour activity for single cisplatin treatment was achieved with 5 
mg/kg using the Dl,5 treatment schedule, resulting in a MST of 27 days. The efficacy 
of the combination was dose and schedule dependent, but, as long as the treatment 
was repeated there does not seem to be a clear preferable schedule for combined drug 
treatment. Although EdSm increased the antitumour activity of cisplatin after treatment 
on day 1 or day 5, the result was not statistically significant different from single 
cisplatin treatment (p = 0.36 for Dl and 0.33 for D5). antitumour activity of cisplatin 
increased progressively as the duration of treatment rose. 
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Although combined treatment with EdSm increased the MST in all treatment schedules 
(Fig 1), the best potentiating contribution was seen with the lower cisplatin doses (3 
mg/kg), increasing the MST from 17 days for single cisplatin treatment to >60 days 
for combined treatment (Dl,5), resulting in 6% and 84% LTS, respectively (fig 2A) 
The contribution of EdSm to the antitumour activity of the combination decreases 
when the efficacy of cisplatin increases (Fig 2) Although the loss of body weight 
(data not shown) caused by cisplatin (5 mg/kg) was severe in the Dl,5,9 treatment 
schedule, toxic deaths did not occur with any regimen at the dose levels used This 
toxicity might explain why the Dl,5 schedule (Fig. IB) gave better results for single 
cisplatin treatment than the Dl,5,9 schedule (Fig 1С) 
Analysis of the interaction type shows that the effect of EdSm on the efficacy of 
cisplatin antitumour activity is synergistic in the treatment schedules Dl,5, Dl,5,9 and 
Dl,8,15, in combination with 3 and 4 mg/kg cisplatin (Fig 3) Antagonism is only 
seen in the treatment schedule Dl,5,9, in combination with cisplatin, 3 mg/kg 
However, only one combination gives statistically significant synergistic interaction 
the combination of EdSm with cisplatin 3 mg/kg in the treatment schedule Dl,5 
Combined chemotherapy in В16 melanoma 
The tumour-take of Ι Ρ implanted B16 melanoma was 100% and resulted in a median 
survival time of 18 ± 0 13 days for 66 placebo treated control animals In comparison 
with L1210, the B16 melanoma is relatively resistant to cisplatin To determine 
whether EdSm could improve the antitumour activity of cisplatin against В16 
melanoma in mice, combinations of cisplatin and EdSm were used at several doses 
and different schedules, as summarised in Table 2 We increased drug doses in the 
combinations till toxicity was observed In comparison with the survival of control 
animals only antitumour activities of >135%, comparable with a MST of 24 days, are 
acceptable as antitumour activity This means that EdSm itself has real antitumour 
activity only after daily treatment for 7 days with 5 mg/kg Contrary to EdSm, 
cisplatin gave acceptable antitumour effects in different schedules 
Nevertheless, all treatment schedule are in favour of combined drug treatment The 
statistical analysis of animal experiments for combined studies shows that in 
comparison with single cisplatin treatment only the treatment schedules 4xDl, Dl-3, 
Dl-7 and 2xDl,8 were statistically significant different from single cisplatin treatment 
107 
TABLE 2: 
Effect of treatment schedules on cisplatin antitumour activity in combination with EdSm against 
B16 melanoma 
TREATMENT EdSm CDDP EdSm CDDP COMB ANT* SYN4 
SCHEDULE mg/kg/inj median survival time P-value 
Dl 
2xDl' 
4xDl' 
Dl-3® 
Dl-7® 
D1,5,9S 
Dl,8 $ 
2xDl,8* 
Dl,8,15 s 
2.5 
2.5 
2.5 
5 
10 
15 
2.5 
5.0 
10 
1 
2 5 
2 5 
2.5 
2.5 
2.5 
1 
1 
2.5 
2 5 
5 
5.0 
5.0 
5 0 
2.5 
2 5 
2 5 
6 
8 
10 
6 
6 
6 
6 
6 
6 
4 
4 
1 
2 
3 
4 
1 
2 
1 
2 
1 
3 
4 
5 
6 
6 
6 
18 
18 
18 
17 
20 
20 
18 
18 
18 
19 
TOX 
18 
18 
18 
18 
21 
21 
22 
22 
28 
18 
18 
18 
20 
19 
18 
21 
20 
21 
21 
21 
21 
21 
21 
21 
18 
18 
18 
21 
24 
26 
22 
31 
22 
31 
22 
22 
23 
26 
25 
25 
18 
21 ns 
21 ns 
TOX 
22 ns 
22 ns 
TOX 
25 ns 
23 ns 
TOX 
20* 
TOX 
24* 
27* 
27* 
TOX 
26* 
30* 
34* 
34* 
31* 
19 ns 
24 ns 
TOX 
24* 
30* 
24 ns 
0 88 
0.16 
ne 
ne 
0 38 
0.05* 
0.09 
0.04* 
ne 
0.45 
0 11 
0.62 
0.007* 
0.023* 
0.16 
0.40 
0 06 
0.35 
0 03* 
0.12 
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*Statistically significant from single cisplatm treatment, P-value < 0 05; ns. not statistically 
significant 
iANT antagonism, SYN: synergism In some cases, due to omitted experiments, the P-value for 
interaction could not be calculated, which we have noted as not-estimable (ne) 
"2xDl and 2xDJ,8 EdSm is given twice, 3 hours before and after a single cisplatm 
administration, 4xDl: EdSm is given 4 times, 3 and 6 hours before and after a single cisplatm 
administration In the other treatment schedules EdSm was always given 3 hours before cisplatm 
injection 
®DI-3 and DI-7: daily injection of both drugs during 3 or 7 days, respectively. 
SD1,5,9, Dl,8 and Dl,8,15 injection of both drugs on the indicated days. 
The best enhancement was obtained using daily drug administration during 7 days 
(Dl-7). The beneficial modulatory effect of 2.5 mg EdSm/kg to 1 mg cisplatin/kg is 
indicated by an increase in median survival time of tumour-bearing mice from 22 days 
to 34 days. The survival function during 60 days of these individual groups are shown 
in Fig. 4. However, in contrast with L1210, single or combined treatment of B16 
melanoma tumours did not produce any long term survivors. 
Again we analyzed our data for synergistic or antagonistic interactions. The results 
are given as antagonism (ANT) or synergism (SYN) including the p-values (Table 2). 
Significant antagonism in combined treatment is seen in the treatment schedules Dl-7, 
EdSm (1 mg/kg) with cisplatm (2 mg/kg), and Dl,8, EdSm (2.5 mg/kg) with cisplatm 
(6 mg/kg). Significant synergism, on the other hand, is found in Dl-3, and Dl,5,9, 
for EdSm (2.5 mg/kg) with cisplatin (1 and 2 mg/kg), and EdSm (5 mg/kg) with 
cisplatin (4 mg/kg), respectively. 
DISCUSSION 
The difference in antitumour activity of cisplatin as well as of EdSm between the В16 
and L1210 animal tumour models mirrors the cytotoxic difference in vitro: to both 
drugs the B16 melanoma cells were less sensitive than the L1210 leukaemia cells. In 
contrast with these in vitro results, in vivo cisplatin was more potent than EdSm m 
both murine tumours. 
Drug-drug interplay of anticancer agents studied in vitro, provides precise information 
on drug potency, but none on drug selectivity. Sometimes a synergistic interaction, 
observed in vitro, is also seen in vivo. This may be expected to be the case when the 
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dose-limiting toxicity of a drug is unrelated to its therapeutic mechanism of action. In 
the case of cisplatin the dose-limiting toxicity is nephrotoxicity, which appears to be 
mechanistically unrelated to the DNA cross-linking activity that causes its antitumour 
effect [128,168,218]. In that case, a drug combination that enhances cisplatin's 
antitumour effect may also increase toxicity to normal tissues, but would not be 
expected to potentiate the nephrotoxicity, so a therapeutic synergism may be obtained. 
COMBINATION RATIO 
CDDP MG/KG/INJ 
FIGURE 3: 
Analysis of the type of drug interaction of EdSm and cisplatin ¡n combined treatment of L1210 
leukaemia, using the individual risk-ratios in the PH-model The combination ratio (CR) is the 
risk-ratio observed (RRO) divided by the risk-ratio expected (RRE) The interaction is antagonistic 
when CR > I, addane v,hen CR = 1, and synergistic when CR < J. 
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When each single drug of a combination exhibits effects by itself, the combined 
effect can be calculated by the Cox's proportional hazards regression model (PH-
model) that uses the antitumour results of the whole range of dosages of the single 
agents in the calculation, as described in material and methods, and may lead to 
synergism or antagonism. In the L1210 tumour model we retained significant 
enhancement of antitumour activity along with diminished cisplatin toxicity by use of 
sub-optimum dosages of individual drugs. This effect was greater than the complete 
response rate, assuming independent drug action. Thus our interpretation is that this 
high complete remission rate is the result of an interplay between the drugs that is 
more than additive. 
% SURVIVAL 
1 0 0 « CONTROL 
- * - EDSM 
Δ ~ ^ ~ CDDP 
-A- COMBINATION 
FIGURE 4: 
Survival of mice with Ι Ρ implanted B16 melanoma, after daily I.P. treatment during seven days 
(Dl-7) MUH EdSm, 2 5 mg/kg/day, and cisplatin, 1 mg/kg/day, as single agents and in 
combination 
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Against B16 melanoma EdSm showed no acceptable antitumour activity, with only 
one exception, the Dl-7 treatment schedule using the highest possible EdSm dose 
(Table 1) However, even drugs which show limited antitumour activity in the used 
tumour model, can still potentiate the antitumour activity of cisplatin in that tumour 
model [53] Therefore, we investigated whether EdSm still could potentiate the 
cisplatin antitumour activity towards В16 The antitumour activity of cisplatin against 
В16 melanoma is weak, although the 172% treated over control value (T/C) found for 
cisplatin in the B16 melanoma I Ρ tumour model is in agreement with the earlier 
reported response of 178% [37] Combined drug treatment in this В16 tumour model 
was much less successful than with L1210 leukaemia, and, although significant 
synergism was found, even maximal tolerable dose levels resulted only in marginal 
improvement of the antitumour activity 
The difference in antitumour activity of cisplatin between these two experimental 
tumour models is a question of the intrinsic sensitivity of the tumour itself to the given 
agent Previous investigations from this laboratory have demonstrated that single 
cisplatin treatment is deficient in advanced L1210 leukaemia, but not the combination 
with EdSm, resulting in increased median survival times as well as several cures 
[364] Therefore, a more plausible explanation of the difference between the efficacy 
of the combination in both tumour models is the difference in their sensitivity to both 
drugs used in this combination As already mentioned by Schabel et al [282,283], an 
otherwise effective drug will not kill a drug-sensitive rumour cell that it cannot or does 
not reach in lethal concentration [72,73] Dose-response curves give an indication of 
the minimum drug concentrations and exposure times required (C χ Τ) to effect a 
response in vitro and would suggest that if these levels are experimentally achievable 
in \ivo the tumour should respond Treatment with therapeutic doses of cisplatin in 
human patients have been found to have tissue concentrations of the drug as high as 33 
μΜ [26] Apparently, this cisplatin concentration is not reached in В16 melanoma, 
otherwise these tumour cells should be killed efficiently by cisplatin 
The cisplatin and EdSm concentrations needed to give 50% growth inhibition, as 
single drugs, were much higher in B16 melanoma than in L1210 cells So, the EdSm-
CDDP interplay might be tumour dependent, suggesting a cellular basis for the 
therapeutic synergism achieved in vivo in L1210 leukaemia Inhibitors of protein 
synthesis induce a cell cycle arrest in exponentially growing cells, and these cells 
accumulate in the Gl [20,214,308] Therefore, synergism might be explained on the 
basis of cytokinetic considerations Scambia et al [281] demonstrated cisplatin 
synergism when the cell transition from the G0-G1 to the S phase of the cell cycle is 
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blocked Furthermore, Gl-phase cells are more sensitive to platinum bound to their 
DNA than mid S phase or asynchronously treated cells [107] 
These results reveal that administration of EdSm in combination with cisplatin 
leads to significant synergistic effects, which are dose, schedule and tumour 
dependent However, this synergism is minimal and it is obtained using an Ι Ρ /I Ρ 
design on very early stage tumours Moreover, this therapeutic advantage can reflect a 
specific interaction at the cellular level, but enhancement by favourable 
pharmacological interactions can not be excluded 
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PART IV 
EFFECTS OF EDSM IN COMBINATION WITH OTHER 
ANTITUMOUR AGENTS 

CHAPTER 8 
CONCENTRATION AND SEQUENCE DEPENDENT 
SYNERGISM OF ETHYLDESHYDROXY-SPARSOMYCIN IN 
COMBINATION WITH ANTITUMOUR AGENTS. 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, H VAN RENNES, 
HCJ OTTENHEIJM, WJ DE GRIP 
Anti-Cancer Drugs 5: 35-42, 1993. 
Conclusion: 
In vitro synergism was observed upon pre- and post-treatment of EdSm in 
combination with cisplatin, cytosine arabinoside, methotrexate, and 5-fluorouracil. 

SUMMARY 
The modulating effect of ethyldeshydroxy-sparsomycin (EdSm), an inhibitor of nboso-
mal protein synthesis, on cytostatic agents was studied on cultured B16 melanoma 
cells using the microculture tetrazolium test (MTT) The data were analyzed for true 
synergism using the combination-index and the median-effect principle The extent of 
cytotoxic drug interaction was influenced by the duration of drug exposure, the dose 
ratio, as well as the treatment schedule When drug ratios were used, synergism was 
observed upon pre- and post-treatment in combination with cisplatin (CDDP), cytosine 
arabinoside (ARA-C), methotrexate (MTX), and 5-fluorouracil (5-FU) The 
combination of a fixed dose of EdSm was synergistic with cisplatin, ARA-C, 
vincristine (VCR) and MTX, in the order MTX > ARA-C > VCR > cisplatin, 
while the combinations with doxorubicin, 5-FU and etoposide (VP16) were shown to 
be antagonistic These results suggest that only certain drugs and treatment schedules 
might be worthrul for combination studies with EdSm in vivo and indicate a role for 
EdSm as modifier of antitumour responses in cancer chemotherapy 
INTRODUCTION 
Sparsomycin and several derivatives are well-established inhibitors of nbosomal 
protein synthesis [32,69,120,303] Previous reports from our laboratory clearly 
demonstrated that sparsomycin and some analogues can potentiate the antitumour 
activity of cisplatin in vivo [146,362,365] Furthermore, it was shown that combined 
treatment of cisplatin and EdSm was order-independent [146] Recently, it has been 
described for leukaemia cells [147] that this interaction did not directly depend on 
pharmacological effects, but rather strongly on the cellular properties of the target 
tumour-cell populations A comparison of the cellular basis of drug sensitivity of 
human colon, pancreatic, and renal carcinoma cell lines with that of leukaemia cell 
lines [244] suggests that the refractoriness of solid tumours to chemotherapy compared 
with leukaemia cells is, at least in part, due to drug resistance of the tumour cell 
itself A second important factor might be, however, that the sensitivity of tumour 
cells as well as the cytotoxicity of drug combinations depends on the schedule of 
administration as well as the doses used [76,161] 
The purpose of this study was to investigate at the cellular level the optimal dose 
ratio and schedule dependency for maximal cytotoxic interaction of EdSm with 
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antitumour agents with different intracellular targets. To analyze the experimental data 
of the drug combination studies and to quantify synergism or antagonism, we applied 
computer software based on the median-effect principle developed by Chou [60]. 
MATEMALS AND METHODS 
Cell culture 
Murine B16 melanoma cells were kindly supplied by Dr.G. Atassi (Inst. Jules Bordet, 
Lab. for Experimental Chemotherapy, Brussels, Belgium). These cells were grown 
routinely as monolayer culture in closed tissue culture flasks (Costar, Cambridge, 
MA) at 37°C in a humidified atmosphere (Heraeus incubator) of 5% C02 in air. As 
growth medium we used Eagle minimum essential medium with Earle's salts (Gibco, 
Grand Island, NY) supplemented with 25 mM HEPES (4-(2-hydroxyethyl)-l-
piperazine ethanesulfonic acid) buffer, 10% heat-inactivated foetal calf serum (Gibco), 
2 mM glutamine (Boehringer-Mannheim GmbH, Mannheim, FRG), and 50 μg 
gentamycin/ml (Boehringer-Mannheim GmbH). Cells were harvested by treatment 
with 0.025% trypsin (type III; Sigma Chemical Co., St. Louis, MO) and 0.05% 
EDTA for 3 minutes at 37°C. 
Drugs 
Ethyldeshydroxy-sparsomycin was synthesised by the department of Organic 
Chemistry of the University of Nijmegen, the Netherlands [38], and was acquired in a 
lyophihsed form. The drug was dissolved in phosphate buffered saline and kept in 
dark flasks at 4 е C. The antitumour agents we used were formulated for clinical use, 
and were stored as indicated for each drug. Cisplatin (Platinol), 5-FU and 
methotrexate were kindly provided by Pharmachemie B.V., Haarlem, The 
Netherlands. The other antineoplastic agents were derived from Bristol-Myers (VP 16), 
Upjohn (ARA-C), Eli Lilly (vincristine), and Pharmacia (doxorubicin) All drug 
solutions were prepared immediately before use to prevent loss of activity due to 
decay. The agents were firstly dissolved in the prescribed solvent and subsequently 
diluted in growth medium. Before final conclusions can be drawn concerning the 
schedule dependency of an anticancer drug based on in vitro studies using the MTT, it 
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is essential to document drug stability under in vitro assay conditions The drugs used 
in these studies, with exception of etoposide, cisplatin and doxorubicin, maintain their 
chemical and biological stability for up to 10 days [33,34,352] Degradation of 
etoposide is rapid under in vitro culture conditions, where it shows a half-life of 2 
days [207] Cisplatin has a half-life of 18 5 h under in vitro culture conditions 
Definitive statements about doxorubicin stability are confusing, but it probably slowly 
degrades in medium So, apart from doxorubicin, the drugs used in our experiments, 
will exert their cytotoxic action during the entire treatment period of 18 hours 
Drug treatment 
For drug treatment B16 melanoma cells were seeded at 1000 cells/well, allowed to 
grow for 24 h, and then drugs were applied In the single-agent experiments, cells 
were exposed to increasing concentrations of the individual drugs EdSm treatment 
was 3 hours or 24 hours The duration of exposure of the other drugs was always 18 
h Following drug exposure, the cells were washed with phosphate-buffered saline 
(PBS) and fresh medium was added Combination treatments were always performed 
using sequential exposure to the two agents EdSm was given before (pre-treatment) or 
after (post-treatment) the exposure of the second drug Treatment schedules A = 
exposure to EdSm for 3 h, followed by exposure to an antitumour agent for 18 h, В = 
exposure to an antitumour agent for 18 h, followed by exposure to EdSm for 3 h, С 
= exposure to EdSm for 24 h, followed by exposure to an antitumour agent for 18 h, 
D = exposure to an antitumour agent for 18 h, followed by exposure to EdSm for 24 
h Cells were washed with PBS after each exposure step and allowed to grow in fresh 
growth medium All experiments were performed in triplicate 
Microculture tetrazolium test (MTT) 
The MTT assay was used as previously described by Mosmann [223] This assay is 
based on the reduction of a yellow tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide by mitochondrial dehydrogenase in viable cells to a blue 
formazan product that can be measured spectrophotometncally This reaction directly 
indicates cell viability [50] The relation between cell density and formazan crystal 
formation was determined using increasing cell densities (100 to 20,000 cells/well, 
plated in 96-wells culture plates) Seven days after cell plating 0 02 mg (20 μ\ of 1 
mg/ml in growth medium) MTT was added to each well and incubated at 37°C for a 
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further 4 h The formazan was dissolved in dimethylsulfoxide (DMSO) and measured 
spectrophotometncally at 550 nm Underestimation of the antitumour efficacy of 
certain compounds can occur in the MTT assay due to a possible effect of the drugs 
on cell size [294] Therefore, all microwell plates were microscopically checked at the 
end of each experiment 
TABLE 1: Cytotoxic effects of antitumour drugs on B16 melanoma cells treated for 18 hours 
EdSm treatment was 3 or 24 hours 
AGENT 
EdSm (3h) 
EdSm (24h) 
CDDP 
ARA-C 
VCR 
MTX 
5-FU 
VP16 
DX 
Dm (μΜ)* 
22 
1 8 
6 1 
1 3 
0 13 
0 35 
8 3 
0 88 
0 12 
± 4 
± 0 3 
± 0 7 
± 0 2 
± 0 04 
± 0 0 4 
± 0 6 
± 0 06 
± 0 03 
m** 
3 4 ± 0 8 
2 4 ± 0 9 
3 6 ± 0 6 
2 2 ± 0 2 
19 + 0 5 
3 0 ± 0 4 
2 7 ± 0 3 
1 5 + 0 1 
3 8 ± 0 4 
993 
984 
970 
980 
976 
956 
982 
969 
980 
D * * * 
± 004 
± 009 
± 012 
± 006 
± 007 
± 011 
± 003 
± 016 
± 012 
* Dm is the median-effect dose (ED50) 
** m ¡s the coefficient signifying the shape of the dose-effect curve for the agent used (m = 1, 
> 1, and < 1 indicates a hyperbolic, sigmoidal, and negatively sigmoidal curie, respectively) 
*** R is the linear correlation coefficient of the median-effect plots 
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Quantization of synergism and antagonism of two drugs 
Dose effect relationships were analyzed by the median-effect equation derived by 
Chou [60] and is given by 
D = D
m
[f,/(1 - f
a
)]1/m, 
in which D is dose of the drug used, D
m
 is the median-effect dose signifying the 
potency, f, is the fraction affected (= % decreased formazan production compared to 
untreated cells) and m is a coefficient signifying the shape of the dose-effect curve, 
ι e , m = 1 for hyperbolic (first order or Michaehs-Menten) systems, m > 1 for 
sigmoidal, and m < 1 for negatively sigmoidal shapes The median effect equation 
describes the behaviour of many biological systems and has been effectively used to 
analyze multiple drug effects Synergism or antagonism for drug combinations is 
determined by the combination index (CI), on the basis of the multiple drug-effect 
equation of Chou and Talalay [57-59] 
(^comb)l (Ц-отЬЛ (^comb)l(^comb)2 
CI = + + a -
(Цікте/І \"i\o:\Jl (ЦіІоііеМЦіІопе/г 
CI= 1 indicates an additive effect, < 1 indicates synergism, > 1 indicates 
antagonism CI can be presented as a function of the fractional effect, /a 
(D
a
io,Ji the dose of drug 1 alone required for a given effect (/a) (DCI)mh), the dose of 
drug 1 in the combination required for a given effect (fa) (D
alone)2 the dose of drug 2 
alone required for a given effect (fa.) (D
comb)2 the dose of drug 2 in the combination 
required for a given effect (fa) а = 0 if the effects of the two drugs are mutually 
exclusive (which means that the median-effect plots for parent drugs and their 
mixtures are parallel, indicating the same mode of actions), and 1 if the effects of the 
two drugs are mutually nonexclusive (independent or different mode of actions) 
The dose reduction index (DRI) defines the extent (folds) of dose reduction in a 
combination for a given degree of effect as compared with the dose of each drug 
alone 
V^alone/fa 
( Ц . , m b )fj 
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RESULTS 
Single drug treatment 
The chemotherapeutic agents have been chosen because their antiproliferative activity 
is based on different mechanisms of action, and the cytotoxicity of each drug in B16 
melanoma tumour cells has been evaluated (Table 1) These results show a broad 
difference in sensitivity of В16 cells for the drugs used The individual Dm's varied 
from 0 12 μΜ for DX to 8 30 μΜ for 5-FU Although the shape of the dose-response 
curves are all sigmoidal (m > 1), their specific m-values vary and increased in 
steepness from 1,5 for VP16 to 3 84 for DX 
Drug combinations at fixed dose ratios 
В16 melanoma cells were treated with different drugs and drug-doses for a period of 
18 hours The modulating capacity of EdSm in combination with a specific agent was 
evaluated after pre-treatment and post-treatment of the 18 hours period of cytostatic 
drug exposure EdSm was given at a fixed dose ratio of the drug in that combination, 
and the dose-ratios were based on their individual Dm-values Computer-generated 
curves describe the combined effects at these fixed ratios Computed regression 
coefficients for the linearised dose-effects curves of the drug combinations were > 0 9, 
which means that the data fulfilled the criteria for computation of the CI according to 
Chou Figure 1 shows an example of the results of such an analysis when tumour cells 
are exposed to drug combinations dependent of drug-dose, exposure-time and 
treatment schedule 
B16 cells were treated with EdSm for either 3 or 24 h, before or after exposure to 
cisplatin or MTX These results are plotted as a function of the fraction of treated 
cells affected (fa) versus the combination index (fa-CI plot) under mutually 
nonexclusive assumption, which means that we assume that the mode of action of the 
drugs in the combinations are not comparable Time-dependent cytoxicity effects were 
found The combination of EdSm with cisplatin showed no preferent treatment 
schedule when the EdSm treatment was only 3 hours at a dose ratio of cisplatin to 
EdSm is 1 1 (Fig 1A) and resulted in synergistic interactions when the fa was above 
0 2 On the other hand, when the EdSm treatment was prolonged to 24 hours at a dose 
ratio of cisplatin to EdSm from 1 3 (Fig IB), it becomes important whether the EdSm 
treatment is before or after the cisplatin treatment 
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TABLE 2: Summary of computer derived data analysis The results are expressed as the 
individual dose reduction index (DRI) and calculated combination index (CI) at the 50% and 90% 
effect level (resp ED50 and ED90) BÌ6 melanoma cells were exposed to EdSm in combination 
Hith individual agents at a fixed dose ratio 
agent 
CDDP 
ARA-C 
MTX 
5 FU 
scheme 
* 
A 
В 
С 
D 
A 
В 
С 
D 
A 
В 
С 
D 
А 
В 
С 
D 
ratio 
** 
1 1 
1 1 
3 1 
3 1 
1 3 
1 3 
1 10 
1 10 
1 100 
1 100 
1 10 
1 10 
1 3 
1 3 
1 1 
1 1 
DRI-ED50 
agent 
1 7 
1 6 
8 1 
2 2 
0 8 
1 0 
11 0 
7 1 
1 8 
4 2 
5 4 
7 6 
2 8 
4 4 
6 0 
1 6 
EdSm 
3 9 
3 8 
6 5 
1 6 
6 4 
9 3 
2 0 
1 3 
1 8 
2 3 
2 4 
2 2 
2 9 
3 6 
1 8 
1 3 
CI 
1 00 
1 05 
0 39 
1 34 
1 60 
1 22 
064 
1 02 
1 42 
0 78 
0 68 
0 65 
0 83 
0 57 
0 81 
1 88 
DRI ED90 
agent 
2 3 
2 3 
5 6 
2 4 
1 4 
3 9 
23 0 
12 4 
1 5 
12 1 
2 9 
4 9 
1 4 
3 5 
7 6 
4 3 
EdSm 
4 2 
4 2 
16 3 
7 3 
4 9 
7 6 
2 3 
4 6 
1 6 
3 2 
3 7 
1 8 
8 6 
2 5 
5 2 
4 0 
CI 
0 78 
0 78 
0 19 
0 61 
1 06 
0 42 
0 50 
0 32 
1 71 
0 42 
071 
0 87 
0 91 
0 80 
0 35 
0 54 
* See Materials and Methods for detailed information 
** Molar ratio of the dose of the antitumour agent to the dose of EdSm 
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EdSm pre-treatment gives strong synergistic interaction over the whole range of 
affected fraction, while EdSm post-treatment results in strong antagonistic effects from 
fa zero to 0.5, but changes to synergism when the affected fraction is greater than 0.5 
The combination of EdSm with MTX shows the opposite result The 24 hours EdSm 
treatment gives schedule-independent synergism over the complete fa-area, while the 
EdSm 3 hours pre-treatment gives increasing antagonism, and increasing synergism 
after post-treatment. 
a COMBINATION-INDEX ^ COMBINATION-INDEX 
С 
к ANTAGONISTIC n 
fa fa 
Combhatlon hdex Combnation ridex 
>i 1 a τ 
fa fa 
FIGURE 1: 
Antagonistic and synergistic effects of EdSm in combination with cisplatin and methotrexate based 
on median-effect analysis A and В combination of EdSm with cisplatin at a molar drug-ratio for 
cisplatm EdSm of 1 I in A and 3 1 in В С and D combination of EdSm with MTX The molar 
drug-ratio used for MTX EdSm is I 100 in С and 1 10 ¡n D EdSm treatment was 3 hours m A 
and C. and 24 hours in В and D Cl> 1 antagonistic, CK 1 synergistic, CI = 1 additne 
fdSin pre-treatment ( ), EdSm post-treatment ( ) 
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The results of EdSm in combination with ARA-C and 5-FU are summarised and 
presented in Table 2, together with the cisplatin and MTX effects. Instead of 
presenting all CI results from fa zero to 1, we show the results at the levels of 0.5 and 
0.9 fraction affected, based on their computer-calculated combination index. The 
combination of EdSm with ARA-C results mainly in antagonistic effects at the 50% 
effect level, which reverses to strong synergism at the 90% effect level, except for 
short EdSm pre-treatment. In combination with 5-FU we see synergism in all 4 
treatment schedules, but there seems to be preference for long EdSm treatment. At 
short EdSm exposure the CI increases from ED50 to ED90, while at long EdSm 
exposure the opposite effect is obtained, resulting in strong synergism. 
COMBINATION INDEX 
CDDP ARA-C 5-FU VP-16 VCR MTX 
FIGURE 2: 
Interaction of 10 μΜ EdSm (3 h), with increasing doses of seven different cytostatic agents The 
combination index value for each pair of drugs is calculated at the Dm CI> 1 antagonistic 
interaction, C1<1 synergistic interaction 
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In addition to the CI-values we get information about the individual DRI of the drugs 
in combinations In Table 2, we see not only a modulating effect of EdSm on the 
drugs used in the combination, but often these drugs have a modulating capacity on 
EdSm This phenomenon is even more obvious at the 90% effect level, where a 
maximum dose-reduction of 16 3 fold is calculated for EdSm in combination with 
cisplatin Synergistic results are obtained when the drugs in the combination have 
mutual dose-reduction effects 
Drug combinations with fixed EdSm Doses 
In these combinations we used 1 μΜ EdSm in the 24 h and 3 or 10 μΜ in the 3 h 
treatment period These exposures periods give less than 10% growth inhibition of 
В16 cells (fa < 0 1) The combination-index is only calculated at the Dm Broad 
differences in the cytotoxic modulations were demonstrated at the level of Dm, and 
the results are summarised in Table 3 In contrast with dose ratios, we see that a fixed 
EdSm dose and exposure during 24 hours always resulted in antagonistic drug 
interaction Different results were obtained after short EdSm exposures Pre-treatment 
with 3 μΜ EdSm for 3 h (data not shown) always resulted in antagonistic cytotoxicity 
which was more obvious in combination with 10 μΜ EdSm Synergistic interactions 
were seen when EdSm was given as second drug in combination with ARA-C, MTX, 
VCR, and moderately with cisplatin The combinations of EdSm with DX, 5-FU and 
VP 16 were shown to be antagonistic 
DISCUSSION 
Cell-culture laboratories have adopted the MTT assay to predict the clinical 
effectiveness of various chemotherapeutic agents against human malignancies 
[8,45,344] as well as to study synergistic interactions between cytotoxic agents [23] 
Several reports have indicated that use of the appropriate drug sequence and drug 
doses can produce potentiation of cytotoxic action [21,87,97,206], but completely 
different patterns of synergistic interaction were seen 
Our results give an impression ot the complexity of drug combination studies The 
importance of this analysis is that the results give information about the character of 
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drug interaction in stead of absolute numbers It will be obvious that when drugs are 
used in other dose-ratios the fa-CI plot will change of curve For EdSm it is clear 
(Fig 1 and Table 2) that its modulating capacity is present and increasing when the 
affected cell fraction is 50% or more, which indicates that synergism will occur when 
EdSm reaches an active concentration at the cellular level This might be the reason 
for the mainly antagonistic effects when a fixed EdSm dose is used which has less 
than 10% growth inhibition on its own (Table 3 and Fig 2) 
There does not seems to be a general optimal treatment schedule for EdSm in 
combination with antitumour drugs However, the CI-results in Table 2 and Fig 2 
show preference for EdSm post-treatment An understanding of the mechanism 
underlying synergistic interaction may help us to anticipate the selectivity of a given 
combination of drugs against neoplastic cells relative to normal tissues (therapeutic 
ratio) prior to the initiation of clinical trials or to develop additional strategies 
designed to enhance synergy through the addition of other agents or the 
implementation of changes in the schedule of drug administration Regarding cisplatin, 
additive antitumour effects and no enhancement of toxicity's have been found in 
combination with N-methylformamide (NMF) [133], synergism has been described for 
compounds that interfere with plasma membrane functions like inhibitors of protein 
kinase С [145], and inhibition of nucleoside membrane transport [162] The synergism 
of combinations with EdSm and cisplatin might be explained on the basis of 
cytokinetic considerations Inhibitors of protein synthesis as well as protein kinase С 
block the cell transition from the G0-G1 to the S Phase of the cell cycle [219,281] It 
is known that Gl-phase cells are more sensitive to platinum bound to their DNA than 
mid S phase or asynchronously treated cells [107] 
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TABLE 3: Summon, of the calculated individual dose-reduction index (DR¡) at the 50% effect 
le\e\ (ED50) of the combination, when EdSm was gi\en as a fixed dose in combination with 
indiudual agents at various doses 
TREATMENT-SCHEDULE' 
DRUGS 
EdSm-PRE-TREATMENT 
1 μΜ*24 Η 10 μΜ*3Η 
EdSm-POST-TREATMENT 
1 μΜ*24Η 10μΜ*3Η 
CDDP 
ARA-C 
5-FU 
DX 
VP-16 
VCR 
MTX 
1,08 ANT : 
0,92 ANT 
1,80 ANT 
1,79 ΑΝ Γ 
1,08 ANT 
1,29 ANT 
1,17 ANT 
2,10 ANT 
0,68 ANT 
1,40 ANT 
1,12 ANT 
0,52 ANT 
0,95 ANT 
1,32 ANT 
1,06 ANT 
2,81 ANT 
4,60 ANT 
1,65 ANT 
0,95 ANT 
1,47 ANT 
1,76 ANT 
4,30 SYN 
3,62 SYN 
1,50 ANT 
2,38 ANT 
1,25 ANT 
3,70 SYN 
15,7 SYN 
' B16 melanoma cells were exposed to EdSm, Ι μΜ for 24 hours or 10 μΜ for J hours, before 
(pre-treatment) or after (¡wst-treatment) treatment with antitumour agents for 18 hours 
'For each combination we calculated the combination index (CI), but instead of the exact number 
we indicate the tendency of drug interaction ANT antagonistic, CI > 1, SYN synergistic, CI < 
1 
Synergistic drug interactions in vitro suggest greater therapeutic activity. However, 
drug-drug interactions of anticancer agents studied in vitro provides precise 
information on drug potency, but none on drug selectivity The dose-reduction index 
(DRI) is a more intuitive measure of drug dose reduction due to synergism and is 
particularly helpful when attempting to minimise toxic side effects of one of the 
agents 
Although the MTT-assay may be used to select a specific drug-dosing schedule for 
clinical use, the in vitro/in vivo correlation of drug exposure studies still has to be 
established Factors other than the inherent chemosensitivity of tumour cells 
significantly influence the outcome of chemotherapy in vivo [254) An improvement ot 
clinical response might be secondary chemotherapy based on in vitro selected drug-
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sensitivity of individual patients' tumour specimens [115] Attention to the doses of the 
agents used in sequential combinations is important because the synergistic effects 
observed in cell culture may translate into formidable toxicity when combinations are 
used in vivo [117] This makes preclinical animal studies and Phase I trials necessary 
even when the maximal tolerated doses for the individual agents are well known 
The underlying mechanism of the interaction between antitumour agents and EdSm 
is unknown and might be different for each drug combination Our results indicate that 
interactions between EdSm and antitumour drugs are phenomena which must be dealt 
with separately for each combination In vivo pharmacokinetic aspects also have to be 
considered in view of both enhancing the therapeutic ratio and of detecting any 
potential deleterious combinations There are a large number of non-chemotherapeutic 
agents that have potentiated the efficacy of chemotherapy in preclinical studies, too 
few clinical trials have been done to conclusively prove or disprove the value of any 
of these approaches in humans [141,297] 
Clearly, the application of data from model systems is limited, but it is a step 
toward less empirical use of chemotherapy modifiers 
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CHAPTER 9 
SCHEDULE DEPENDENT ENHANCEMENT OF ANTITUMOUR 
ACTIVITY BY ETHYLDESHYDROXY-SPARSOMYCIN IN 
COMBINATION WITH CLASSICAL ANTINEOPLASTIC 
AGENTS 
HOFS HP, DJTh WAGENER, V DE VALK-BAKKER, H VAN RENNES, 
D DE VOS, WH DOESBURG, HCJ OTTENHEIJM, WJ DE GRIP 
Accepted for publication in Anti-Cancer Drugs 
Conclurions 
EdSm is not capable of potentiating the antilumour activity of cisplatin, cytosine 
arabinoside, methotrexate, and 5-fluorouracil in vivo in the B16 tumour model 
In L1210 leukaemia, antagonism was observed for 5-FU leading to complete loss of 
antitumour activity when EdSm was given 3 or 24 h after 5-FU Enhanced 5-FU 
activity was never noticed 
In combination with vincristine and ARA-C, potentiation of activity was obtained 
when EdSm was given at least 6 h after vincristine, or 24 h after ARA-C No 
antagonistic or synergistic modulatory effects were seen in combination with 
BCNU, VPlóandDX 

SUMMARY 
The efficacy of the protein synthesis inhibitor ethyldeshydroxy-sparsomycin (EdSm) as 
biochemical response modifier of several antitumour agents against L1210 leukaemia 
and В16 melanoma is described For this combination study 7 drugs with different 
intracellular targets have been selected Tumour implantation and drug treatment both 
were I Ρ and the time interval between the administration of EdSm and the cytostatic 
agent was varied Our results show that in the B16 tumour model EdSm is not able to 
potentiate any of these drugs, whereas antagonism is seen in combination with DX In 
the L1210 tumour model, however, no loss of activity is seen for this specific 
combination The effect of the combination of ARA-C, 5-FU or VCR with EdSm in 
the L1210 model is strongly time interval dependent Loss of 5-FU antitumour activity 
is seen when EdSm is given 3 or 24 h after 5-FU, however no effect is observed when 
EdSm is given 6 h after 5-FU Enhancement of the 5-FU activity is not noticed The 
VCR activity is potentiated when EdSm is given at least 6 h after VCR administration, 
which increases the antitumour response from 32 to >60 days and the % survivors 
from 33 to 83% (p = 0 04) In combination with ARA-C potentiation of antitumour 
activity is seen only when EdSm is given 24 h after ARA-C, which increases the 
antitumour response from 32 to >55 days and the % survivors from 11 to 50% (p = 
0 008) No modulatory effects are found when EdSm is combined with BCNU or DX 
Our results suggest that EdSm changes the antitumour efficacy of selected 
antitumour agents (ARA-C and VCR) in a schedule-dependent way, and that 
potentiation is largely restricted to cell-cycle phase specific cytostatic agents 
INTRODUCTION 
Incomplete response of malignancies to antineoplastic agents remains a major clinical 
problem Sometimes their efficacy can be improved by combining cytostatic agents 
with different modes of action, but also non-chemotherapeulic agents are capable of 
improving the efficacy of cytostatics, e g by reversing the resistance to 
chemotherapy 
Sparsomycin and its analogues are inhibitors of nbosomal protein synthesis 
[32,69,120,303] and previous reports from our laboratory clearly demonstrated that 
these compounds potentiate the antitumour activity of cisplatin in vivo [146,362,365] 
Furthermore, it was shown that the effect of combined treatment of cisplatin and 
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EdSm was independent of administration order [146] This potentiation was not a 
result of pharmacological factors, but was strongly dependent on the cellular 
properties of the target tumour-cell populations [147] Comparison of the cellular basis 
of drug sensitivity of solid tumours with that of leukaemia cells suggests that a large 
part of the resistance of solid tumours to treatment is due to low drug sensitivity of the 
tumour cell itself [244] Another parameter might be that the sensitivity of tumour 
cells as well as the cytotoxicity of drug combinations may depend on the schedule of 
administration as well as the doses used [76,161] 
To investigate whether the synergistic effect of EdSm on cisplatin's efficacy is a 
general phenomenon of EdSm applicable to other anticancer drugs we studied the 
effect of EdSm on the antitumour activity of agents with different intracellular targets 
Moreover we searched for the optimal dose ratio and schedule dependency for 
maximal antitumour enhancement by EdSm 
MATERIAL AND METHODS 
Tumour cells 
Murine L1210 leukaemia cells and B16 melanoma were kindly supplied by Dr G 
Aussi (Inst Jules Bordet, Lab for Experimental Chemotherapy, Brussels, Belgium) 
L1210 leukaemia cells were maintained in logarithmic growth as suspension culture 
and В16 melanoma cells were grown routinely as monolayer culture at 37°C in a 
humidified atmosphere of 5% C02 in air as described previously [147] 
Animals 
CD2F[ mice weighing between 18 and 22 g were used as a host for the L1210 
leukaemia and C57B1/6 mice were used for the В16 melanoma tumour In each 
experiment, phosphate-buffered saline (PBS) treated tumour-bearing animals served as 
controls All mice were obtained from Charles River Breeding Laboratories, Sulzfeld, 
Germany 
Antitumour activity 
Mice were inoculated intraperitoneal^ with 105 L1210 cells or 106 B16 melanoma 
cells suspended in 0 2 ml PBS, pH 7 4 Acceptable median control survival times 
range from 8-11 days for the L1210 Ι Ρ tumour model and 14-22 days for the B16 
I Ρ tumour model [116] In each experiment tumour-bearing mice were randomised in 
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the treatment and control group Each group consisted of six animals Drugs were 
administered at various doses I Ρ into mice using 0 01 ml/g body weight Different 
treatment schedules were used, starting on day 1, which was 24 hours after tumour 
implantation Animal survival was recorded daily during 60 days and the MST of each 
group was calculated Final antitumour results were computed as median survival time 
in days after tumour implantation A T/C value of >135% is generally taken as a 
positive indication for antitumour activity according to the NCI criteria T/C is the 
median survival time of the test group divided by that of the control group L1210 and 
B16 experiments were terminated after day 60 Mice alive at the end of an experiment 
were autopsied and judged to be cured if no signs of tumour were visible 
Drugs 
EdSm was synthesised at the department of Organic Chemistry of the University of 
Nijmegen, the Netherlands [38], and was acquired in a lyophilised form The drug 
was dissolved in PBS and kept in dark flasks at 4°C For our combination studies 7 
drugs with different intracellular targets were selected two S-phase specific 
antimetabolites, ι e cytosar (ARA-C) and 5-fluorouracil (5-FU), one mitose-phase 
specific agent, ι e vincristine (VCR), two topoisomerase II inhibitors, ι e etoposide 
(VP16) and doxorubicin (DX), and two DNA crosslinking compounds, ι e cisplatin 
and carmustine (BCNU) Cisplatin and 5-FU were kindly provided by Pharmachemie 
В V , Haarlem, The Netherlands BCNU and VP16 were obtained from Bristol-
Myers, Syracuse, NY, ARA-C from Upjohn, Kalamazoo, MI, VCR from Eli Lilly, 
Indianapolis, IN and DX from Farmitalia, Milan All drug solutions were prepared 
freshly before each use The agents were dissolved in the prescribed solvent 
Subsequently, from these stocks solutions with the required drug concentration were 
prepared by dilution with isotonic NaCl just before administration 
Statistical analysis 
Our experimental data have been analyzed by Cox's proportional hazards regression 
model (PH-model) [171] Each presented data point was calculated on basis of 
repeated experiments As usual, in this PH-model dummy variables were used to 
indicate the given doses of EdSm and of drugs Product terms of these dummy 
variables were included in the model to account for interaction effects of both drugs 
on survival A tumour specific hazard has been obtained by censuring death within 6 
days for L1210 and within 14 days for B16 as due to drug toxicity This occurred only 
in some В16 experiments For each treatment schedule the median survival times were 
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calculated within this (complete) PH-model The percentages long term survivors 
(LTS) were also calculated using the PH survival function, and were in very good 
agreement with the observed number of LTS after 60 days The risk-ratios of 
individual as well as of combined drug treatment, compared to the non-treated 
animals, are directly given by PH-analysis All P-values were calculated according to 
Wald's chi-squared test P-values less than 0 05 were considered to be significant 
RESULTS 
Combined chemotherapy in B16 melanoma 
The tumour-take of I Ρ inoculated В16 melanoma was 100% and resulted in a median 
survival time of 18 ± 0 13 days for 66 placebo treated control animals B16 
melanoma is relatively resistant to single drug treatment, except for doxorubicin To 
determine whether EdSm could improve the antitumour activity of these drugs against 
B16 melanoma in mice, we varied drug doses as well as the treatment schedules The 
eflect of EdSm was studied using doses of 2 5 or 5 mg EdSm/kg, given on day 1, 4 
and 7 (Dl,4,7) or on day 1, 5 and 9 (Dl,5,9) The results of these experiments are 
summarised in Table 1 Drug doses were increased till toxicity was observed The 
classical antitumour agents gave acceptable antitumour effects (>135% T/C, i e 
MST> 24 days, NCI protocol), except for ARA-C The combination studies with 
EdSm showed that in comparison with single drug treatment none of the combinations 
gave improved results Whereas our results showed that in this В16 tumour model 
EdSm is not capable of potentiating any of the drugs studied, a pronounced effect was 
seen when EdSm was combined with DX, producing loss of the single dose (1 mg/kg 
per injection) DX activity from 60 days to 22 days, and reducing the number of long 
term survivors from 4 to zero (out of 6 animals) This antagonistic effect of EdSm was 
less obvious in combination with a DX dose of 2 mg/kg per injection 
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TABLE 1: Dose and schedule dependent antitumour activity of several cytostatic agents m 
combination with EdSm against B16 melanoma I Ρ 
Drugs 
Control11 
VCR 
VP16 
5-FU 
ARA-C 
cisplatin 
DX 
treatm3 
Dl.4,7 
Dl,5,9 
Dl,4,7 
Dl,5,9 
Dl,4,7 
Dl,5,9 
Dl.8,15 
Dl,4,7 
Dl,5,9 
Dl,5,9 
doseb 
0 5 
1 0 
0.25 
0 50 
0 75 
10 
2.5 
5 0 
50 
100 
50 
100 
50 
100 
3 
5 
0.5 
1 
2 
Median survival time 
single 
18 
24 
25 
20 
20 
22 
32 
29 
29 
23 
TOX 
19 
22 
19 
19 
23 
26 
32 l/6e 
60 4/6 
60 4/6 
2.5 
20 
--
--
22 
22 
--
-
29 
28 
-
--
19 
19 
--
--
--
-
--
--
-
(days) 
+ EdSmbc 5 
18 
5 TOX 
6 TOX 
6 TOX 
--
--
6 TOX 
6 TOX 
5 TOX 
7 TOX 
8 TOX 
--
--
19 
18 
22 
13 TOX 
22 0/6 
22 0/6 
54 2/6 
"In the treatment schedules Dl,4, 7 and DI,5,9 these drugs were given I P. on day 1, 4 and 7 or 
on day 1, 5 and 9 after tumour implantation bMg/kghnjection 
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cEdSm was given Ι Ρ 3 h after injection of the first drug 
dThe median survival time of Ι Ρ implanted B16 melanoma was 18 ± 0 13 days for control 
animals, 'number of long term survivors 
Combined chemotherapy in L1210 leukaemia 
The treatment schedules of EdSm in combination with cytostatic agents were varied in 
several experiments performed with I.P. implanted L1210. The median survival time 
of 66 placebo treated control animals was 10 days + 0.35, and the tumour-take was 
100% EdSm at 5 mg/kg/inj showed a moderate antitumour response by increasing the 
MST to 12 days using the Dl,5,9 treatment schedule whereas no response was 
observed at 2.5 mg/kg/inj. The results of combined drug treatment in L1210 are 
summarised in Table 2. 
TABLE 2: Antitumour activity of several cytostatic agents in L1210 leukaemia IP, m 
combination with EdSm post-treatment after 3, 6 or 24 h Treatment schedule was Dl,5,9 
Between parentheses number of animals treated 
Drags 
control 
EdSm 
VCR 
5-FU 
ARA-C 
BCNU 
DX 
dose 
mg/kg/inj 
0 
2 5 
0 5 
1 0 
50 
100 
500 
10 
3 
single drug 
MSTa 
10 (66) 
10(12) 
32 (18) 
46(6) 
>60(18) 
14(6) 
32(18) 
>60 (12) 
> 60 (24) 
+ 
+ 3 h 
24 (12) 
18(6) 
26 (12) 
14(6) 
24 (12) 
> 60 (6) 
>60(18) 
EdSm 2.5 mg/kg/i 
+ 6 h 
>60 (12) 
-
>60 (12) 
-
24 (12) 
> 60 (6) 
>60(6) 
inj 
+ 24 h 
>60(12) 
-
30(12) 
--
>55 (12) 
>44 (6) 
> 60 (6) 
p-value 
004 
0 23 
0.16 
0 88 
0 008 
0 63 
0 20 
° The median survival time of 66 placebo treated control animals was 10 days ± 0 35 
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Although we have described earlier [146] that the modulatory capacity of EdSm in 
combination with cisplatin was independent of drug sequence administration as well as 
of time interval between drug administration, we now see the importance of timing. In 
this L1210 model EdSm modified the antitumour activity of ARA-C, 5-FU and VCR, 
and the time interval between drug administration is crucial for potentiation of 
antitumour activity. Even a antagonistic effect was seen when EdSm was given 3 or 
24 h after 5-FU administration, although this antagonistic effect was not observed 
when EdSm was given 6 h after 5-FU. The MST of single 5-FU treatment was >60 
days, therefore potential enhancement by EdSm could not be studied at this 5-FU 
dose. The antitumour activity of VCR, on the other hand, could be potentiated when 
EdSm was given at least 6 h after VCR (Figure 1), thereby increasing the MST from 
32 to >60 days and the % survivors from 33 to 83% (p = 0.04). Potentiation of 
ARA-C's antitumour activity was only noticed when the EdSm administration was 
postponed till 24 h after the administration of ARA-C (Figure 2), increasing the MST 
from 32 days to >55 days and the % survivors from 11 to 50% (p = 0.008). 
TABLE 3: Effect of EdSm (5 mg/kg) on the antitumour activity of doxorubicin in L12I0 I Ρ . 
DOSE DXa 
0 
0 5 
1 
2 
3 
4 
p-value 
EdSm = 0 
10c (66)" 
20 (12) 
19(12) 
19(12) 
> 60 (24) 
23 (12) 
0 000 Ie 
EdSm = 5, - 3 h' 
12 (48) 
21 (12) 
19(12) 
19(12) 
>60(18) 
24(6) 
0 97f 
EdSm = 5, + 3 h 
14(6) 
17(6) 
44(6) 
> 60 ( 18) 
18(6) 
0.20f 
" EdSm was given I Ρ 3 h before or 3 h after doxorubicin injection. 
b
 Treatment schedule was I Ρ on day 1, 5 and 9 after tumour implantation (Dl,5,9) 
rMedian survival time in days 
d
 Total number of animals used for analysis. 
" Overall p-value for DX compared to the control level. 
'Overall p-value of the combination compared to single DX treatment. 
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Potentiation of the antitumour activity could not be measured due to maximal activity 
of BCNU as single drug. On the other hand our results show that EdSm has no 
antagonistic effect on the BCNU activity. 
As in both tumour models doxorubicin is a very strong antitumour agent on its own 
the modulatory effect of EdSm was investigated in more detail using lower DX doses. 
Table 3 shows the results of this study. EdSm (5 mg/kg) given before or after certain 
DX doses did not significantly improve the activity of the latter drug. The overall p-
value for EdSm pre-treatment was 0.97 and for EdSm post-treatment 0.20. Finally, a 
reduction in DX antitumour activity, as seen in the B16 model, was not noticed in the 
L1210 model. 
DISCUSSION 
The results of the present study show that the modulating capacity of EdSm on 
antineoplastic agents is schedule dependent. The treatment schedule used in our 
experiments was based upon the results of the combination study of EdSm with 
cisplatin [149]; these results were independent of time and order of drug 
administration In combination with cisplatin EdSm could be given from 24 h before 
up to 24 h after cisplatin injections, without loss of synergy [146]. However, recent 
results from our laboratory revealed that when EdSm was combined in vitro with 
drugs other than cisplatin the outcome was dose and schedule dependent [148] and 
synergism was most pronounced when EdSm was given as the second drug in the 
combination. 
In this chapter the efficacy of these drug combinations in vivo is discussed in two 
murine tumour models. In contrast to what was seen with cisplatin the time interval 
between the administration of the two drugs is very important and determines whether 
the antitumour activity the classical cytostatic agents is potentiated or inhibited. These 
effects were most obvious in the combination with 5-FU, ARA-C, VCR, or DX. No 
significant effects were found in combination of EdSm with BCNU and VP16. In 
order to explain the occurrence of the chemomodulatory effects caused by EdSm we 
must consider the intercellular response to treatment with the various drugs. 
Metabolism of 5-FU produces 2 critical intermediates: fluorouridine-5'-triphosphate 
(FUTP), which is incorporated into RNA and interferes with its function, and 
fluorodeoxyundylate (FdUMP), which prevents normal DNA replication [16]. 5-FU is 
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phase-specific for the S-phase of the cell cycle, which may explain why the effects of 
5-FU are schedule dependent [105]. The cytotoxic activity of ARA-C is due to its 
triphosphorylated metabolite ARA-CTP, which blocks DNA synthesis through 
competitive inhibition of DNA polymerase. ARA-C nucleotides may also become 
incorporated into DNA [272] Intracellular deamination by the enzyme cytidine 
deaminase converts ARA-C to an inactive metabolite, uracil arabinoside (ARA-U). 
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FIGURE 1: 
Sunnal of mice inoculated IP with 10s L1210 cells Mice were treated IP with ARA-C (500 
mg/kg per injection) as single drug (з) and m combination with EdSm (2 5 mg/kg per injection), 
given 3 (Щ, 6 Ш or 24 h fe) öfter ARA-C administration Drug treatment started 24 h after tumour 
implantation, once daily e\er\ four da\s for 3 doses (o) Untreated control group 
143 
Hence ARA-C is also S-phase-specific and again its efficacy has shown to be 
schedule-dependent [49] Vincristine produces metaphase arrest by binding to tubulin, 
which results in a marked increase in the population of cells in mitosis, which is 
maximal 6 to 12 hours after drug administration [108,169] Inhibitors of protein 
synthesis are known to cause a reversible cell-cycle arrest in Gl [153,308], and as 
long as tumour cells remain in Gl, no antitumour activity of S-phase specific agents 
like 5-FU and ARA-C can be expected 
This might be the rational for the reduction in antitumour activity that we observed 
when EdSm was given too soon (3 h) after the first drug, blocking the cell transfer 
from Gl to S-phase In addition, protein synthesis inhibition may also decrease the 
cellular deaminase activity, which leaves more ARA-C nucleotides to be incorporated 
into DNA, increasing the cytotoxicity of ARA-C, assumed that the phosphorylation of 
ARA-C by nucleoside mono- and diphosphate kinase is not inhibited On the other 
hand if EdSm was given before ARA-C treatment the DNA-replicative synthesis 
would have been reversibly turned down by EdSm as well as the phosphate kinase 
activity and temporary the intracellular ARA-C molecules can not be incorporated into 
DNA, which means loss of ARA-C antitumour activity These biochemical 
implications indicate the importance of liming when EdSm is given in combination 
with 5-FU, ARA-C, or VCR In this context the synergism of EdSm and cisplatin 
could for instance result from glutathione depletion by EdSm, inhibition of de novo 
synthesis of glutathione-S-transferases and/or inhibition of the repair of cisplatin 
induced DNA-damage The apparent induction by EdSm of the cytotoxic effects of 
DX and BCNU is less obvious The mechanism of cytotoxicity of doxorubicin is very 
complex, including inhibition of DNA synthesis [75], DNA-intercalation 
[255,264,360], DNA single strand breaks [361], the production of superoxide free 
radicals [224], binding to the cell membrane and altering its function [315], and 
interaction with topoisomerase II [78,256,361] EdSm might contribute to this 
cytotoxicity by inhibition of de novo topo II synthesis and DNA-repair proteins, but 
the extend of these effects can only be small to effect the miscellaneous DX targets 
and the strong activity of DX as single drug in L1210 as well as B16 melanoma 
BCNU, on the other hand, undergoes spontaneous chemical degradation to a 
carbonium ion that alkylates DNA and an isocyanate intermediate that carbamoylates 
proteins, such as DNA repair enzymes [178,338] DNA alkylation by BCNU 
subsequently results in DNA crosslinks which is critical for cancer cell lethality The 
cytotoxic DNA damage induced by BCNU is normally repaired by the DNA repair 
enzyme 06-alkylguanine-DNA alkyltransferase The use of a direct alkyltransferase 
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inhibitor, such as 06-methylguamne, inactivates the alkyltransferase and sensitises cells 
to BCNU [117]. One of the effects of EdSm might be based on an inhibition of de 
novo synthesis of this repair enzyme and thereby indirectly increasing the antitumour 
activity of BCNU. This effect is dependent on the turnover time of this 
alkyltransferase. In the L1210 tumour model BCNU by itself gave complete 
antitumour responses at a dose of 10 mg/kg. Thus, improvement by EdSm can not be 
expected under these conditions. On the other hand our results did not show the 
antagonistic interaction between EdSm and BCNU, as was clearly observed in the 
combination with 5-FU. 
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FIGURE 2: 
Sunnal of mice inoculated Ι Ρ with 105 L1210 cells Mice were treated ! Ρ with vincristine (0 5 
mg/kg per injection) as single drug (bj and in combination with EdSm (2 5 mg/kg per injection), 
given 3 (Щ, 6 b) or 24 h (щ) after VCR administration Drug treatment started 24 h after tumour 
implantation, once daily every four days for 3 doses (Ql Untreated control group 
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83 
58 
39 
33 
ρ = 0.04 
The two tumour models used in this report are hardly comparable The L1210 
leukaemia is a rapidly growing rumour with a high percentage of cells synthesising 
DNA Because all cells are actively progressing through the cell cycle, its life cycle is 
consistent and predictable [353] The relationship between cell number and survival in 
L1210 leukaemia is linear The time to death of animals bearing L1210 leukaemia is 
the interval required to achieve a population size of about one billion (109) cells With 
a growth fraction of 100% 109 cells will accumulate by 10 days after the injection of 
ΙΟ
1
* cells The Ι Ρ inoculated B16 melanoma cells will grow as solid tumour, have a 
longer cell cycle and therefore grow less rapidly than LI210 cells Injection of 106 
cells acquire 18 days to reach lethality This tumour model has a low percentage of 
cells synthesising DNA and will be less sensitive to S-phase specific drugs like 5-FU 
and ARA-C Moreover, in the L1210 model drug treatment starts on day one and 
continues till the number of tumour cells in control animals has reached the maximum 
cell number The B16 tumour model is more advanced (106 cells) at the start and the 
last drug treatment is given nine days before MST of the control animals EdSm by 
itself has no measurable antitumour activity against B16 tumours, probably because, 
contrary to the L1210 cell cycle time, the reversible inhibition of protein synthesis 
does not last enough to cause measurable problems for the viability of В16 tumour 
cells 
In summary, the modulation of antitumour activity by EdSm is tumour type 
dependent and is limited to cell-cycle-phase specific drugs like ARA-C and VCR, with 
the exception that it also potentiates the activity of cisplatin Moreover, this report 
shows that the antitumour activity of drug combinations depends on the timing of the 
drug administration 
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PARTY 
GENERAL DISCUSSION 

CHAPTER 10 
CAN INHIBITORS OF PROTEIN SYNTHESIS IMPROVE THE 
EFFICACY OF CANCER CHEMOTHERAPY: PAST, PRESENT 
AND FUTURE 
HENNY Ρ HOFS, CAROLINE СЕН VERKOELEN and DJ THEO 
WAGENER 
INTRODUCTION 
Selective protection of normal tissue against antitumour therapy and selective 
potentiation of antitumour effect are two greatly desired goals for the medical 
oncologist. No or incomplete responses of malignancies to antineoplastic agents 
remain a major clinical problem. Increased efficacy can be obtained by combining 2 
or more cytostatic agents with different mode of action, but also non-chemotherapeutic 
agents have been found to enhance the effectiveness of chemotherapy by potentiation 
of antitumour activity or by reversing the resistance to chemotherapy. Some of the 
agents that block the protein synthesis are also known to have antitumour properties. 
In this chapter we give an overview of inhibitors of the protein synthesis that have 
been of interest for cancer chemotherapy. These drugs are extracted from different 
natural sources and consist of nonrelated chemical structure. We pay special attention 
to those agents that are investigated over a longer period as promising antitumour 
agents or as modulator of the antitumour activity from cytostatic agents used in 
clinical practice. In a retrospective way the discovery, the mechanism of action, the 
experimental preclinical results and the clinical results will be described in alphabetical 
order of the names of the drug as presented in Table 1. 
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TABLE J: Inhibitors of the protein synthesis which ate investigated as antuumour agents 
INHIBITOR 
1 anguidine 
2 L-asparaginase 
3 benzaldehyde 
4 bouvardin 
5 bruceantine 
6 cyclohcximide 
7 emetine 
8 L-histidmol 
9 homoharnngtonine 
10 puromycin 
11 ricin/abnn 
12 sparsomycin 
DISCOVERY 
Brian. 1961 
Broome, 1961 
Takeuchi, 1978 
Jolad, 1977 
Kupchan, 1973 
Whiffen, 1946 
Vedder, 1912 
Powell, 1969 
Porter, 1952 
Lin, 1970 
Owen, 1962 
SOURCE 
Fusarium equistle 
Escherichia coll 
Serrana marcescens 
Ficus carica L 
Bou\ ardía ternifolia 
Bracea antidysentenca 
Streptomyces gnseus 
Cephaelis ipecacuanha 
Radix epicaciianha 
Cephalotaxus 
harnngtoma 
Streptomyces albomger 
Ricinus communis/ 
Abrus precatonus 
Streptomyces 
sparsogenus 
NSC-NUMBER* 
141537 
109229 
— 
259968 
165563 
185 
33669 
74518 
141633 
— 
— 
59729 
:
 Number gi\en by the National Cancer Institute of the USA for screening of пен compounds 
151 
1. ANGUIDINE 
Anguidine (diacetoxyscirpenol) is a metabolic product of the plant fungus Fusarium 
equiseti [35] The chemical structure is shown in Figure 1 The mechanism of action 
ot anguidme is thought to be irreversible blockade of protein synthesis [198], after the 
formation of the first peptide bond [220] 
FIGURE 1: Structure of anguidme 
СИ 
H 
Preclinical data 
Anguidme has antitumour activity against Ι Ρ P388 leukaemia, L1210 leukaemia and 
only slight activity in the intraperitoneal (Ι Ρ ) implanted B16 melanoma [14] Activity 
has also been demonstrated against Line 38 colon adenocarcinoma in mice, as well as 
synergism with 5-fluorouracil in the same model [71] This antitumour potentiation 
was obtained when the combination was injected intravenously (IV) simultaneously on 
a q7d schedule, resulting in 80% cures [71] Exponentially growing Chinese hamster 
ovary cells are reversibly arrested by anguidme treatment thereby protecting these 
cells to ARA-C, 5-FU, doxorubicin cytotoxicity and hydroxyurea, while potentiating 
the lethal effects of cis-platinum, melphalan and bleomycin [155,308] Moreover, 
anguidme enhanced cis-platinum's cytotoxicity in human brain tumour cells in vitro by 
ten-fold, by enhancement of cis-platinum induced DNA cross-linking [153] The 
combination of 5-FU and anguidme was very active against the murine colon 
adenocarcinoma 38 
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Clinical results 
Phase I trials with anguidine were conducted by Murphy et al in 1978 [227] and 
Goodwin et al in 1978 [122] The maximal tolerated dose depended on the presence or 
absence of liver metastases or impairment of liver function Several phase II clinical 
studies have been reported A phase II trial of anguidine performed by Murphy et al 
showed no responses in 39 patients with colorectal carcinoma [226] In 1979 Yap et 
al [354] carried out a phase II evaluation of anguidine in 30 patients with advanced 
refractory breast cancer Among these patients there was one partial responder and 
one additional patient who showed improvement Both responses occurred in soft 
tissue sites The third phase II study was conducted in 1982 by Bukowski et al [42] in 
134 patients with gastrointestinal malignancies Response rates for patients with colon 
carcinoma were 22% (four of 18 patients without previous chemotherapy) and 6% 
(tour of 63 patients with previous chemotherapy) There were no responses in patients 
with pancreatic cancer or gastric cancer Another phase II study was conducted in 
1983 by Goodwin et al [123] in patients with central nervous system tumours Of 16 
patients evaluated for response, two had partial responses, three had stable disease, 
and nine had progressive disease A broad phase II study was conducted in 1984 by 
Adler [4] in 276 patients with solid tumours The overall evaluation rate was 68% 
There were no complete responses, two partial responses, and 12 stabilisation's It 
seemed that anguidine was not of benefit for the treatment of solid tumours Its role in 
the treatment of leukaemia remains undefined 
Anguidine has been evaluated as a single agent in most of the important tumour 
types, without evidence of therapeutic activity All studies with anguidine have been 
completed in 1983 [14] and the Investigational Drug Branch of the NCI stopped 
further evaluation of anguidine 
2. L-ASPARAGINASE 
In 1953 Kidd et al found antitumour activity in Gardner lymphosarcoma after 
treatment with whole guinea pig serum [183] Several years later, in 1961, Broome 
proved that this antitumour activity was induced by L-asparaginase [39] Fortunately, 
this enzyme is also widely distributed among bacteria, but only species of Escherichia 
coll and Serratia marcescens produce enzymes with useful levels of antitumour activity 
[322] L-asparaginase hydrolyses circulating asparagine to aspartic acid and ammonia, 
and thus causes depletion of asparagine While normal mammalian cells can synthesise 
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asparagine using asparagine synthetase, several malignant cells are dependent of the 
amino acid asparagine for growth [261] Asparagine depletion by L-asparaginase will 
selectively block the protein synthesis in tumour cells lacking asparagine synthetase 
Preclinical data 
L-asparaginase has been shown to be active against a large number of murine 
tumours, several rat tumours and 1 canine tumour [3] It was shown that L-
asparaginase-sensitive tumours have little or no capacity to synthesise L-asparagine, 
while resistant tumours can synthesise asparagine [40,151] Several studies have been 
performed in combination with cytostatic agents as summarised by Charles and Bono 
in 1981 [52] Therapeutic benefits of L-asparaginase in animal tumour models were 
obtained in combination with carmustine (BCNU) and vinblastine A negative 
therapeutic effect resulted when L-asparaginase was combined with methotrexate 
(MTX), 5-FU, or daunomycin L-asparaginase antagonises MTX cytotoxicity through 
non specific inhibition of protein synthesis, MTX polyglutamate formation and MTX 
uptake, in utro [165] and in \i\o [301] 
Clinical results 
L-asparaginase is effective in inducing remissions of leukaemia in humans Acute 
lymphatic leukaemia responds most readily Although human myeloblastic leukaemia 
and malignant melanoma cells are sensitive to asparaginase m vitro, clinical results 
were disappointing and asparaginase should be used only in combination with other 
drugs, to achieve complete remission Asparaginase was successful in the treatment of 
acute lymphoblastic leukaemia (ALL), where it induced partial or complete remissions 
[24,92] A treatment program using four-drug induction and intensive asparaginase 
theiapy resulted in improved event-free survival in children with acute ALL [63] 
Therapeutic benefit was obtained when sequential high dose ARA-C and asparaginase 
were given versus high-dose ARA С alone in the treatment of adults with relapsed and 
refractory acute leukaemia, or adults with refractory and relapsed acute myelogenous 
leukaemia [46-48] The effectiveness of high-dose cytosine arabinoside (ARA-C) with 
L-asparaginasc was evaluated by Evans et al in 1990 in 41 patients with "poor risk" 
acute non-lymphocytic leukaemia (ANLL) They concluded that this combination is a 
moderately effective regimen for patients with poor prognosis ANLL including 
secondary ANLL [91] Moreover, a combination of L asparaginase and MTX in 
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another 41 children with childhood ANLL showed antileukaemic activity as well 
[157] 
3. BENZ ALDEHYDE 
The effective agent of the experimental extract used in clinical trials was identified as 
benzaldehyde (BA) [306] Exposure of tumour cells to В A reduced the rate of cell-
cycle progression to the same degree in G„ S and G2 BA is not cell-phase specific, 
although it seemed that cells in mitosis are more sensitive to BA than cells in the 
interphase [249] It was found that these effects were primarily reduced by inhibition 
ot the protein synthesis [250] 
Preclinical data 
BA showed dose-dependent inhibition of HL60 promyelocytic leukaemia cells and 
normal human granulocyte/macrophage colonies, but no in vitro activity was found 
against either KG-1 myeloid leukaemia cells or chronic lymphocytic leukaemia cells 
grown in colony culture [304] Although Kochi et al reported a high degree of 
clinical activity in heavily pre-treated patients with cancer [184] However, inhibition 
of colony growth of tumour cells from patients with solid tumours was seen in 20% of 
the samples only Furthermore BA failed to show antitumour activity in 2 human 
tumour xenografts [304] In combination with cisplatin BA reduced the cytotoxicity of 
cisplatm in vitro BA by reducing the cellular uptake of cisplatin [80,81] 
Because BA is a reactive compound, which is easily oxidisable, it has been given in 
the form of an inclusion compound, ι e , bound to either ß-cyclodextrine (CDBA) 
[184] or to 4,6-benzyhdene D-glucose (BG) [306] BG does not metabolise to free BA 
but acts in the torm of BG, and inhibits protein synthesis at the same concentration as 
В A does in a reversible way [251] However, CDBA [304] and BG [306], had no 
effect on most implanted tumours in mice, although BG showed antitumour effect in 
rats with hepatocellular carcinoma [253] 
Clinical results 
Between 1965 and 1975, 83 patients were treated ìv with a volatile fraction of the fig 
This fraction proved to be effective in 12 patients, four of them responded completely, 
while no appreciable effect was noted in the other 71 patients 
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After 1975 ninety patients with inoperable carcinoma in the terminal stages and 12 
patients in serious condition with other tumour types were given CDBA orally or 
rectally daily divided in four doses. Fifty-seven of the patients treated were évaluable; 
19 patients responded completely and ten patients responded partially (>50% 
regression) [184]. When BG was given iv daily to 65 patients with inoperable 
carcinoma in the advanced stages, the overall objective response rate was 55%; seven 
patients achieved complete response, 29 achieved partial response, 24 remained stable, 
and five showed progressive disease. Response was seen in various cell types. 
Prolongation of survival was apparent for the patients. Toxic reactions were not 
observed during long-term injection with BG [185]. 
4. BOUYARDIN (NSC-259968) 
Bouvardin (BVD) is a cyclic hexapeptide (Fig. 2) which is isolated from Bouvardia 
temifolia (Rubiaceae). 
о 
FIGURE 2: Structure of Bouvardin 
CH 
It has been isolated and characterised by Jolad at al. in 1977 [164]. BVD inhibits the 
protein synthesis in eukaryotic cells by inhibiting the elongation factor EF1-dependent 
binding of aminoacyl-tRNA to 80S ribosomes and the EF2-dependent translocation of 
peptidyl-tRNA [358]. Besides protein synthesis BVD inhibits the DNA and RNA 
synthesis in P388 leukaemia cells in a dose-dependent manner. As a result these cells 
arrested cell cycle progression uniformly [313]. This inhibition was reversible when 
the cells were washed free of the drug [56]. 
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Preclinical data 
Antitumour activity of BVD was shown against P388 murine leukaemia and the В16 
melanoma, but not against 4 other leukaemia and 3 solid tumour models [55] A 
comparative study of cytostatic drug combinations was carried out by Adwanker et al 
in early and advanced P388 by using BVD along with the known anticancer drugs 
vincristine and cisplatin [6] Their results indicated that the combination of BVD and 
cisplatin enhances the antineoplastic activity in comparison with single-agent therapy 
in early leukaemia However, BVD could not indicate its superiority by way of 
tumour cell killing in three drug combinations, when administered with VCR and/or 
cisplatin, against advanced leukaemia The antitumour activity of BVD was improved 
at elevated temperatures [5] or when tween-80 was used as a vehicle 
To our knowledge a clinical trial has not been started yet 
5. BRUCEANTINE 
Bruceantin (Fig 3) is an alcohol extract isolated from the bark of Brucea 
antidysenterica, a simaroubaceous tree, that is used in Ethiopia to treat cancer patients 
[187,188] Bruceantin irreversibly inhibits protein synthesis of eukaryotic cells, has a 
secondary effect on DNA synthesis, but little effect on the synthesis of RNA [199] 
The protein synthesis is inhibited because bruceantin binds strongly to the 
peptidyltransferase centre The affinity for polyribosomes is considerably lower, which 
explains that bruceantin only stabilises polyribosomes at high drug concentrations 
[109] 
FIGURE 3 Structure of bruceantin 
сн„ 
Preclinical data 
Antitumour activity of BVD was shown against P388 and L1210 murine leukaemia, 
the B16 melanoma, and the colon 38 tumour system [57] 
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Clinical results 
Three phase I studies with bruceantin were reported The first study was conducted in 
66 patients with various types of advanced solid tumours Hypotension was the dose-
limiting toxic effect and occurred more often in patients with abnormal pre-treatment 
liver function No objective rumour regressions were observed [25] In the second 
study bruceantin was administered to 33 patients with advanced solid tumours or 
haematological neoplasms Of 18 patients évaluable for antitumour response one 
patient with adenocarcinoma of the cervix experienced a <50% disease regression 
lasting 10 months and one patient with pleural mesothelioma experienced disease 
stabilisation lasting 4 months [114] The third study was in fifteen adult patients with 
advanced solid tumours The dose limiting toxic effect was nausea and vomiting, 
which was more severe in patients with hepatic metastases or function abnormalities 
[200] 
A phase II study was carried out in 15 patients with metastatic breast carcinoma 
[346] of which two patients achieved stable disease No complete or partial response 
was observed The second phase II study was conducted in malignant melanoma, in 
which bruceantin produced only 2 partial responses in 22 patients [18] Bruceantin was 
furthermore evaluated in 38 patients with previously treated advanced soft tissue 
sarcoma bone sarcoma, or mesothelioma, but no effects were seen [9] 
6. CYCLOHEXIMIDE 
FIGURE 4 structure of C\clohe\imide 
H3C 
Cycloheximide (Fig 4) is an antibiotic that was first isolated by Whiffen et al 1339] 
from Streplo/mces griseus Cycloheximide is an inhibitor of eukaryotic protein 
synthesis that interferes with the enzymatic transfer of peptidyl tRNA from the 
acceptor to the peptidyl site of the nbosome [90,225] 
XX 
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Preclinical data 
Inhibition of protein synthesis by cycloheximide during Gl phase of the cell cycle 
results in the decay of the initiation and continuation of DNA synthesis [289] This 
decay caused protective effects on bone marrow damage induced by cytosine 
arabinoside and nitrogen mustard [27] Moreover cycloheximide prevented the 
cytotoxicity of vincristine and colchicine against human osteosarcoma cells [276], 
diminished the cytotoxic potential of etoposide-mediated topoisomerase-DNA complex 
[61], and prevented the incorporation of 6-thioguanine into DNA [62] Cycloheximide 
induced modulation of TNF-mediated cytotoxicity in sensitive and resistant ovarian 
tumour cells [233] In tumour-bearing mice cycloheximide has increased the survival 
times slightly, but the required doses have been at near-toxic levels The apparent 
antitumour activity was due to their toxic effects on the host For clinical use 
cycloheximide was too toxic [103] 
7. EMETINE 
Emetine hydrochloride (Fig 5) is an alkaloid of the root Cephaehs ipecacuanha and 
Radix epicacuanha known for centuries as a remedy for a wide variety of clinical 
conditions The mechanism of action of emetine has been studied extensively by 
Grollman [126,127] who demonstrated that this drug is an irreversible inhibitor of 
protein synthesis, although cells treated with emetine are reversibly blocked before 
mitosis [337] Emetine prevents the translation of amino-acyl transfer RNA to 
nbosomal peptide [126,127] 
Preclinical data 
Interest in emetine as an antineoplastic agent was revived by its demonstration of 
activity in several animal rumour models including L1210 and P388 murine leukaemia, 
and the B16 melanoma [2,167] 
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Clinical results 
The first report on antitumour activity of emetine was in 1918 by Lewisohn [197]. The 
early results in two cases of breast carcinomas seemed rather promising, but 
experiments in animal carcinomas and sarcomas showed that emetin had no effect on 
malignant tumours. However, in a series of patients with a variety of malignancies 
several regressions were seen after emetine therapy. There had been no further reports 
of the use of this agent in malignant disorders until 1966. /Dd-Rabbo accidentally 
discovered antitumour activity of dehydroemetine, an analogue of emetine, in a case of 
chronic myeloid leukaemia receiving the drug for a concomitant Schistosoma mansoni 
infection [1]. Wyburn-Mason reported in 1966 responses in 3 cases of Hodgkin's 
disease, as well as a complete remission in a rectal adenocarcinoma [351]. 
Phase I studies by Panettiere et al. in 1971 [246] and by Mastrangelo et al. in 1972 
[212], indicated that the principal toxic effects of emetine were reversible muscle 
weakness and electrocardiographic changes. A phase II trial by Siddiqui in 1973 failed 
to show any antitumour response [291]. In 1974, Moertel treated 25 patients with 
metastatic carcinoma with emetine, but only one patient showed incomplete and 
evanescent tumour regression [221]. 
In another study by Kane in 1975, 15 men with epidermoid brochogenic carcinoma 
were treated with emetine. Tumour response was noted in only one patient [177]. An 
additional four patients had stable decease after 4 weeks but progression was 
documented by 6-9 weeks. 
8. HISTIDINOL 
L-Histidinol (NSC 74518, Fig. 6), an analogue of the essential amino acid L-histidine, 
is a protein synthesis inhibitor which acts at the level of initiation. 
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FIGURE 6: Structure of L-Histidmol CH,OH 
Histidinol 
In vitro it inhibits the growth of В16 melanoma cells [234]. It can protect against the 
cytotoxic action of ARA-C and 5-FU [328] and has the capacity to modulate 
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antineoplastic drug action in vitro [334] and in a number of murine models, including 
a mastocytoma (P815) and two leukaemias (P388 and L1210) 
L-histidinol improves both the specificity and the efficacy of a number of commonly-
used agents, including ARA-C, 5-FU, carmustine (BCNU), cyclophosphamide (CY), 
cisplatin, adnamycin and daunomycin [88,89,279,327,329,331,335,336], although not 
with 5-FU against murine breast tumours [300] In addition, L-histidinol has the 
ability to overcome the multidrug resistance trait of cell lines which over-express P-
glycoprotein [332] 
L-Histidinol has been proposed as a modulator for anticancer agents [330], but till 
now L-histidinol has not been entered in clinical trials 
9. HOMOHÄRRINGTONINE 
Homohamngtonine (HHT) and its congener, harnngtonine (HT), are cephalotaxine 
alkaloids derived from the evergreen trees Cephalotaxus fortunei, which are 
distributed throughout southern and north eastern China The drug was first isolated in 
1969 by Powell et al [258] The structure is shown in Figure 7 [259] The parent 
compound harnngtonine, and the derivative, homoharnngtonine have been used in 
China as folk remedies [54] HHT has been found to induce the breakdown of 
polyribosomes lo monosomes with concomitant release of complete globin chains 
[156] Inhibition of protein synthesis by HHT has been confirmed by Baaske and 
Heinstein [20] In synchronised cells, protein synthesis was preferentially inhibited in 
the Gl and G2 phases of the cell cycle Fresno et al [110] have reported blockage of 
the peptide bond formation by HHT and HT The alkaloids bind to free nbosomes and 
monosomes, but do not interact with polyribosomes In addition, these drugs inhibit 
enzymatic binding of aminoacyl-tRNA This is most likely due to an interaction on the 
acceptor site of the 60S nbosomal subunit and thus protein synthesis inhibition in the 
initial cycles of elongation Fang et al showed that harnngtonine inhibited the 
formation of the first peptide bond in protein synthesis [107] In addition it was 
proposed by Tujebajeva et al that the site of HHT binding on 80S nbosomes should 
overlap or coincide with the acceptor site of the nbosome [317] 
Preclinical data 
Preclinical screening of HHT in mice demonstrated good antitumour activity in I Ρ 
implanted murine P388 (327% T/C) and s с implanted colon 38 (208% T/C) cell 
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lines Moderate activity was seen against a s с implanted CD8F1 mammary 
carcinoma and an Ι Ρ implanted L1210 leukaemia HHT was only slightly effective 
against the I Ρ implanted В16 melanoma and was ineffective against Lewis lung 
carcinoma [65,260] 
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FIGURE 7: Structure of HHT and harrtngtomne 
HHT was not active against human tumour xenografts of colon, lung, or mammary in 
athymic mice [92] Furthermore, HHT was tested against fresh surgical expiants of 
human tumours in a 6-day in vivo subrenal capsule assay Eighty tumours were used 
of 13 different histologic types HHT had a response rate of 16% and the average 
tumour regression value for responsive tumours 38% [67]. HT has also been tested 
against 10 human leukaemia-lymphoma cell lines As a result of this it was shown that 
cell lines with rapid cell growth tended to be more sensitive to HT [305] HHT has 
been tested in vitro in combination with several antitumour agents in an effort to detect 
synergistic interactions, but synergy was not found On the contrary, antagonism was 
noted in combination with doxorubicin and 5-FU [236] On the other hand, in murine 
P388 leukaemia in VÌVO HHT and 5-FU were synergistic [190] 
Clinical results 
A summary of preclinical and clinical data till 1986 was reported by O'Dwyer et al. 
[235] The initial phase I studies of HHT encountered severe hypotension on the bolus 
schedule. To eliminate or reduce this toxicity, the way oí administration of all studies 
was changed to continuous infusion Clinical development of HHT in China yielded 
responses in both myeloid and lymphoblastic leukaemia [51] The later development of 
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purified HHT in the United States has confirmed that HHT is an active antileukaemic 
drug 
Phase I studies Legna et al [196] treated 44 patients with solid malignancies and 
leukaemia Dose-limiting toxicity was hypotension No objective rumour regressions 
were documented, but in 4 leukaemia patients the peripheral blood was cleared of 
blast The phase I study reported by Neidhart et al in 1983 [231] also mentioned 
hypotension as dose-limiting toxicity, while Whiteacre et al reported the treatment of 
11 patients with HHT without clinically significant hypotension [340] Nevertheless, 
this study was closed because of fatal hypotension following HHT administration at 
other institutions Coonly et al [70] treated 31 patients in 1983 with HHT in which 
myelosuppression was dose-limiting In another study in 1985 by Stewart et al the 
dose-limiting toxicity's were hypotension as well as cardiotoxicity [298] Hypotension 
was the dose-limiting toxicity during the first Phase I trials utilising the bolus 
schedule Avoidance of hypotension requires the use of continuous infusion schedules, 
the dose-limiting toxicity is now myelosuppression [208,232] 
Phase II studies in leukaemia were conducted by Warrell et al in 1985 [326] in 51 
patients with acute leukaemia of which 7 achieved complete remission When HHT 
was given as a low-dose continuous infusion a definite but low antileukemic effect was 
found [179] Single-agent HHT was evaluated by Stewart et al [299] as induction 
therapy in 20 patients with advanced acute non-lymphocytic leukaemia (ANLL) They 
concluded that, despite a definite antileukaemic effect, HHT as a single agent cannot 
be recommended as a useful salvage regimen in patients with far advanced ANLL 
In solid tumours several phase II studies were reported In a study of Kavanagh et 
al in 1984 only 1 partial remission was observed among 86 évaluable patients, 
however, nearly every patient on the studies had extremely advanced disease and 
multiple prior treatment regimens [180] In another study conducted by Ajani et al in 
1986 80 patients who had advanced solid tumours were treated with HHT [7] The 
five categories of solid tumours included malignant melanoma, sarcoma, head and 
neck, breast, and colorectal carcinomas Among the 74 évaluable patients there were 
no complete or partial remissions They concluded that HHT given by intermittent 
schedule is an inactive drug against these solid tumours previously exposed to 
chemotherapy HHT treatment in advanced squamous cell carcinoma of the head and 
neck was not effective [273] 
The addition of HHT to the chemotherapy protocol CMF (cyclophosphamide, 
methotrexate, fluorouracil) gave no additional benefit [359] While HHT has shown 
some activity in the United States in ANLL, investigator interest in the US has waned 
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because of toxicity and inconvenient schedules [124] The Chinese trials have used 
different schedules than have US studies and have been associated with less toxicity 
[307,355] These trials may lead to further investigations of the cephalotaxme esters in 
the United States 
10. PUROMYCIN 
Puromycin is an antibiotic obtained from Streptomyces alboniger and was isolated by 
Porter et al in 1952 [257] Nowadays, puromycin, functioning as analogue of the 3' 
end of the aminoacyl-tRNA, is used extensively as an acceptor in model assays for 
peptide bond formation, called the puromycin reaction N-blocked aminoacyl-tRNAs 
bound to the peptidyl transferase P-site on the nbosome react with puromycin, 
forming N-acetylaminoacyl-puromycin [265] 
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Preclinical data NM, 
Puromycin has been found active in vivo on murine adenocarcinoma 755 [316] 
Because of this activity, puromycin entered a clinical trial 
Clinical results 
A clinical study was conducted by Wright et al. in 1955 [350] Puromycin was 
administered to 51 patients with incurable neoplastic diseases, mainly carcinomas 
Regressions were seen in 14 patients, but there seemed to be no alteration in the 
patient's progressive downhill clinical course The clinical toxicity of puromycin 
consisted of nausea, vomiting, and diarrhoea Puromycin has not been evaluated 
further as antitumour agent 
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11. RICIN AND ABRIN 
Abrin and ricin are highly toxic proteins, which were isolated from seeds of Abrus 
precatonus and from Ricinus communis, respectively [170,202] Both have a 
molecular weight of 65 000 but a different chemical structure concerning the N and С 
terminal amino-acid residues For abrin these are leucine, while the N-termini of nein 
are alanine and isoleucine, and the C-termini are phenylalanine and serine These 
proteins consist of 2 polypeptide chains joined by a disulfide bond The B-chain is a 
glycoprotein which binds the toxin to cell surface receptors, whereas the A-chain 
penetrates into the cytosol, where it inactivates the large 60S nbosomal subunit and 
thus inhibits protein synthesis [237] 
Preclinical data 
Total inhibition of Ehrlich ascites tumour growth has been demonstrated by 
simultaneous injection of a sublethal dose of ricin and abnn, and for abrin against B16 
melanoma as well as several human tumour xenografts [102] Abrin was capable to 
reduce the number of lung metastases of Lewis Lung carcinoma in mice and 
potentiated the therapeutic effect of cyclophosphamide in this tumour model without 
increasing the toxicity [129] Combinations of abrin or ricin with cisplatin produced 
markedly synergistic action in prolonging survival times of mice bearing L1210 
leukaemia or Ehrlich ascites carcinoma [325] 
Clinical results 
A phase I study by Fodstad et al [101] in 1984 was carried out with ricin on 54 
patients with advanced disease At the highest levels, flu-like symptoms with fatigue 
and muscular pain appeared and, in some patients, nausea and vomiting occurred No 
myelosuppression was seen Of 38 évaluable patients, one patient with lymphoma had 
a partial response Stable disease was observed in four patients with renal cancers, in 
two with soft tissue sarcomas, and in one patient each with mesothelioma, thyroid, and 
rectal cancer 
3. SUMMARY AND PROSPECTS 
Protein synthesis inhibitors have been studied for the chemotherapy of cancer over a 
long period In this chapter we attempted to present, in general outline, a discussion of 
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those agents whose possible usefulness have been investigated preclmically and in 
phase I or phase II clinical trials For some drugs, too few clinical trials have been 
done to conclusively prove or disprove the value of any of these approaches in humans 
(Benzaldehyde and Puromycin) Cycloheximide was too toxic for clinical use Other 
drugs have been in clinical trials extensively but failed to show any beneficial activity 
(Anguidine, Bruceantine and Emetine) 
Effective drugs are L-asparaginase, homohamngtonine (HHT) and ncine L-
asparaginase is effective in inducing remissions of leukaemia in humans, but should be 
used only in combination with other drugs, like ARA-C or MTX, to achieve complete 
remissions The development of purified (HHT) has confirmed that HHT is an active 
antileukaemic drug The addition of HHT to the chemotherapy protocol CMF 
(cyclophosphamide, methotrexate, fluorouracil) gave no additional benefit In the US 
the interest in this drug has waned because of toxicity and inconvenient schedules 
Chinese trials have used different schedules than have US studies and have been 
associated with less toxicity These trials may lead to further investigations of this 
drug in the United States Ricin has been in clinical phase I trial without good 
antitumour responses Nowadays Ricin is investigated conjugated to tumour-specific 
antibodies These so called immunotoxins might improve cancer chemotherapy, 
because they possess higher selectivity for tumour cells and are less toxic 
Two promising drugs are Bouvardin and L-Histidinol, which showed preclinical 
antitumour activity as single drug as well as in combination with other cytostatic 
agents but a clinical trial has not been started yet 
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CHAPTER 11 
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SUMMARY 
Selective potentiation of antitumour effect and protection of normal tissue against 
antitumour therapy and are two greatly desired goals for the medical oncologist The 
efficacy of cancer chemotherapy can be increased by combining two or more cytostatic 
agents with different modes of action Non-chemotherapeutic agents can also enhance 
the effectiveness of chemotherapy by potentiation of the antitumour activity of the drug 
or by reversing the resistance to specific agents Most currently used cytotoxic drugs 
interact directly or indirectly with DNA, or with the microtubules 
of the mitotic spindles Sparsomycin (NCS-059729) is cytotoxic because it inhibits the 
nbosomal protein synthesis in cells Sparsomycin (Sm) is a sulphur-containing 
antibiotic isolated from Streptomyces sparsogenes and is a potent inhibitor of the 
growth of many organisms including bacteria, mammalian cells and yeast's, and is 
also active against tumour cells In addition, Sm potentiates the antitumour activity of 
cisplatin in an animal tumour model 
The usefulness of Sm as a very potent protein synthesis inhibitor and as a potential 
anticancer drug has stimulated the synthesis of sparsomycin analogues Following a 
successful total synthesis of the antibiotic many new analogues have been synthesised 
An overview of the development of Sm since its discovery as antibiotic in 1962 and as 
an antitumour agent thereafter is presented in Chapter 1 This includes a synthetic 
strategy approach and the use of derivatives to unravel the mechanism of action, as 
well as to develop molecules with stronger biological activities Several of these 
analogues were found to have a broader therapeutic index than Sm itself Of these 
active analogues, ethyldeshydroxy-sparsomycin (EdSm) appeared to be the most 
promising analogue in potentiating the antitumour activity of cisplatin 
This thesis describes the investigations of ethyldeshydroxy-sparsomycin as an 
antitumour agent and as modulator of the efficacy of cytostatic drugs 
In order to evaluate the efficacy of EdSm as antitumour agent, cells freshly prepared 
from human tumour xenografts were used m vitro (chapter 2) EdSm was shown to 
have a clear dose-response effect in vitro At continuous exposure with 0 01 μg/ml, 
growth inhibition was found in 2/11 of the tumours (a gastric and a small cell lung 
carcinoma), and 1 μg/πú EdSm was cytostatic to all tumours tested 
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In addition, EdSm was studied in several selected murine tumour models. The 
maximum tolerable dose of EdSm in mice indicated that the tolerance of a cumulative 
dose increased when lower doses were given more frequently. This resulted in better 
antitumour activity in L1210 leukaemia as well. EdSm was also active against 
intraperitoneally (LP.) inoculated P388 leukaemia (150% T/C = Treatment over 
Control χ 100%), B16 melanoma (156% T/C) and RC carcinoma (197% T/C), and the 
subcutaneously (S.C.) inoculated L1210 (139% T/C) and RC (138% T/C). 
Because Sm is historically suspected to be retinotoxic, the toxic effects of EdSm on 
the protein biosynthetic capacity of the retina was studied by assaying the rhodopsin 
and opsin levels in mice. In none of these cases a reduction in either the opsin or 
rhodopsin level could be measured and no changes were seen histologically. The 
results are also reported in chapter 2. 
EdSm can only be biologically active when it penetrates the plasma membrane of 
the tumour cell. Therefore, the uptake of EdSm was studied in L1210 leukaemic cells 
and compared with the uptake in an Sm resistant variant (chapter 3). This EdSm 
uptake appeared to be dependent on dose, time and temperature. During the first 15 
minutes this uptake is a linear process with a maximum of 6 pmol/106 cells using an 
extracellular concentration of 100 /xM. Thereafter, the rate of drug accumulation slows 
down to reach a maximum level of 8 pmol/106 cells after 4 hours. The rate of EdSm 
uptake in the Sm resistant variant of L1210 leukaemia is even slower, resulting in less 
drug uptake than in the parental cell line. The efflux rate of both cell lines is 
comparable. Because drug accumulation is the result of both influx and efflux, our 
data indicate that EdSm enters tumour cells at a very poor rate and that resistance to 
EdSm can be largely, but not completely, explained by a decreased drug influx. 
One of the reasons why EdSm may have an enhanced effect on the cytostatic 
activity of cisplatin is the interaction with cellular detoxification systems like 
glutathione (GSH) and glutathione-S transferase (GST), which are known to diminish 
the cisplatin antitumour activity. We therefore analysed the effects on GSH and GST 
activity in tumour cells after EdSm or cisplatin exposure (chapter 4). For this purpose 
we used three murine leukaemia tumours with different sensitivities towards EdSm and 
cisplatin. Between these three cell lines no significant differences were detectable 
regarding population doubling time, cell size, and the cellular level of protein and 
glutathione. Moreover, P-glycoprotein, a membrane molecule which is known to be 
active in multidrug resistance, is not expressed by these cell lines. When these cell 
lines were exposed to EdSm the cellular protein level and the overall GST activity 
decreased strongly and led to a depletion of GSH Cisplatin exposure, on the other 
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hand, enhanced the amount of protein and GSH, as well as the GST activity These 
effects were dose dependent and correlated well with the sensitivity of the tumour cells 
for EdSm or cisplatin In addition, EdSm exposure dropped the V
max
 of GST in L1210-
WT cells and L1210-SM cells, but increased the V
max
, as well as the K ,^ in L1210-
CDDP This is not a direct effect of EdSm on GST, since in a cell-free system EdSm 
did not influence the GST activity nor acted as a substrate for this enzyme Our results 
suggest that the synergistic combination of EdSm and cisplatin might be explained by 
switching off the cellular detoxification mechanism for cisplatin by EdSm, ι e by 
inhibition of de novo synthesis and a subsequent depletion of GSH and GST 
In the following chapters the modulation of antitumour activity by EdSm is 
described Chapters 5, 6 and 7 describe the effects of EdSm m combination with 
cisplatin Resistance to cisplatin m vivo is a relative term and can at least be partially 
attributed to its narrow therapeutic index Because of lethal toxicity it is often not 
possible to successfully treat tumours which exhibit even a small inherent resistance to 
cisplatin by increasing the dose level of cisplatin Thus, combination therapy with an 
agent which enhances cisplatin's antitumour effects, while the toxicity of cisplatin is 
the same or even less, may be of value in the treatment of tumours which do not 
respond to treatment with cisplatin alone 
In order to investigate the relationship between the results of combined drug treatment 
in vi\o and drug sensitivity of tumour cells in vitro, we used the parent Ieukaemic 
L1210 cells (L1210-WT) and two subclones resistant to Sm (L1210-SM cells) or 
cisplatin (L1210-CDDP cells), which have identical doubling times (chapter 5) 
Combined drug treatment of EdSm and cisplatin against the L1210-WT leukaemia 
revealed strong synergistic antitumour activity In both resistant subclones, however, 
EdSm could not potentiate the antitumour activity of cisplatin These results indicate 
that synergism of combined drug treatment with cisplatin and EdSm is largely 
dependent on the cellular properties of the target tumour cell populations and less on 
host factors Other parameters which might influence the effect of this drug 
combination are further investigated in L1210-WT cells (chapter 6) The optimum 
treatment conditions were studied with regard to the number of doses, the number of 
tumour cells implanted, the interval between, and the priority of the administration of 
the two drugs, and also the route of drug administration EdSm, given before, during 
or after the cisplatin injection, potentiated the antitumour activity of cisplatin equally 
By increasing the number of tumour cells, the antitumour effect of both EdSm as well 
as cisplatin diminished, however, the effect of the drug combination diminished less 
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Changing the route of drug administration from intraperitoneal to intravenous for one 
or both drugs resulted in a complete loss of antitumour potentiation 
The efficacy of combined treatment is often schedule dependent Schedule dependency 
for this drug combination has therefore been investigated in the sensitive LI210 
tumour and in the murine B16 melanoma, which is less sensitive to cytotoxic treatment 
(chapter 7) Against L1210 leukaemia all treatment schedules increased the life-span 
of mice compared to single cisplatin treatment The combination of EdSm with this 
platinum compound yielded a cure rate of >80%, compared to <35% for single 
cisplatin treatment The В16 melanoma is rather insensitive to both cisplatin and EdSm 
as well as to the combinations of these agents, yet schedule dependent efficacy was 
found in certain schedules 
These results suggest that EdSm has significant synergistic capabilities in different 
animal tumour models, but strong therapeutic enhancement of cisplatin efficacy is only 
seen when the tumour is sensitive to cisplatin as well as to EdSm 
To investigate whether the synergism of EdSm and cisplatin is a general 
phenomenon applicable to more antitumour drugs or limited to cisplatin, we studied 
the effect of EdSm on antitumour agents with different intracellular targets and 
investigated the optimum dose ratio and schedule dependency for maximum antitumour 
enhancement by EdSm in vitro (chapter 8) The microculture tetrazohum test (MTT) 
was used as assay with cultured B16 melanoma cells The data were analysed for true 
synergism using the combination-index and the median-effect principle It appeared 
that the extent of cytotoxic drug interaction was influenced by the duration of drug 
exposure, the dose ratio, and the treatment schedule When drug ratios were used, 
based on their individual growth inhibition kinetics, synergism was observed upon pre-
and post-treatment m combination with cisplatin, cytosine arabmoside (ARA-C), 
methotrexate (MTX), and 5-fluorouracil (5-FU) The combination of a fixed dose of 
EdSm was synergistic with cisplatin, ARA-C, vincristine (VCR) and MTX, in the 
order MTX > ARA-C > VCR > cisplatin, while the combinations with doxorubicin, 
5-FU and etoposide (VP 16) were shown to be antagonistic These results suggest that 
only certain drugs and treatment schedules might be worthwhile for combination 
studies with EdSm m vivo 
Several of these drug combinations were further evaluated in the L1210 leukaemia 
and B16 melanoma animal tumour models (chapter 9) This combination study was 
performed using seven drugs with different intracellular targets Tumour implantation 
and drug treatment were I Ρ in all studies, and the time intervals between 
administration of EdSm and the cytostatic agents varied Our results show that in the 
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В16 tumour model EdSm is not capable of potentiating any of these drugs In the 
leukaemic tumour, however, interval dependency was seen to lead to synergistic as 
well as antagonistic effects Antagonism was seen for 5-FU leading to complete loss of 
antitumour activity when EdSm was given 3 or 24 h after 5-FU, but could be 
prevented when EdSm was given 6 h after 5-FU Enhanced 5-FU activity, however, 
was never noticed The opposite effect was seen in the combination with vincristine 
and in the combination with ARA-C When EdSm was given at least 6 h after VCR its 
activity improved, thereby increasing the animal survival time from 32 days (and 33% 
complete responders) to >60 days (and 83% complete responders) In combination 
with ARA-C potentiation of antitumour activity was seen only when EdSm was given 
24 h after ARA-C, thereby increasing the MST from 32 days and 11% survivors to 
>55 days and 50% survivors In combination with BCNU, VP16 and DX, no 
antagonistic or synergistic modulatory effects were seen These results show that 
EdSm can change the antitumour efficacy of selected antitumour agents in a schedule 
dependent way 
Finally, Chapter 10 presents other inhibitors of the nbosomal protein synthesis 
whose possible usefulness has been investigated preclinically and, for some, in clinical 
trials All of these drugs showed antitumour activity in experimental animal tumour 
models, some of them have not been further investigated in clinical trials, ι e 
bouvardin and L-histidinol 
Cycloheximide proved too toxic for clinical use Other drugs like anguidine, 
bruceantine, emetine, and puromycin had appeared to be disappointing in clinical 
trials Benzaldehyde seemed very promising in clinical trials, but to our knowledge 
this study was not continued L-asparaginase was effective in inducing remissions of 
leukaemia in humans, but should be combined with other drugs to achieve complete 
remissions Homoharnngtonine proved to be an active antileukaemic drug The drug 
ricin is still being studied, but only as an immunotoxin, an antibody-toxin conjugate, 
for cancer treatment 
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DISCUSSION AND CONCLUSIONS 
The cellular effects of protein synthesis inhibition are diverse and it is hardly 
possible to predict what the effects will be Attachment of the inhibitor to the ribosome 
influences the production of protein molecules synthesised at that moment Most 
cellular proteins are in a dynamic state of constant turnover Protein turnover is 
extensive and is highly selective specific proteins are degraded within cells at widely 
different rates The levels of intracellular proteins are determined both by the rate of 
synthesis and the rate of degradation, and involve basic cellular functions The 
provision of amino acids in times of need is an additional function of protein 
breakdown, and is greatly accelerated under conditions of nutritional or hormonal 
deprivation (') The individual protein life-spans vary from several minutes to several 
days, ι e the cytoskeletal proteins Thus, the primary inhibition will affect proteins 
which have short live-spans and are needed at that moment, ι e proteins involved in 
regulation processes 
Antitumour agents can be inactivated by certain cellular proteins If these proteins 
are known, a combination of drugs can be targeted to these molecules Sometimes 
drugs are metabolised in biochemical pathways and those specific enzymes are 
therefore subject to investigation (antimetabolites, like 5 FU and ARA-C) Several 
drugs are inactivated by detoxification mechanisms like glutathione and glutathione-S 
transferase (cisplatin) The last cellular defence mechanism is provided by DNA-repair 
enzymes, which remove DNA adducts or repair DNA breaks Decreasing the 
concentration and activities of these molecules can then be a basis for potentiation of 
the antitumour activity in combination therapies The effect of EdSm depends on the 
level of intracellular concentration, which is dose and time dependent and is 
reversible As described in this thesis, sensitivity to EdSm can be limited because of 
low intracellular concentrations Moreover, the effects of EdSm on the activity of GST 
is only measurable at higher concentrations It might be difficult to obtain these 
concentrations in whole body studies In general, drugs that are active in cultured 
tumour cells will not have any activity at all if the drug concentration needed can not 
be reached in whole body situations Since the activity of EdSm is reversible by high 
efflux rates, longer drug exposure times with active concentrations will increase the 
duration of protein synthesis inhibition and therefore potentiate the antitumour 
response of the second drug in that combination Improvement of drug combinations 
with Sm analogues can be obtained if the uptake is enriched This might be obtained 
by using more lipophilic analogues such as the n-pentyl-sparsomycin Reversibility can 
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be decreased when the affinity of Sm analogues to the ribosome is improved. In 
addition, in search for new antitumour agents the screening should be performed at 
short exposure times instead of continuous exposure. Finally, if possible the 
permeation route should be identified not only in terms of the rate of entry of the 
solute in question under the described conditions, but also in terms of transport 
parameters which reflect the underlying mechanisms In this way, the rate of 
permeation can be predicted under different conditions, including antitumour 
responses. In addition, the increased availability of monoclonal antibodies has opened 
new possibilities for cancer therapy, because they can be used for targeting drugs or 
toxins to cancer cells, and so improve the therapeutic window of specific antitumour 
agents. 
The following conclusions can be drawn from the investigations described in this 
thesis: 
1. EdSm is active against the L1210 and P388 leukaemia, the B16 melanoma, and 
the renal cell carcinoma RC, but in general this antitumour activity is only 
modest. 
2. The uptake of EdSm by L1210 cells is a dose, time and temperature dependent 
process. 
3. EdSm enters L1210 tumour cells at a very poor rate. Resistance to EdSm can be 
partly explained by a decreased drug influx. 
4 The synergistic combination of EdSm and cisplatin might be explained by 
switching off the cellular detoxification mechanism for cisplatin by EdSm, i.e. by 
inhibition of de novo synthesis and subsequently depletion of GSH and GST. 
5. Synergism of combined treatment with cisplatin and EdSm is largely dependent 
on the cellular properties of the target tumour cell populations. 
6 The order of drug administration does not influence the antitumour activity of 
cisplatin. EdSm can be given before, during or after cisplatin. 
7 EdSm can have significant synergistic capabilities in several animal tumour 
models, but strong therapeutic enhancement of cisplatin efficacy is only seen if 
the tumour is sensitive to both cisplatin and EdSm. 
8. In vitro synergism was observed upon pre- and post-treatment of EdSm in 
combination with cisplatin, cytosine arabinoside, methotrexate, and 5-
tluorouracil 
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9 EdSm is not capable of potentiating the antitumour activity of cisplatin, cytosine 
arabinoside, methotrexate, and 5-fluorouracil in vivo in the B16 tumour model. 
10. In L1210 leukaemia, antagonism was observed for 5-FU leading to complete loss 
of antitumour activity when EdSm was given 3 or 24 h after 5-FU. Enhanced 5-
FU activity was never noticed. 
11. In combination with vincristine and ARA-C, potentiation of activity was obtained 
when EdSm was given at least 6 h after vincristine, or 24 h after ARA-C. No 
antagonistic or synergistic modulatory effects were seen in combination with 
BCNU, VP16 and DX. 
12. EdSm can be of potential use in cancer chemotherapy by enhancing the 
antitumour efficacy of selected antitumour agents in a schedule dependent way. 
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SAMENVATTING 
Verbetering van de resultaten van de behandeling van tumoren en bescherming van het 
gezonde weefsel tegen de antitumortherapie zijn twee belangrijke doelstellingen van de 
medisch oncoloog De effectiviteit van de chemotherapie van kanker kan worden 
verbeterd door de combinatie van meerdere cytostatica (celgroeiremmende 
geneesmiddelen) welke verschillen zowel in aangrijpingspunt als in toxiciteit Ook 
middelen welke op zich niet cylostatisch zijn kunnen een potentierend effect hebben op 
klassieke cytostatica, b ν door tumorcellen die ongevoelig (resistent) zijn, of zijn 
geworden na chemotherapie, gevoelig te maken voor deze celdodende middelen 
Nieuwe cytostatica worden ontwikkeld enerzijds door screening van zowel chemische 
als natuurlijke verbindingen in verschillende tumorsystemen, anderzijds d m v 
gerichte chemische veranderingen aan te brengen in bestaande cytostatica 
In dit proefschrift wordt de activiteit van ethyldeshydroxy-sparsomycine (EdSm) 
behandeld, welke het resultaat is van gerichte chemische verandering van 
sparsomycine (NCS-059729) De ontwikkeling van sparsomycine als cytostaticum en 
de synthese van derivaten van sparsomycine (sparsomycine verbindingen met een 
gewijzigde chemische structuur) zijn samengevat in deel I, hoofdstuk 1 
Het antibioticum sparsomycine (Sm) werd reeds in 1962 geïsoleerd uit de 
bacterie Streptomyces sparsogenus Vanwege zijn unieke structuur en brede biologische 
activiteit hebben vele onderzoekers grote belangstelling getoond voor deze stof De 
werking van Sm is anders dan van de klassieke cytostatica, welke doorgaans direct of 
indirect op het DNA werken of op de microtubuli van het celdelingsmechanisme Sm 
is een sterke remmer van de eiwitsynthese doordat het interfereert met de vorming van 
de peptide band, welke plaats vindt in het peptidyl transferase centrum van de 
nbosomen De synthese van eiwitten is van essentieel belang voor de regulatie van de 
cellulaire functies Wanneer deze eiwitsynthese gedurende langere tijd wordt 
geblokkeerd zal de desbetreffende cel sterven Op grond van deze eigenschap heeft Sm 
een breed spectrum van biologische activiteit waaronder antiparasitaire, antivirale, 
antibactenele, antischimmel en antikankeractiviteit 
Van alle gesynthetiseerde sparsomycinedenvaten bleek EdSm, als nieuw 
cytostaticum, de beste perspectieven te geven In dit proefschrift wordt daarom 
uitvoerig ingegaan op de biologische eigenschappen en toepassingsmogelijkheden van 
EdSm 
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In deel II (hoofdstukken 2, 3 en 4) worden de biologische activiteiten van EdSm 
beschreven Hoofdstuk 2 behandelt de antitumoractiviteit van EdSm De 
antitumoractiviteit van EdSm is gemeten in een panel van humane tumoren in 
celkweek (in vitro), en daarnaast in tumormodellen in de muis (in vivo) Twee van de 
elf in vitro geteste humane tumoren, een maagcarcinoom en een kleincelhg 
longcarcinoom, waren gevoelig Een continue blootstelling aan 1 μg EdSm/ml 
resulteerde in groeiremming in alle tumoren Vervolgens is EdSm getest in 
verschillende tumormodellen in de muis Meting van de maximaal toelaatbare dosis 
EdSm in verschillende toedieningsschema's toonde aan dat de totale getolereerde dosis 
voor EdSm toeneemt wanneer de totale dosis wordt gegeven in zoveel mogelijk 
stappen Dit resulteerde ook in een betere antitumorwerking in de L1210 leukemie 
Daarnaast gaf EdSm antitumoractiviteit te zien in de P388 leukemie, de В16 melanoma 
en het niercelcarcinoma (RC) Omdat historisch gezien Sm wordt verdacht van het 
veroorzaken van oogtoxiciteit in de vorm van scotomen (vlekken voor de ogen), is 
voor EdSm zowel biochemisch (rhodopsine en opsine) als histologisch nagegaan of bij 
hoge doseringen EdSm in de ogen van behandelde proefdieren veranderingen optreden 
Hiervoor werden geen aanwijzingen gevonden 
In hoofdstuk 3 en hoofdstuk 4 worden de gebeurtenissen beschreven die 
plaatsvinden op het moment dat EdSm bij de tumorcel arriveert Bij de behandeling 
van tumoren is het van groot belang dat de toegediende stof door de tumorcel wordt 
opgenomen Naarmate een verbinding sneller wordt opgenomen, zal de concentratie in 
de tumorcel hoger zijn en zal deze sneller worden uitgeschakeld Opname door de 
tumorcel is de eerste cytotoxische stap, maar opname alleen is niet altijd voldoende 
Om een cel uit te schakelen moet het cytostaticum in de cel op de plaats van 
bestemming komen Veel tumoren zijn van nature in slaat om zich zodanig te weren 
tegen toxische verbindingen, dat het effect van deze cytostatica, zelfs bij hoge 
doseringen, gering is Een cel zal de voor hem toxische verbinding zo snel mogelijk 
onschadelijk maken De eerste mogelijkheid voor de tumorcel is om deze stof te 
verwijderen, vaak via speciale pompsystemen De resultaten betreffende de studies 
naar de opnamesnelheid van EdSm in tumorcellen, alsmede de afgifte (efflux) worden 
in hoofdstuk 3 beschreven voor een tumorcel welke gevoelig is voor EdSm, alsmede 
voor een tumorcel welke minder gevoelig (resistent) is voor EdSm De opname van 
EdSm in een gevoelige tumorcel is lineair gedurende de eerste 15 minuten, daarna 
neemt de opnamesnelheid sterk at Bij een externe druk van 100 μΜ is de totale EdSm 
opname na 4 uur 8 pmol/106 cellen In een voor EdSm resistente tumorcel (L1210-Sm) 
is onder vergelijkbare omstandigheden zowel de opnamesnelheid als de totale opname 
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lager De snelheid waarmee EdSm weer uit deze tumorcellen stroomt (de efflux) is 
echter identiek Het grote verschil in gevoeligheid van deze twee celtypen kan echter 
niet geheel worden verklaard door een verschil in opname Een tweede mogelijkheid 
voor de tumorcel om de toxische verbinding onschadelijk te maken is door de 
verbinding chemische te veranderen tot een inactieve stof of door koppeling aan 
glutathion (GSH) d m v het enzym glutathion S-transferase (GST) Dit onschadelijke 
complex wordt vervolgens uit de cel verwijderd en door het lichaam verder afgevoerd 
In hoofdstuk 4 wordt nagegaan of EdSm in staat is om dit verdedigingsbolwerk uit te 
schakelen Dit is belangrijk als EdSm wordt gebruikt in combinatie met andere 
cytostatica, zoals met cisplatina, waarvan bekend is dat het door glutathion 
onschadelijk gemaakt kan worden, met als gevolg een drastische verlaging van de 
antitumorwerking Als EdSm in staat is de activiteit van glutathion te verminderen, 
dan zal de antitumor werking van b ν cisplatina juist worden versterkt Door gebruik 
te maken van drie L1210 leukemiecellijnen, welke verschillen in gevoeligheid voor 
EdSm en cisplatina, is onderzocht welke invloed de dosis heeft op de effecten van 
behandeling met EdSm oí cisplatina Deze drie cellijnen verschillen niet in 
populatieverdubbelingstijd, celgrootte, het eiwitgehalte en hoeveelheid GSH 
Bovendien is het plasmamembraaneiwit P-glycoprotein, welke bij "multidrug-
resistente" cellijnen vaak in verhoogde mate aanwezig is, in geen van deze cellijnen 
detecteerbaar De L1210-WT cellijn is gevoelig voor zowel EdSm als cisplatina, 
L1210-Sm is resistent tegen EdSm en L1210-CDDP is resistent tegen cisplatina 
Wanneer deze cellijnen worden behandeld met EdSm daalt de hoeveelheid eiwit per 
cel en het GSH gehalte Bovendien neemt de totale enzymactiviteit van GST af 
Behandeling met cisplatina, daarentegen, laat het tegenovergestelde effect zien Deze 
effecten zijn afhankelijk van de dosis van het geneesmiddel, en correleren met de 
gevoeligheid van de cellijn voor EdSm of cisplatina Behandeling met EdSm 
vermindert bovendien de maximale GST-activiteit (Vnni) in L1210-WT en in L1210-
SM cellen In de L1210-CDDP cellijn wordt deze enzymactiviteit juist door EdSm 
versterkt Deze resultaten suggereren dat de combinatie van EdSm met cisplatina in 
tumorcellen synergistisch kan werken doordat EdSm in staat is de concentratie van 
GSH en de activiteit van GST in de cel te verlagen, waardoor meer cisplatina 
moleculen in de cel op de plaats van bestemming komen en een groter cytostatisch 
resultaat wordt verkregen 
In deel III, hoofdstukken 5, 6 en 7, wordt beschreven hoe EdSm in 
tumormodellen in de muis de antitumoractiviteit van cisplatina verbetert Resistentie 
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tegen cisplatina in vivo wordt vooral veroorzaakt doordat de concentratie cisplatina die 
nodig is voor antitumorwerking tevens een sterk toxisch effect veroorzaakt (een kleine 
therapeutische index). Soms zou een kleine verhoging van de cisplatina dosis 
voldoende kunnen zijn om de tumor te doen slinken. Helaas is dit vaak niet mogelijk 
door een te grote toxiciteit. Daarom kan combinatietherapie zeer waardevol zijn mits 
de verbinding in staat is de werking van cisplatina te versterken zonder de toxiciteit te 
verhogen. 
In hoofdstuk 5 wordt beschreven of er een correlatie bestaat met de gevoeligheid van 
tumorcellen voor EdSm en cisplatina in vitro (weefselkweek) enerzijds en de 
antitumoractiviteit in vivo (in de muis). De resultaten laten zien dat de combinatie van 
EdSm en cisplatina in de gevoelige tumor (L1210-WT) resulteert in een sterk 
synergistisch antitumor effect. Echter in tumoren welke ongevoelig zijn voor of EdSm 
(L1210-SM) of cisplatina (L1210-CDDP) heeft EdSm geen enkel potentierend effect. 
Deze resultaten tonen aan dat synergisme van deze combinatietherapie sterk 
afhankelijk is van de cellulaire eigenschappen van de behandelde tumorcel en minder 
van farmacokinetische factoren. 
In hoofdstuk 6 wordt ingegaan op de optimale behandelingscondities, met name het 
aantal toedieningen, de grootte van de tumor bij het begin van de therapie, de tijd 
tussen de toediening van EdSm en cisplatina (interval), de volgorde van toediening, 
alsmede de toedieningsroute. Er kan worden vastgesteld dat voor het effect van de 
geneesmiddelencombinatie de volgorde van toediening en het tijdsinterval geen invloed 
hebbenop het synergistisch effect van de combinatie van EdSm en cisplatina. De 
grootte van de tumor bij aanvang van de therapie heeft een duidelijk negatief effect op 
de antitumoractiviteit van EdSm en cisplatina, echter veel minder voor de combinatie. 
Als de toedieningsroute wordt veranderd van ïntrapentoneaal (direct in de buikholte) 
naar intraveneus (in de bloedbaan), dan is de synergistische werking van de combinatie 
volledig verdwenen. 
In hoofdstuk 7 is vervolgens nagegaan welk toedieningsschema het sterkste 
antitumoreffect geeft. Hiervoor is naast de gevoelige L1210-WT tumor ook de minder 
gevoelige В16 melanoma getest. Behandeling van de L1210 tumor met de combinatie 
van EdSm en cisplatina resulteert in bijna alle behandelingsschema's in een beter 
antitumoreffect in vergelijking met alleen een cisplatinabehandeling. De 
combinatiebehandeling geeft een genezingspercentage van >80% van de behandelde 
muizen, terwijl dit voor cisplatina <35% is Het B16 melanoma blijkt weinig gevoelig 
te zijn voor de verschillende behandelingschema's, hoewel in sommige schema's de 
combinatie beter werkte dan wanneer een enkel geneesmiddel werd gegeven. Deze 
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resultaten tonen aan dat EdSm ook in vivo synergistisch of potentierend werkt op de 
antitumoractiviteit van cisplatina, in verschillende tumormodellen, maar dat een grote 
therapeutisch verbetering alleen wordt verkregen in een tumor welke gevoelig is voor 
zowel EdSm als cisplatina 
In deel IV, hoofdstukken 8 en 9, is bestudeerd of EdSm ook potentierend kan 
werken op andere klassieke cytostatica Hoofdstuk 8 beschrijft de resultaten in vitro en 
hoofdstuk 9 in vivo In hoofdstuk 8 is EdSm gecombineerd met cytostatica, waarvan 
de aangrijpingspunten in de tumorcel verschillen In vitro kan direct op cellulair 
niveau worden gemeten of de combinatie een beter effect geeft dan een enkelvoudige 
behandeling Daarnaast kan de aard van de interactie in termen van synergisme en 
antagonisme worden berekend door gebruik te maken van de combinatie-index en het 
mediaan-effect principe Bovendien wordt informatie verkregen over de benodigde 
doseringen, het beste behandelingsschema en de minimale duur van de behandeling 
De dosering waarbij in vitro een synergistisch effect ontstaat kan worden vergeleken 
met de concentraties van de betreffende stof welke in de patient tolerabel zijn Is de 
concentratie van het geneesmiddel op cellulair niveau, vergelijkbaar met of zelfs lager 
dan de in vivo situatie, dan is de verwachting dat in vivo ook synergisme met deze 
combinatie kan worden bereikt Daarnaast wordt direct concrete informatie verkregen 
over een optimaal behandelingsschema De uitkomst van de combinaties in vitro was 
afhankelijk van de duur van de behandeling, de ratio van de gebruikte doseringen, en 
de volgorde van toediening Wanneer werd uitgegaan van een dosis-ratio (een vaste 
concentratieverhouding van twee geneesmiddelen), werd synergism gemeten in 
combinatie met cisplatina, cytosine arabinoside (ARA-C), methotrexaat (MTX) en 5-
fluorouracil (5-FU) Waarbij de volgorde van toediening afhankelijk was van de 
behandelingsduur met EdSm Wanneer één vaste dosis EdSm werd gebruikt werd 
antagonisme gemeten voor alle combinaties, tenminste als EdSm als eerste werd 
gegeven Wanneer EdSm als laatste werd geven, resulteerde dit in een synergistisch 
effect in combinatie met cisplatina, ARA-C, vincristine (VCR) en MTX, in de 
volgorde MTX > ARA-C > VCR > cisplatina De combinatie van EdSm met 
doxorubicine, 5-FU en etoposide (VP 16) was altijd antagonistisch Deze resultaten 
tonen aan dat een select aantal cytostatica geschikt is voor combinatie met EdSm. 
Een aantal van deze combinaties is toegepast in 2 tumormodellen in de muis de 
L1210 leukemie en de B16 melanoma In hoofdstuk 9 worden de resultaten van 7 
combinaties met EdSm weergegeven In het B16 model is EdSm niet in staat gebleken 
de antitumoractiviteit van de geteste cytostatica te verbeteren In de leukemische tumor 
daarentegen, wordt wel synergisme gevonden, echter afhankelijk van het tijdsinterval 
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ook een antagonism Antagonisme werd ook vastgesteld in combinatie met 5-FU 
wanneer EdSm 3 of 24 uur na 5-FU werd gegeven, maar was afwezig bij het 6 uurs 
interval De combinatie van 5-FU en EdSm was echter nooit beter dan 5-FU alleen 
Het tegenovergestelde werd gevonden voor de combinatie van EdSm met ARA-C of 
VCR In de combinatie met VCR werd bij het 6-uurs interval de antitumoractiviteit 
verbeterd van 33% rumorvrije muizen voor alleen VCR naar 83% voor de combinatie 
De antitumoractiviteit van ARA-C werd verbeterd wanneer EdSm 24 uur na ARA-C 
werd gegeven, resulterend in 50% tumorvrije muizen voor de combinatie t o ν 11% 
voor ARA-C In combinatie met BCNU, VP16 en DX werd geen enkel effect 
gemeten, noch antagonistisch noch synergistisch 
In hoofdstuk 10 wordt tenslotte een overzicht gepresenteerd van de preklinische 
en klinische resultaten die tot nu toe zijn verkregen met andere cytotoxische 
verbindingen die, net zoals sparsomycine, de eiwitsynthese remmen Al deze 
verbindingen hebben antitumoractiviteit in preklinische proefdiermodellen Slechts 4 
van de 11 verbindingen vertonen ook in Phase I en Phase II klinische studies een 
gunstig antitumorgedrag L-asparaginase en homoharnngtonine zijn actief tegen 
leukaemieen Van de andere 2 verbindingen is voorzover bekend benzaldehyde niet 
verder ontwikkeld als cytostaticum, en wordt ncine gebruikt in de vorm van een 
immunotoxine, d w z gekoppeld aan een specifiek antihchaam, met de bedoeling 
meer ncine in de tumorcel te krijgen dan in gezonde cellen 
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Uit het verrichte onderzoek kunnen de volgende conclusies worden getrokken 
• EdSm heeft een goede antitumorwerking in de volgende experimentele 
rumormodellen de L1210 en P388 leukemia, de B16 melanoma en het niercel 
carcinoma (RC), maar in het algemeen is de antitumoractiviteit matig 
• De opname van EdSm door L1210 cellen is afhankelijk van de dosis, de 
incubatietijd en de mcubatietemperatuur 
• EdSm wordt door L1210 cellen langzaam opgenomen en resistentie tegen EdSm 
kan grotendeels worden verklaard door een verminderde opname 
• De synergistische werking van EdSm en cisplatina kan worden verklaard doordat 
EdSm de cellulaire detoxificatie mechanismen vermindert Vooral blokkering van 
de novo synthese van GST en depletie van glutathion zijn daarin belangrijk 
• Synergisme van EdSm met cisplatina wordt vooral bepaald door de gevoeligheid 
van de betreffende tumorcel en is minder afhankelijk van farmacokinetische 
factoren 
• De volgorde van toediening van EdSm en cisplatina is niet belangrijk 
• EdSm vertoont een significant synergisme in combinatie met cisplatina in 
verschillende rumormodellen, maar een sterke therapeutische verbetering wordt 
alleen waargenomen wanneer de betreffende tumor gevoelig is voor beide 
cytostatica 
• EdSm werkt synergistisch in B16 melanoma cellen in vitro in combinatie met 
cisplatina, ARA-C, MTX en 5-FU, en kan zowel ervoor als erna worden 
gegeven 
• In vivo is EdSm echter niet in staat de werking van deze cytostatica in de B16 
melanoma te versterken 
• In de L1210 tumor in vivo heeft EdSm een antagonistisch effect in combinatie 
met 5-FU, welke afhankelijk is van het tijdsinterval Verbetering van de 
antitumorwerking vindt niet plaats 
• Verbetering van de antitumorwerkng vindt wel plaats in combinatie met VCR en 
ARA-C In combinatie met VCR is de potentienng optimaal wanneer EdSm 6 
uur na VCR wordt gegeven In combinatie met ARA-C is dit 24 uur 
• EdSm heeft in vivo geen enkele invloed op de antitumoractiviteit van BCNU, 
VP16 en DX 
• De toepassing van EdSm in de chemotherapie van kanker kan nuttig zijn in 
combinatie met cytostatica zoals cisplatina, VCR en ARA-C 
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STELLINGEN 
behorende bij het proefschrift 
ETHYLDESHYDROXY-SPARSOMYCIN 
as modulator of antitumour response 
Hendricus P. Hofs 
Nijmegen, 20 januari 1995 
1. Chemische verbindingen die de ribosomale eiwitsynthese remmen kunnen de 
werking van specifieke citostatica verbeteren, mits zij als laatste worden 
toegediend. (Dit proej'schrifi). 
2. Ter voorkoming van misverstanden zou het begrip "synergisme " een uniforme 
definitie dienen te krijgen. (Du proefschrift). 
3. Bij het zoeken naar nieuwe derivaten van cytostatica dient mede gelet te 
worden op de cellulaire dynamiek van de tumorcel als selectiekriterium. 
(Dit proefschrift) 
4. Een aanvulling voor de "therapeutische index" van een stof zou kunnen zijn 
het verschil in het induceren van apoptose in normale en tumorcellen. 
5. De stroom van publicaties over apoptose (geprogrammeerde celdood) 
versterkt het gezegde: "de één zijn dood is de ander zijn brood". 
6. Voor de zakenman is tijd geld, voor de wetenschapper geldt meestal het 
omgekeerde. 
7. De ontwikkeling van software is te meten aan de hand van de wetenschappe-
lijke figuren in de publicaties. 
8. Socialisme is een goede zaak, maar de mensen zijn er niet geschikt voor. 
(Uitspraak van een topsportsier van de ex-DDR). 
9. Aangezien steeds meer mannen hun eigen maaltijd bereiden, moet het 
spreekwoord: "De liefde van de man gaat door de maag " drastisch worden 
herzien. 
10. Gezien de sterke toename van praatprogramma's op TV, lijkt het juister om 
de naam televisie te vervangen door beeldradio. 
11. De moderne wetenschapper is als een nomade: net ingewerkt kijkt hij/zij 
alweer uit naar een nieuw project. 
12. De amusementswaarde van de "champions league" is zodanig laag dat 
voortzetting moet worden ontraden. 
13. Hoewel wordt beweerd dat aan hard werken nog nooit iemand is doodge-
gaan, wordt in Japan nu voor ongeveer 30 sterfgevallen per jaar officieel 
erkend dat zij zijn veroorzaakt door te hard werken. 
(De Gelderlander, 1992). 
14. De bereidheid om te verhuizen voor een tijdelijke baan is recht evenredig met 
de duur van het arbeidscontract. 



